被験者番号 [redacted] (Investigator [redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
上室性頻脈	X			

Treatment Group	Age at Study Start	Sex	Race
ABT-494 30 mg QD	5[redacted]	FEMALE	WHITE

Medical History	Onset Year
OTHER: INTERMITTENT HEADACHES	19[redacted]
OTHER: PLAQUE PSORIASIS	19
OTHER: INDIGESTION	20
HYPERLIPIDEMIA: HYPERCHOLESTEROLEMIA; NO MEDS; DIET CONTROLLED	20
OTHER: HERPES ZOSTER	20
DEGENERATIVE DISC DISEASE: LUMBAR	20
OTHER: LOW BACK PAIN	20
OTHER: DYSPAREUNIA	20
CARDIAC ARRHYTHMIA: PALPITATIONS	20
OSTEOARTHRITIS: BILATERAL OSTEOARTHRITIS OF HANDS	20
OTHER: POSTMENOPAUSAL	20
OTHER: LUMBAR SPONDYLOLITHESIS	20
OTHER: SACROILIITIS	20
OTHER: INSOMNIA	20
OTHER: OCCASIONAL BLURRY VISION	20
OTHER: ANKYLOSED TOE LEFT 3RD	20
OTHER: THORACIC SPONDYLOSIS	20
OTHER: PSORIATIC NAIL DYSTROPHY	20

Prior Procedures	Procedure Year
SURGERY: LASIK BOTH EYES	20[redacted]

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
Not reported.				

Alcohol Use	Status	Number/Day
ALCOHOL	NEVER	

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)

ABT-494	30MG	ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 168	168
ABT-494	30MG	ORAL	QD	[redacted]20[redacted] / 169	[redacted]20[redacted] / 393	225
ABT-494	30MG	ORAL	QD	[redacted]20[redacted] / 394	/	

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
CORTISONE	1 OTHER: APPLICATION	QID	Y-M: 20[redacted]
ALKA SELTZER	2 OTHER: TABLETS	PRN	Y-M: 20[redacted]
CALCIUM CARBONATE	2 OTHER: TABS	PRN	Y-M: 20[redacted]
IBUPROFEN	200 mg	QID	Y-M: 20[redacted]
CALCIUM WITH VITAMIN D	1 OTHER: TABLET	QD	Y-M: 20[redacted]
FISH OIL	1 OTHER: CAPSULE	QD	Y-M: 20[redacted]
OSPEMIFENE	60 mg	QD	Y-M: 20[redacted]
FOLIC ACID	1 mg	QD	Y-M: 20[redacted]-
METHOTREXATE	20 mg	EVERY WEEK	Y-M: 20[redacted]-
PROBIOTICS	1 OTHER: TABLET	QD	Y-M: 20[redacted]
ADALIMUMAB	40 mg	EVERY 2 WEEKS	Y-M: 20[redacted]-
METHOTREXATE	20 mg	EVERY WEEK	Y-M: 20[redacted]-
METHYLPREDNISOLONE	80 mg	OTHER: SINGLE DOSE	Y-M: 20[redacted]-
CERTOLIZUMAB PEGOL	400 mg	OTHER: Q 4 WEEKS	Y-M: 20[redacted]-[redacted] / -236
CURCUMA LONGA	2 OTHER: TABLETS	QD	Y-M: 20[redacted]-[redacted] / -145
DOXYLAMINE	12.5 mg	PRN	Y-M: 20[redacted]-[redacted] / -114
MELATONIN	3 mg	PRN	Y-M: 20[redacted]-[redacted] / -114

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
ALKA SELTZER	2 OTHER: TABLETS	PRN	Y-M: 20[redacted]	Not reported.
CALCIUM CARBONATE	2 OTHER: TABS	PRN	Y-M: 20[redacted]	Not reported.
IBUPROFEN	200 mg	QID	Y-M: 20[redacted]	Not reported.
CALCIUM WITH VITAMIN D	1 OTHER: TABLET	QD	Y-M: 20[redacted]	Not reported.
FISH OIL	1 OTHER: CAPSULE	QD	Y-M: 20[redacted]	Not reported.
OSPEMIFENE	60 mg	QD	Y-M: 20[redacted]	Not reported.
PROBIOTICS	1 OTHER: TABLET	QD	Y-M: 20[redacted]	Not reported.
METHOTREXATE	20 mg	EVERY WEEK	Y-M: 20[redacted]	Not reported.
CURCUMA LONGA	2 OTHER: TABLETS	QD	Y-M: 20[redacted] / -145	Not reported.
DOXYLAMINE	12.5 mg	PRN	Y-M: 20[redacted] / -114	Not reported.
MELATONIN	3 mg	PRN	Y-M: 20[redacted] / -114	Not reported.
ESTROGENS CONJUGATED	1 OTHER: APPLICATION	QD	Y-M: 20[redacted] / 2	Not reported.
MAGNESIUM	400 mg	QD	Y-M: 20[redacted] / 43	Not reported.
OMEPRAZOLE	20 mg	QD	Y-M: 20[redacted] / 114	Not reported.
BIOTIN	10,000 ug	QD	Y-M: 20[redacted] / 118	Not reported.
FOLIC ACID	4 mg	QD	Y-M: 20[redacted] / 169	Not reported.
VITAMIN B COMPLEX	1 OTHER: TABLET	QD	Y-M: 20[redacted] / 372	Not reported.
COLECALCIFEROL	4000 IU	QD	Y-M: 20[redacted] / 373	Not reported.
FOLINIC ACID	5 mg	EVERY WEEK	Y-M: 20[redacted] / 394	Not reported.
MACROGOL 3350	17 g	PRN	Y-M: 20[redacted] / 460	Not reported.
DILTIAZEM	30 mg	TID	Y-M: 20[redacted] / 493	Not reported.
ACETYLSALICYLIC ACID	324 mg	OTHER: SINGLE DOSE	Y-M: 20[redacted] / 493	Y-M: 20[redacted] / 493
ADENOSINE	12 mg	OTHER: SINGLE DOSE	Y-M: 20[redacted] / 493	Y-M: 20[redacted] / 493
ADENOSINE	6 mg	OTHER: SINGLE DOSE	Y-M: 20[redacted] / 493	Y-M: 20[redacted] / 493
CEPACOL ANESTHETIC	1 OTHER: LOZENGE	OTHER: SINGLE DOSE	Y-M: 20[redacted] / 493	Y-M: 20[redacted] / 493

MYLANTA	30 mL	OTHER: SINGLE DOSE	Y-M: 20[redacted] / 493	Y-M: 20[redacted] / 493

Event #1: Serious Adverse Event

Event Description	PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA
Preferred term	上室性頻脈
AE Onset Date / Rx Day	[redacted]20[redacted] / 493
Age at AE Onset	5[redacted]

Laboratory Testing

[redacted]20[redacted] (RX DAY 493): NPTST101-PC BN PEPTIDE: LESS THAN 20.0 [0 - 100] pg/mL; NPTST102-PC TROPONIN 1: 0.01 [0 - 0.06] ng/mL; NPTST137-TROPONIN-1: 0.02 [0 - 0.05] ng/mL; NPTST139-TSH: 2.54 [0.36 - 3.74] ng/mL; [redacted]20[redacted] (RX DAY 494): NPTST027-BN PEPTIDE: 52.2 [0 - 100] pg/mL

Microbiology

NOT REPORTED

SAE Supplemental Procedure

[redacted]20[redacted] (RX DAY 493): CHEST X-RAY 1 VIEW: NORMAL; ECHOCARDIOGRAM: WITHIN NORMAL LIMITS; EKG: SINUS TACHYCARDIA WITH SHORT PR OTHERWISE NORMAL; [redacted]20[redacted] (RX DAY 494): EKG: NORMAL SINUS RHYTHM NONSPECIFIC T WAVE ABNORMALITY

AE Stopped Rx Day	493
Duration of AE	1 DAY
Relation to Study Drug by Investigator	NO REASONABLE POSSIBILITY
Investigator Alternative Etiology	HISTORY OF PALPITATIONS; PREEXISTING CONDUCTION ISSUE
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554

治験責任医師からの報告。本被験者は米国の 5[redacted] 歳女性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，発作性上室性頻脈（悪化）の事象を発現した。

Event 1 の臨床経過：

関連する病歴は局面型乾癬，高脂血症，発作性上室性頻脈，閉経後，乾癬性関節炎，不眠症，胸部脊椎症，非喫煙者及び非飲酒者であった。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は発作性上室性頻脈（悪化）を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，発作性上室性頻脈（悪化）は消失した。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は運転中に動悸を自覚し，脱力感及び頭のふらつきが出現し，気分が悪くなり，発汗も来した。友人によると，被験者の血圧は 200/110 mmHg で，心拍数は速すぎて数えられなかった。救急隊員が要請された。到着時，被験者は PSVT の状態にあり，アスピリン及びアデノシンが投与された。2 回目のアデノシン投与で PSVT が消失し，心電図検査により NSR が確認された。同日，被験者は入院した。被験者によると，過去数年間に同様の事象が起こっていたが，それらは不安によるものと思われ，気分が落ち着くと治まった。Cardizem の投与が開始された。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は退院した。

投与された薬剤は，アスピリン，アデノシン，cardizem 及びプラバスタチンであった。

The patient's past medications include:

HUMIRA for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

Causality for UPADACITINIB (Blinded)

---

1) Paroxysmal supraventricular tachycardia (10034044) (Supraventricular tachycardia (10042604)) [v.22.0] [10034044]

Causality as per reporter (Drug/Vaccine): No reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Yes

Rechallenge: rechallenge was done, reaction did not recur

Alternative Etiology for UPADACITINIB (Blinded)

Event of PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (WORSENING)

- Investigator: History of palpitations, preexisting conduction issue.

- AbbVie: Risk factor includes pre-existing palpitations since 20[redacted].

Relevant Laboratory & Other Diagnostic Tests

[redacted] **20[redacted] BLOOD PRESSURE:** 200/110 mmHg

[redacted] **20[redacted] CHEST X-RAY:** NORMAL

[redacted] **20[redacted] ECHOCARDIOGRAM:** WITHIN NORMAL LIMITS

[redacted] **20[redacted] EKG:** SINUS TACHYCARDIA WITH SHORT PR OTHERWISE NORMAL; VENTRICULAR RATE: 105 bpm

[redacted] **20[redacted] EKG:** NORMAL SINUS RHYTHM NONSPECIFIC T WAVE ABNORMALITY

[redacted] **20[redacted] PC BN PEPTIDE:** <20.0 pg/mL

[redacted] **20[redacted] PC BN PEPTIDE:** 52.2 PG/ML (normal 0.00 to 100.0)

[redacted] **20[redacted] POTASSIUM:** 4.4 no unit

[redacted] **20[redacted] RBC:** 3.72 no unit

[redacted] **20[redacted] TOTAL CHOLESTEROL:** 210 no unit

[redacted] **20[redacted] TROPONIN 1:** 0.01 NG/ML (normal 0.00 to 0.06)

[redacted] **20[redacted] TROPONIN 1:** 0.016 NG/ML (normal 0.00 to 0.06)

[redacted] **20[redacted] TSH:** 2.540 NG/ML (normal 0.358 to 3.740)

被験者番号 [redacted] (Investigator [redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
急性腎障害	X			X
蜂巣炎	X			X

Treatment Group	Age at Study Start	Sex	Race
ABT-494 15 mg QD	5[redacted]	MALE	WHITE

Medical History	Onset Year
OTHER: INGUINAL HERNIA	NOT REPORTED
OTHER: ROTATOR CUFF TEAR	NOT REPORTED
OTHER: SEASONAL ALLERGIES	NOT REPORTED
OTHER: JOINT PAIN	19[redacted]
HYPOTHYROIDISM	20[redacted]
OSTEOARTHRITIS: KNEE	20[redacted]
KIDNEY DISORDER: ABNORMAL KIDNEY FUNCTION	20[redacted]
OTHER: PLAQUE PSORIASIS	20[redacted]

Prior Procedures	Procedure Year
SURGERY: LEFT KNEE REPLACEMENT	20[redacted]
SURGERY: RIGHT HIP REPLACEMENT	20[redacted]

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
Not reported.				

Alcohol Use	Status	Number/Day
ALCOHOL	FORMER	Less than 2

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
ABT-494	15MG	ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 169	169
ABT-494	15MG	ORAL	QD	[redacted]20[redacted] / 170	[redacted]20[redacted] / 392	223
ABT-494	15MG	ORAL	QD	[redacted]20[redacted] / 393	/	

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
LEVOTHYROXINE	200 OTHER: MCG	QD	Y-M: 20[redacted]-
INFLIXIMAB	UNK mg	OTHER: UNKNOWN	Y-M: 20[redacted]-
ETANERCEPT	UNK mg	EVERY WEEK	Y-M: 20[redacted]-
ADALIMUMAB	UNK mg	EVERY 2 WEEKS	Y-M: 20[redacted]-
DICLOFENAC	1 OTHER: APPLICATION	QID	Y-M: 20[redacted]-
METHOTREXATE	12.5 mg	EVERY WEEK	Y-M: 20[redacted]-
FOLIC ACID	1 mg	QD	Y-M: 20[redacted]-
TRIAMCINOLONE	80 mg	OTHER: ONCE	Y-M: 20[redacted]- / -57

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
LEVOTHYROXINE	200 OTHER: MCG	QD	Y-M: 20[redacted]	Not reported.
DICLOFENAC	1 OTHER: APPLICATION	QID	Y-M: 20[redacted]	Not reported.
METHOTREXATE	12.5 mg	EVERY WEEK	Y-M: 20[redacted]	Not reported.
FOLIC ACID	1 mg	QD	Y-M: 20[redacted]	Not reported.
NYSTATIN	2 OTHER: APPLICATION	BID	Y-M: 20[redacted] / 113	Not reported.
CLINDAMYCIN	300 mg	TID	Y-M: 20[redacted] / 499	Not reported.
ERGOCALCIFEROL	1.25 mg	QD	Y-M: 20[redacted] / 510	Not reported.
MUPIROCIN	1 OTHER: APP	TID	Y-M: 20[redacted] / 510	Not reported.
PARACETAMOL	650 mg	OTHER: Q6HR PRN	Y-M: 20[redacted] / 510	Not reported.
CEFEPIME	50 mL	OTHER: Q8HR	Y-M: 20[redacted] / 510	Y-M: 20[redacted] / 518
ERGOCALCIFEROL	50000 OTHER: INTL_UNITS CAP	EVERY WEEK	Y-M: 20[redacted] / 510	Y-M: 20[redacted] / 518
MORPHINE	2 mg	OTHER: Q4HR PRN	Y-M: 20[redacted] / 510	Y-M: 20[redacted] / 518
ONDANSETRON	4 mg	OTHER: Q4HR PRN	Y-M: 20[redacted] / 510	Y-M: 20[redacted] / 518
PIP/TAZO	15 mL	OTHER: Q6HR	Y-M: 20[redacted] / 510	Y-M: 20[redacted] / 518
AMLODIPINE	5 mg	BID	Y-M: 20[redacted] / 516	Not reported.
CEFTRIAXONE	2 g	QD	Y-M: 20[redacted] / 518	Y-M: 20[redacted] / 528
TRAMADOL	50 mg	BID	Y-M: 20[redacted] / 648	Not reported.

Event #1: Serious Adverse Event, Study Specific Adverse Events of Interest

Event Description	CELLULITIS LEFT LEG, ACUTE RENAL FAILURE
Preferred term	急性腎障害
AE Onset Date / Rx Day	[redacted]20[redacted] / 510
Age at AE Onset	5[redacted]

Laboratory Testing

[redacted]20[redacted] (RX DAY 510): Creatinine: 160.01 [56.58 - 112.27] umol/L; Glucose: 9.55 [3.89 - 5.5] mmol/L; Hematocrit: 0.39 [0.4 - 0.5] fraction of 1; Hemoglobin: 134 [137 - 170] g/L; Leukocytes: 24.7 [4 - 11] 10^9/L; Lymphocytes: 0.25 [0.5 - 4.8] 10^9/L; NPTST020-BAND MAN: 8 [0 - 5] %; NPTST057-EGFR AA: 48 [30 - 59] mL/min/1.73m2; NPTST086-LYMPH MAN: 1 [19 - 48] %; NPTST122-SED RATE: 84 [0 - 10] mm/h; NPTST123-SEGS MAN: 91 [40 - 74] %; Neutrophils: 24.5 [1.6 - 8.5] 10^9/L; [redacted]20[redacted] (RX DAY 518): Creatinine: 162.66 [56.58 - 112.27] umol/L; Erythrocytes: 3.35 [4.2 - 5.6] mU/L; Glucose: 5.77 [3.89 - 5.5] mmol/L; Hematocrit: 0.32 [0.4 - 0.5] fraction of 1; Hemoglobin: 111 [137 - 170] g/L; NPTST087-LYMPHOCYTES: 10.4 [19 - 48] %; NPTST095-NEUTRO ABSOLUTE: 8.8 [1.6 - 8.5] 10^3/uL; NPTST096-NEUTROPHILS: 84.5 [40 - 74] %; Platelets: 563 [150 - 400] 10^9/L

Microbiology

[redacted]20[redacted] (RX DAY 510): WOUND NPTST097-NON-CULTURE MICROBIOLOGY: NEGATIVE-MRSA NAAT - NEGATIVE 2+ STREPTOCOCCUS PYOGENES (GROUP A)

SAE Supplemental Procedure

[redacted]20[redacted] (RX DAY 510): MAGNETIC RESONANCE IMAGING: BONE MARROW THERE IS A PARTIALLY INCLUDED KNEE PROSTHESIS. NORMAL SIGNAL, WITHOUT EVIDENCE FOR EDEMA OR FRACTURE. MUSCULOTENDIOUS STRUCTURES. NORMAL APPEARANCE. SUBCUTANEOUS SOFT TISSUES NO EVID

AE Stopped Rx Day	NOT REPORTED
Duration of AE	NOT REPORTED
Relation to Study Drug by Investigator	NO REASONABLE POSSIBILITY
Investigator Alternative Etiology	TRAUMA TO THE LEG
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Event #2: Serious Adverse Event, Study Specific Adverse Events of Interest

Event Description	CELLULITIS LEFT LEG, ACUTE RENAL FAILURE
Preferred term	蜂巣炎
AE Onset Date / Rx Day	[redacted]20[redacted] / 510
Age at AE Onset	5[redacted]

Laboratory Testing

[redacted]20[redacted] (RX DAY 510): Creatinine: 160.01 [56.58 - 112.27] umol/L; Glucose: 9.55 [3.89 - 5.5] mmol/L; Hematocrit: 0.39 [0.4 - 0.5] fraction of 1; Hemoglobin: 134 [137 - 170] g/L; Leukocytes: 24.7 [4 - 11] 10^9/L; Lymphocytes: 0.25 [0.5 - 4.8] 10^9/L; NPTST020-BAND MAN: 8 [0 - 5] %; NPTST057-EGFR AA: 48 [30 - 59] mL/min/1.73m2; NPTST086-LYMPH MAN: 1 [19 - 48] %; NPTST122-SED RATE: 84 [0 - 10] mm/h; NPTST123-SEGS MAN: 91 [40 - 74] %; Neutrophils: 24.5 [1.6 - 8.5] 10^9/L; [redacted]20[redacted] (RX DAY 518): Creatinine: 162.66 [56.58 - 112.27] umol/L; Erythrocytes: 3.35 [4.2 - 5.6] mU/L; Glucose: 5.77 [3.89 - 5.5] mmol/L; Hematocrit: 0.32 [0.4 - 0.5] fraction of 1; Hemoglobin: 111 [137 - 170] g/L; NPTST087-LYMPHOCYTES: 10.4 [19 - 48] %; NPTST095-NEUTRO ABSOLUTE: 8.8 [1.6 - 8.5] 10^3/uL; NPTST096-NEUTROPHILS: 84.5 [40 - 74] %; Platelets: 563 [150 - 400] 10^9/L

Microbiology

[redacted]20[redacted] (RX DAY 510): WOUND NPTST097-NON-CULTURE MICROBIOLOGY: NEGATIVE-MRSA NAAT - NEGATIVE 2+ STREPTOCOCCUS PYOGENES (GROUP A)

SAE Supplemental Procedure

[redacted]20[redacted] (RX DAY 510): MAGNETIC RESONANCE IMAGING: BONE MARROW THERE IS A PARTIALLY INCLUDED KNEE PROSTHESIS. NORMAL SIGNAL, WITHOUT EVIDENCE FOR EDEMA OR FRACTURE. MUSCULOTENDIOUS STRUCTURES. NORMAL APPEARANCE. SUBCUTANEOUS SOFT TISSUES NO EVID

AE Stopped Rx Day	NOT REPORTED
Duration of AE	NOT REPORTED
Relation to Study Drug by Investigator	NO REASONABLE POSSIBILITY
Investigator Alternative Etiology	TRAUMA TO THE LEG
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554

治験責任医師からの報告。本被験者は米国の 5[redacted] 歳男性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，左脚の蜂巣炎及び急性腎不全の事象を発現した。

Event 1 及び 2 の臨床経過：

関連する病歴は元紙巻タバコ喫煙者（1 日 1 箱を 4.5 年間），甲状腺機能低下症，血清反応陽性関節リウマチ，腎機能異常，局面型乾癬及び元飲酒者（1 日 2 杯未満）であった。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は左脚の蜂巣炎及び急性腎不全を発現した。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は金づちで負傷した左下肢の蜂巣炎のため入院した。膝下に紅斑が見られ，右下肢と比べると中等度の浮腫が認められた。創傷はすねの中央の高さにあり，淡黄色の排出液を伴っており，触ると温感があった。被験者は白血球増加症，杆状核球増加症及び急性腎障害を発現した。被験者は感染症のため診察を受け，創傷培養で連鎖球菌が検出された。バンコマイシンの静脈内投与が 3 日間行われた後，セフェピム投与下で退院となった。被験者の状態ははるかに良くなり，発熱，悪寒及び寝汗は認められなかった。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は退院した。

投与された薬剤は，クリンダマイシン，タイレノール，セフェピム，モルヒネ，ムピロシン，セフトリアキソン及びゾシンであった。

The patient's past medications include:

INFLIXIMAB for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

ADALIMUMAB for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

ETANERCEPT for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

TRIAMCINOLONE ACETONIDE for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

Causality for UPADACITINIB (Blinded)

---

1) Acute renal failure (10001041) (Acute kidney injury (10069339)) [v.22.0] [10001041]

Causality as per reporter (Drug/Vaccine): No reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Not Applicable

2) Cellulitis of leg (10007912) (Cellulitis (10007882)) [v.22.0] [10007912]

Causality as per reporter (Drug/Vaccine): No reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Not Applicable

Alternative Etiology for UPADACITINIB (Blinded)

Event of CELLULITIS LEFT LEG, ACUTE RENAL FAILURE

- Investigator: Trauma to the leg

- AbbVie: Event is more likely related to accidental trauma sustained to the left lower extremity and pre-existing abnormal kidney function.

Relevant Laboratory & Other Diagnostic Tests

[redacted] **20[redacted] ABSOLUTE LYMPHOCYTES:** 0.25 K/UL (normal 0.5 to 4.8)

[redacted] **20[redacted] ABSOLUTE NEUTROPHIL:** 24.5 K/UL (normal 1.60 to 8.50)

[redacted] **20[redacted] ABSOLUTE NEUTROPHIL:** 8.80 K/UL (normal 1.60 to 8.50)

[redacted] **20[redacted] BAND MAN:** 8 % (normal 0 to 5)

[redacted] **20[redacted] CREATININE:** 1.81 mg/dL (normal 0.64 to 1.27)

[redacted] **20[redacted] CREATININE:** 1.84 mg/dL (normal 0.64 to 1.27)

[redacted] **20[redacted] CULTURE:** WOUND CULTURE: MRSA NAAT - NEGATIVE 2+ STREPTOCOCCUS PYOGENES (GROUP A)

[redacted] **20[redacted] ERYTHROCYTE SEDIMENTATION RATE:** 84 MM/HR (normal 0 to 10)

[redacted] **20[redacted] GFR:** 48 ML/Min (normal 30 to 59)

[redacted] **20[redacted] GLUCOSE:** 172 mg/dL (normal 70 to 99)

[redacted] **20[redacted] GLUCOSE:** 104 mg/dL (normal 70 to 99)

[redacted] **20[redacted] HCT:** 39.3 % (normal 40 to 50)

[redacted] **20[redacted] HCT:** 31.6 % (normal 40 to 50)

[redacted] **20[redacted] HGB:** 13.4 G/DL (normal 13.7 to 17)

[redacted] **20[redacted] HGB:** 11.1 G/DL (normal 13.7 to 17)

[redacted] **20[redacted] LYMPH MAN:** 1 % (normal 19 to 48)

[redacted] **20[redacted] LYMPHOCYTES:** 10.4 % (normal 19 to 48)

[redacted] **20[redacted] MAGNETIC RESONANCE IMAGING:** Bone marrow there is a partially included knee prosthesis. Normal signal, without evidence for edema or fracture. Musculotendious structures. Normal appearance. Subcutaneous soft Tissues no evidence of a mass or fluid collection is seen by the noncontrast technique. There is extensive subcutaneous soft tissue edema seen circumferentially about the leg.

[redacted] **20[redacted] NEUTROPHILS:** 84.5 % (normal 40 to 74)

[redacted] **20[redacted] PLATELET COUNT:** 563 X10**9/L (normal 150 to 450)

[redacted] **20[redacted] RED BLOOD CELLS:** 3.35 X10**6/MCL (normal 4.20 to 5.60)

[redacted] **20[redacted] SEGS MAN:** 91 % (normal 40 to 74)

[redacted] **20[redacted] WBC:** 24.7 K/uL (normal 4 to 11)

被験者番号 [redacted] (Investigator [redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
全身性炎症反応症候群	X			

Treatment Group	Age at Study Start	Sex	Race
ABT-494 30 mg QD	6[redacted]	FEMALE	WHITE

Medical History	Onset Year
OTHER: PHOTOSENSITIVITY	19[redacted]
OTHER: SEASONAL ALLERGIES	19
OTHER: CERVICAL DYSPLASIA LEADING TO HYSTERECTOMY	19
GASTROESOPHAGEAL REFLUX DISEASE	19
OTHER: INTERMITTENT CONSTIPATION	19
OTHER: INTERMITTENT DIARRHEA	19
OTHER: GELLING PHENOMENON	19
OTHER: JOINT SWELLING	19
OTHER: PLAQUE PSORIASIS	19
OTHER: MORNING STIFFNESS	19
OTHER: DRY EYES/MOUTH	20
OTHER: ELEVATED LIVER TRANSAMINASIS	20
CHOLECYSTITIS	20
DIABETES MELLITUS	20
LIVER DISEASE (EXCLUDING HEPATITIS): METHOTREXATE INDUCED LIVER CHANGES	20
HYPERLIPIDEMIA: HIGH CHOLESTEROL	20
HYPERTENSION	20
OTHER: LEFT LATERAL EPICONDYLITITS	20
DEGENERATIVE DISC DISEASE: LUMBER SPINE L3-L5	20
OTHER: ROTOSCOLIOSIS LUMBER SPINE	20
MIGRAINE HEADACHE: MIGRAINE WITH TIA SYMPTOMS	20
OTHER: RIGHT SACROILIITIS	20
OTHER: SCLEROSIS LEFT SACROILIAC JOINT	20
OTHER: TRANSIENT APHASIA	20
PERIPHERAL NERVE DISORDER: RIGHT LEG NUMBNESS	20
OTHER: FRACTURE L SECOND METATARSAL	20
OTHER: ALOPECIA	20
HYPOTHYROIDISM	20

Prior Procedures	Procedure Year

SURGERY: HYSTERECTOMY	19[redacted]
SURGERY: NOSE RECONSTRUCTION DUE TO TRAUMA	19[redacted]
SURGERY: CHOLESCYSTECTOMY	20[redacted]
SURGERY: LUMBER RADICULOPATHY	20[redacted]

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
Not reported.				

Alcohol Use	Status	Number/Day
ALCOHOL	NEVER	

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
ABT-494	30MG	ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 177	177
ABT-494	30MG	ORAL	QD	[redacted]20[redacted] / 178	[redacted]20[redacted] / 402	225
ABT-494	30MG	ORAL	QD	[redacted]20[redacted] / 403	/	

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
ETANERCEPT	25.0 mg	OTHER: TWICE/WK	Y-M: 20[redacted]
FOLIC ACID	1.0 mg	QD	Y-M: 20[redacted]
LEFLUNOMIDE	20.0 mg	QD	Y-M: 20[redacted]
INSULIN ASPART	100.0 OTHER: UNITS	QD	Y-M: 20[redacted]
ADALIMUMAB	40.0 mg	EVERY 2 WEEKS	Y-M: 20[redacted]
SULINDAC	200.0 mg	BID	Y-M: 20[redacted]
OMEPRAZOLE	20.00 mg	QD	Y-M: 20[redacted]
GOLIMUMAB	50.0 mg	OTHER: QMONTH	Y-M: 20[redacted]
LOSARTAN	25.0 mg	QD	Y-M: 20[redacted]
PRAVASTATIN	10.0 mg	QD	Y-M: 20[redacted]
FLUTICASONE	50.0 ug	QD	Y-M: 20[redacted]
SECUKINUMAB	300.0 mg	OTHER: Q MONTH	Y-M: 20[redacted]
INSULIN DEGLUDEC	65.0 OTHER: UNITS	QD	Y-M: 20[redacted]
LEVOTHYROXINE	25.0 ug	QD	Y-M: 20[redacted] / -337
METHOTREXATE	25.0 mg	EVERY WEEK	Y-M: 20[redacted] / -156

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-	Stop Year-

			Month / RX Day	Month / RX Day
FOLIC ACID	1.0 mg	QD	Y-M: 20[redacted]-	Not reported.
INSULIN ASPART	100.0 OTHER: UNITS	QD	Y-M: 20[redacted]	Y-M: 20[redacted]- [redacted] / 377
SULINDAC	200.0 mg	BID	Y-M: 20[redacted]-	Not reported.
OMEPRAZOLE	20.00 mg	QD	Y-M: 20[redacted]-	Not reported.
LOSARTAN	25.0 mg	QD	Y-M: 20[redacted]-	Not reported.
PRAVASTATIN	10.0 mg	QD	Y-M: 20[redacted]-	Not reported.
FLUTICASONE	50.0 ug	QD	Y-M: 20[redacted]- [redacted]	Y-M: 20[redacted]- [redacted] / 194
INSULIN DEGLUDEC	65.0 OTHER: UNITS	QD	Y-M: 20[redacted]- [redacted]	Y-M: 20[redacted]- [redacted] / 377
LEVOTHYROXINE	25.0 ug	QD	Y-M: 20[redacted]- [redacted] / -337	Not reported.
GLUCOSE	4.0 g	PRN	Y-M: 20[redacted]- [redacted] / 61	Not reported.
PILOCARPINE	.005 ug	QD	Y-M: 20[redacted]- [redacted] / 73	Not reported.
CEFDINIR	300 mg	BID	Y-M: 20[redacted]- [redacted] / 76	Y-M: 20[redacted]- [redacted] / 86
METHOTREXATE	25.00 mg	EVERY WEEK	Y-M: 20[redacted]- [redacted] / 83	Y-M: 20[redacted]- [redacted] / 262
IOPAMIDOL	70.0 mg	OTHER: ONCE	Y-M: 20[redacted]- [redacted] / 115	Y-M: 20[redacted]- [redacted] / 115
IOPAMIDOL	70.00 mL	OTHER: ONCE	Y-M: 20[redacted]- [redacted] / 115	Y-M: 20[redacted]- [redacted] / 115
VANCOMYCIN	125.00 mg	TID	Y-M: 20[redacted]- [redacted] / 115	Y-M: 20[redacted]- [redacted] / 116
ONDANSETRON	4.0 mg	BID	Y-M: 20[redacted]- [redacted] / 115	Y-M: 20[redacted]- [redacted] / 120
SODIUM CHLORIDE	2000.00 mL	OTHER: CONTINUOUS DRIP	Y-M: 20[redacted]- [redacted] / 115	Y-M: 20[redacted]- [redacted] / 121
LACTOBACILLUS ACIDOPHILUS	1.0 OTHER: CAPSULE	QD	Y-M: 20[redacted]- [redacted] / 116	Not reported.
PIP/TAZO	3.3 g	TID	Y-M: 20[redacted]- [redacted] / 116	Y-M: 20[redacted]- [redacted] / 117
VANCOMYCIN	10 mg/kg	TID	Y-M: 20[redacted]- [redacted] / 116	Y-M: 20[redacted]- [redacted] / 118
ENOXAPARIN	40.0 mg	QD	Y-M: 20[redacted]- [redacted] / 116	Y-M: 20[redacted]- [redacted] / 119
FLEBOBAG RING LACT	2000.00 mL	OTHER: CONTINUOUS	Y-M: 20[redacted]- [redacted] / 116	Y-M: 20[redacted]- [redacted] / 120

LATANOPROST	1.0 gtt	BID	Y-M: 20[redacted]- [redacted] / 116	Y-M: 20[redacted]- [redacted] / 120
LIDOCAINE	2.0 %	PRN	Y-M: 20[redacted]- [redacted] / 116	Y-M: 20[redacted]- [redacted] / 120
MAGNESIUM SULFATE	2.0 g	QD	Y-M: 20[redacted]- [redacted] / 116	Y-M: 20[redacted]- [redacted] / 120
MEROPENEM	500.00 mg	OTHER: ONCE	Y-M: 20[redacted]- [redacted] / 116	Y-M: 20[redacted]- [redacted] / 120
VALSARTAN	80.0 mg	QD	Y-M: 20[redacted]- [redacted] / 116	Y-M: 20[redacted]- [redacted] / 120
AUGMENTIN	125.0 mg	BID	Y-M: 20[redacted]- [redacted] / 116	Y-M: 20[redacted]- [redacted] / 125
NEUTRA-PHOS	10.0 mEq	OTHER: ONCE	Y-M: 20[redacted]- [redacted] / 117	Y-M: 20[redacted]- [redacted] / 117
POTASSIUM	20.0 mEq	OTHER: ONCE	Y-M: 20[redacted]- [redacted] / 117	Y-M: 20[redacted]- [redacted] / 117
VANCOMYCIN	125.00 mg	OTHER: 6 TIMES/DAY	Y-M: 20[redacted]- [redacted] / 117	Y-M: 20[redacted]- [redacted] / 121
DICYCLOVERINE	10.0 mg	OTHER: ONCE	Y-M: 20[redacted]- [redacted] / 118	Y-M: 20[redacted]- [redacted] / 118
PARACETAMOL	650.0 mg	OTHER: ONCE	Y-M: 20[redacted]- [redacted] / 118	Y-M: 20[redacted]- [redacted] / 118
LACTOBACILLUS ACIDOPHILUS	1.0 OTHER: CAPSULE	QD	Y-M: 20[redacted]- [redacted] / 118	Y-M: 20[redacted]- [redacted] / 120
PANTOPRAZOLE	40.0 mg	QD	Y-M: 20[redacted]- [redacted] / 118	Y-M: 20[redacted]- [redacted] / 120
KETOTIFEN	1.00 gtt	BID	Y-M: 20[redacted]- [redacted] / 119	Not reported.
EMOLLIENTS AND PROTECTIVES	1 OTHER: APPL	BID	Y-M: 20[redacted]- [redacted] / 119	Y-M: 20[redacted]- [redacted] / 119
FLUCONAZOLE	150.0 mg	OTHER: ONCE	Y-M: 20[redacted]- [redacted] / 119	Y-M: 20[redacted]- [redacted] / 119
MAALOX	30.0 mL	QD	Y-M: 20[redacted]- [redacted] / 119	Y-M: 20[redacted]- [redacted] / 120
ALUMINIUM W/MAGNESIUM HYDROXIDE/SIMETICONE	30.00 mL	TID	Y-M: 20[redacted]- [redacted] / 120	Y-M: 20[redacted]- [redacted] / 120
LOPERAMIDE	4.0 mg	OTHER: ONCE	Y-M: 20[redacted]- [redacted] / 120	Y-M: 20[redacted]- [redacted] / 120
PROMETHAZINE	12.5 mg	OTHER: ONCE	Y-M: 20[redacted]- [redacted] / 120	Y-M: 20[redacted]- [redacted] / 120
COLESEVELAM	1250.0 mg	BID	Y-M: 20[redacted]- [redacted] / 120	Y-M: 20[redacted]- [redacted] / 125

Event #1: Serious Adverse Event

Event Description	SYSTEMIC INFLAMMATORY RESPONSE SYNDROME
Preferred term	全身性炎症反応症候群
AE Onset Date / Rx Day	[redacted]20[redacted] / 115

Age at AE Onset 7[redacted]

Laboratory Testing

[redacted]20[redacted] (RX DAY 115): Albumin: 41 [34 - 48] g/L; Alkaline Phosphatase: 88 [25 - 150] U/L; Aspartate Aminotransferase: 44 [5 - 34] U/L; Basophils: 0 [0 - 0.2] 10^9/L; Bilirubin: 22.24 [0 - 20.52] umol/L; Calcium: 2.3 [2.17 - 2.57] mmol/L; Calcium: 2.27 [2.1 - 2.64] mmol/L; Chloride: 100 [98 - 109] mmol/L; Creatinine: 96.36 [50.39 - 88.4] umol/L; Eosinophils: 0 [0 - 0.5] 10^9/L; Erythrocytes: 4.6 [3.8 - 5.3] 10^12/L; Glucose: 11.27 [3.61 - 5.5] mmol/L; Hemoglobin: 144 [111 - 159] g/L; Leukocytes: 13.5 [3.4 - 10.8] 10^9/L; Lymphocytes: 0.7 [0.7 - 3.1] 10^9/L; Monocytes: 0.5 [0.1 - 0.9] 10^9/L; NPTST026-BLOOD UREA NITROGEN: 30 [8 - 25] mg/dL; Neutrophils: 12.3 [1.4 - 7] 10^9/L; Platelets: 300 [150 - 379] 10^9/L; Potassium: 4.5 [3.5 - 5.3] mmol/L; Protein: 79 [60 - 85] g/L; Sodium: 133 [134 - 144] mmol/L; [redacted]20[redacted] (RX DAY 480): Hematocrit: 0.43 [0.34 - 0.47] fraction of 1; NPTST082-LACTIC ACID: 1.9 [0.5 - 2.2] mmol/L; NPTST134-TROPONIN: 0.02 [0 - 0.78] ng/mL

Microbiology

[redacted]20[redacted] (RX DAY 115): BLOOD NPTST047-CULTURE: NOT APPLICABLE-NEGATIVE CULTURE; [redacted]20[redacted] (RX DAY 482): STOOL NPTST132-TOXIGENIC CLOSTRIDIUM DIFFICILE: NEGATIVE

SAE Supplemental Procedure

[redacted]20[redacted] (RX DAY 115): CHEST RADIOGRAPHS: NO ACUTE FINDINGS; CT ABD AND PELVIS WITH CONTRAST: NO ACUTE FINDING; EKG: SINUS RHYTHM WITH 1ST DEGREE A=V BLOCK; [redacted]20[redacted] (RX DAY 116): CT NECK WITH CONTRAST: MILD ASYMMETRIC THICKENING OF LEFT PALATINE TONSIL WITH NO EVIDENCE OF ABCESS; [redacted]20[redacted] (RX DAY 117): NASAL ENDOSCOPY: ENLARGED TONSILLS; [redacted]20[redacted] (RX DAY 480): VITAL SIGNS: BP=145/70 HR=108 TEMP=101.2 O2 SAT=94%

AE Stopped Rx Day	121
Duration of AE	7 DAYS
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	NOT REPORTED
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554

治験責任医師からの報告。本被験者は米国の 7[redacted] 歳女性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，全身性炎症反応症候群の事象を発現した。

Event 1 の臨床経過：

関連する病歴は元喫煙者（1 日 0.5 箱を 10 年間），乾癬性関節炎，糖尿病，高血圧，甲状腺機能低下症及び非飲酒者であった。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は全身性炎症反応症候群を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，全身性炎症反応症候群は消失した。

本事象発現前の 20[redacted] 年 [redacted] 月 [redacted] 日から 20[redacted] 年 [redacted] 月 [redacted] 日，被験者は扁桃炎（非重篤な事象）を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，CK 値増加（非重篤な事象）を発現した。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は，発熱を伴う急性の激しい嘔吐及び突発性の下痢のため入院した。20[redacted] 年 [redacted] 月 [redacted] 日，本事象は消失し，被験者は退院した。本事象に関連する家族歴はなかった。

医療記録によると，被験者は当初，原因不明の SIRS／敗血症の症状のために入院した。被験者は最近（数週間前），クリンダマイシンを投与されており，入院時には経験的にバンコマイシンの投与が開始された。症状は改善し，経口抗生物質に切り替えられた。被験者はその後，安定状態で退院し，経口抗生物質を継続することとなった。被験者には，ここ最近において，旅行歴，病人との接触，キャンプ歴はなかった。

投与された薬剤は，ロペラミド，バンコマイシン，ゾシン，アシドフィルス菌，メロペネム，生理食塩液，水酸化アルミニウム・水酸化マグネシウム・シメチコン合剤，enoxa，硫酸マグネシウム，乳酸リンゲル液，塩化カリウム，neutraphos，タイレノール，bentyl，lactocap，protonix，マーロックス，ジフルカン及びオーグメンチンであった。

The patient's past medications include:

ENBREL for PSA THERAPY ([redacted] 20[redacted] - [redacted] 20[redacted])

ARAVA for PSA ([redacted] 20[redacted] - [redacted] 20[redacted])

HUMIRA for PSA ([redacted] 20[redacted] - [redacted] 20[redacted])

SIMPONI for PSA ([redacted] 20[redacted] - [redacted] 20[redacted])

COSENTYX for PSA ([redacted] 20[redacted] - [redacted] 20[redacted])

Causality for UPADACITINIB (Blinded)

---

1) Systemic inflammatory response syndrome (10051379) (Systemic inflammatory response syndrome (10051379)) [v.22.0] [10051379]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Yes

Rechallenge: rechallenge was done, reaction did not recur

Alternative Etiology for UPADACITINIB (Blinded)

Event of SYSTEMIC INFLAMMATORY RESPONSE SYNDROME

- Investigator: Not applicable.

- AbbVie: Risk factors include age, diabetes mellitus and obesity.

Relevant Laboratory & Other Diagnostic Tests

[redacted] **ASPARTATE AMINOTRANSFERASE:** 44 U/L (normal 5 to 34)

[redacted] **BLOOD CULTURE:** negative

[redacted] **BNP:** 10 PG/ML (normal <100)

[redacted] **BUN:** 30 mg/dL (normal 8 to 25)

[redacted] **CBC WITH DIFFERENTIAL:** WBC =13.5 (REF 3.4-10.8)

[redacted] **CHEST RADIOGRAPHS:** No acute findings

[redacted] **CMP:** CO2 = 16 (20-32)/NA 133(134-144)

[redacted] **CREATININE:** 1.09 mg/dL (normal 0.57 to 1.00)

[redacted] **CT ABDOMEN AND PELVIS WITH CONTRAST:** No acute finding

[redacted] **CT NECK WITH CONTRAST:** Mild asymmetric thickening of left palatine tonsil with no evidence of abscess

[redacted] **EKG:** Sinus rhythm with 1st degree AV block

[redacted] **GLUCOSE:**203 mg/dL (normal 65 to 99)

[redacted] **NASAL ENDOSCOPY:** Enlarged tonsils

[redacted] **NEUTROPHILS:** 12.3 X10**3/MM**3 (normal 1.4 to 7.0)

[redacted] **20[redacted] SEPSIS LACTIC ACID:** 1.9 MMOL/L (normal 0.5 to 5.2)

[redacted] **20[redacted] STOOL FOR C. DIFF:** negative

[redacted] **20[redacted] TROPONIN:** 0.02 NG/ML (normal 0.00 to 0.78)

[redacted] **20[redacted] URINALYSIS:** Within normal limits

[redacted] **20[redacted] WHITE BLOOD CELLS:** 13.5 X10**3/MM**3 (normal 3.4 to 10.8)

被験者番号 [redacted] (Investigator [redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
急性呼吸不全	X			

Treatment Group	Age at Study Start	Sex	Race
ABT-494 30 mg QD	5[redacted]	FEMALE	WHITE

Medical History	Onset Year
OTHER: SEASONAL ALLERGIES	19[redacted]
OTHER: VITILIGO	19
OTHER: PLAQUE PSORIASIS	19
OTHER: PSORIASIS	19
HYPERTENSION	19
OTHER: ABNORMAL LIVER FUNCTION TEST	19
OTHER: NERVE PAIN	20
OTHER: MENOPAUSE	20
LIVER DISEASE (EXCLUDING HEPATITIS): FATTY LIVER	20
SLEEP APNEA	20
OTHER: LEFT ANKLE FRACTURE	20
OTHER: LOW VITAMIN D	20

Prior Procedures	Procedure Year
SURGERY: MYOMECTOMY	20[redacted]
SURGERY: UMBILICAL HERNIA REPAIR	20

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
Not reported.				

Alcohol Use	Status	Number/Day
ALCOHOL	CURRENT	Less than 2

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
ABT-494	30MG	ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 160	160

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
DIPHENHYDRAMINE	25 mg	QD	Y-M: 19[redacted]
ETANERCEPT	50 mg	EVERY WEEK	Y-M: 19[redacted]
LISINOPRIL	40 mg	QD	Y-M: 19[redacted]
ADALIMUMAB	40 mg	EVERY 2 WEEKS	Y-M: 19[redacted]
SULFASALAZINE	1000 mg	BID	Y-M: 20[redacted]
INFLIXIMAB	UNKNOWN OTHER: UNKNOWN	OTHER: UNKNOWN	Y-M: 20[redacted]
AMLODIPINE	5 mg	QD	Y-M: 20[redacted]
GABAPENTIN	1200 mg	TID	Y-M: 20[redacted]
METOPROLOL	25 mg	QD	Y-M: 20[redacted]
USTEKINUMAB	90 mg	OTHER: EVERY 8 WEEKS	Y-M: 20[redacted]
METHOTREXATE	20 mg	EVERY WEEK	Y-M: 20[redacted]
HEPATITIS B IMMUNIZATION	NOT REPORTED	NOT REPORTED	Y-M: 20[redacted]-[redacted]
SECUKINUMAB	300 mg	OTHER: UNKNOWN	Y-M: 20[redacted]
IXEKIZUMAB	160 mg	EVERY 2 WEEKS	Y-M: 20[redacted]
GUSELKUMAB	100 mg	OTHER: EVERY 8 WEEKS	Y-M: 20[redacted]-[redacted]
ERGOCALCIFEROL	50000 IU	OTHER: EVERY MONTH	Y-M: 20[redacted]-[redacted] / -97

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
DIPHENHYDRAMINE	25 mg	QD	Y-M: 19[redacted]	ONGOING
LISINOPRIL	40 mg	QD	Y-M: 19[redacted]	ONGOING
AMLODIPINE	5 mg	QD	Y-M: 20[redacted]	ONGOING
GABAPENTIN	1200 mg	TID	Y-M: 20[redacted]	ONGOING
METOPROLOL	25 mg	QD	Y-M: 20[redacted]	ONGOING
ERGOCALCIFEROL	50000 IU	OTHER: EVERY MONTH	Y-M: 20[redacted] / -97	ONGOING
CEFUROXIME	500 mg	QD	Y-M: 20[redacted] / 62	Y-M: 20[redacted] / 67
LEVOFLOXACIN	750 mg	OTHER: ONCE	Y-M: 20[redacted] / 67	Y-M: 20[redacted] / 67
LEVOFLOXACIN	750 mg	QD	Y-M: 20[redacted] / 68	Y-M: 20[redacted] / 72
SALBUTAMOL	1 OTHER: PUFF	TID	Y-M: 20[redacted] / 68	Y-M: 20[redacted] / 74

Event #1: Serious Adverse Event

Event Description ACUTE HYPOXEMIC RESPIRATORY FAILURE

Preferred term 急性呼吸不全

AE Onset Date / Rx Day [redacted]20[redacted] / 67

Age at AE Onset 5[redacted]

Laboratory Testing

NOT REPORTED

Microbiology

NOT REPORTED

SAE Supplemental Procedure

[redacted]20[redacted] (RX DAY 67): CHEST COMPUTED TOMOGRAPHY ANGIOGRAPHY: NEGATIVE FOR PULMONARY EMBOLISM; CHEST X-RAY: NEGATIVE FOR INFILTRATE; OXYGEN THERAPY: TOLERATED; TEMPERATURE ONSET: 101.6 F

AE Stopped Rx Day 68

Duration of AE 2 DAYS

Relation to Study Drug by Investigator REASONABLE POSSIBILITY

Investigator Alternative Etiology NOT REPORTED

Discontinued Study Drug Due to the Event NO

SAE Criteria REQUIRES OR PROLONGS HOSPITALIZATION, OTHER MEDICALLY IMPORTANT SERIOUS EVENT

Generated: [redacted]

Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554

治験責任医師からの報告。本被験者は米国の 5[redacted] 歳女性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，急性低酸素血症性呼吸不全の事象を発現した。

Event 1 の臨床経過：

関連する病歴は季節性アレルギー，乾癬，現喫煙者（1 日 1 箱を 36 年間），現飲酒者（2 杯未満）であった。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は急性低酸素血症性呼吸不全を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，急性低酸素血症性呼吸不全は消失した。

20[redacted] 年 [redacted] 月 [redacted] 日以前から 20[redacted] 年 [redacted] 月 [redacted] 日，被験者は咽喉痛（非重篤）を発現した。20[redacted] 年 [redacted] 月 [redacted] 日から 20[redacted] 年 [redacted] 月 [redacted] 日まで，被験者は連鎖球菌性咽頭炎（非重篤）を発現した。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は，咳嗽，息切れ及び発熱のため，救急治療室を受診した。同日，被験者は，酸素投与，抗生物質の静脈内投与及びネブライザーによる治療のため，一晩入院した。診断検査が行われた。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は安定状態で退院した。

投与された薬剤は，levoquin 及び albuterol であった。

The patient's past medications include:

CIPROFLOXACIN for STREP THROAT ([redacted] 20[redacted] - [redacted] 20[redacted])

AUGMENTIN for STREP THROAT ([redacted] 20[redacted] - [redacted] 20[redacted])

CEFUROXIME for STREP THROAT ([redacted] 20[redacted] - [redacted] 20[redacted])

Causality for ABT-494 (Blinded)

---

1) Acute respiratory failure (10001053) (Acute respiratory failure (10001053)) [v.22.0] [10001053]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Yes

Rechallenge: rechallenge was done, reaction did not recur

Alternative Etiology for ABT-494 (Blinded)

Event of ACUTE HYPOXEMIC RESPIRATORY FAILURE

- Investigator: NOT APPLICABLE

- AbbVie: ETIOLOGY OF THE EVENT IS UNLIKELY RELATED TO STUDY DRUG'S MECHANISM OF ACTION. ADDITIONAL RISK FACTORS INCLUDE CURRENT SMOKING STATUS AND PRECEDING STREP THROAT.

Relevant Laboratory & Other Diagnostic Tests

[redacted] **20[redacted] CHEST COMPUTED TOMOGRAPHY ANGIOGRAPHY:** Negative for pulmonary embolism.

[redacted] **20[redacted] CHEST X-RAY:** Negative for infiltrate.

[redacted] **20[redacted] TEMPERATURE ONSET:** 101.6 F

被験者番号 [redacted] (Investigator [redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
ブドウ球菌感染性滑液包炎	X			X

Treatment Group	Age at Study Start	Sex	Race
Placebo/ABT-494 30 mg QD	6[redacted]	FEMALE	WHITE

Medical History	Onset Year
OTHER: BILATERAL WRIST PAIN	19[redacted]
OTHER: INSOMNIA	19
OTHER: POST MENOPAUSAL	20
DEPRESSION: MILD DEPRESSION	20
HYPERTENSION	20
OTHER: BILATERAL CARPAL TUNNEL	20
OTHER: LOWER BACK PAIN	20
OTHER: NECK PAIN	20
OTHER: PLAQUE PSORIASIS	20
GASTROESOPHAGEAL REFLUX DISEASE	20
INFLAMMATORY BOWEL DISEASE: NOT SYMPTOMATIC AT THIS TIME	20
OTHER: BENIGN HEPATIC LESION	20
OTHER: DIVERTICULOSIS	20
OTHER: LACTOSE INTOLERANT	20
OTHER: RIGHT ADRENAL ADENOMA	20
OTHER: HISTORY MICROSCOPIC C0LITIS	20[redacted]

Prior Procedures	Procedure Year
Not reported.	

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
Not reported.				

Alcohol Use	Status	Number/Day
ALCOHOL	NEVER	

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
PLACEBO		ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 80	80

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
HEPATITIS B IMMUNIZATION	NOT REPORTED	NOT REPORTED	Y-M: 19[redacted]
FLUOXETINE	20 mg	QD	Y-M: 20[redacted]
LISINOPRIL	10 mg	QD	Y-M: 20[redacted]
ADALIMUMAB	40 mg	EVERY 2 WEEKS	Y-M: 20[redacted]
FAMOTIDINE	20 mg	QD	Y-M: 20[redacted]
MULTIVITAMIN	1 OTHER: TAB	QD	Y-M: 20[redacted]
INFLIXIMAB	300 mg	OTHER: Q4W	Y-M: 20[redacted]
SECUKINUMAB	300 mg	OTHER: MONTHLY	Y-M: 20[redacted]
COLON HEALTH	1 OTHER: TAB	QD	Y-M: 20[redacted]
NAPROXEN	220 mg	PRN	Y-M: 20[redacted] / -53

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
LISINOPRIL	10 mg	QD	Y-M: 20[redacted]	ONGOING
FLUOXETINE	20 mg	QD	Y-M: 20[redacted]	Y-M: 20[redacted] / 83
FAMOTIDINE	20 mg	QD	Y-M: 20[redacted]	Y-M: 20[redacted] / 83
MULTIVITAMIN	1 OTHER: TAB	QD	Y-M: 20[redacted]	ONGOING
COLON HEALTH	1 OTHER: TAB	QD	Y-M: 20[redacted]	ONGOING
NAPROXEN	220 mg	PRN	Y-M: 20[redacted] / 53	Y-M: 20[redacted] / 83
PARACETAMOL	1000 mg	OTHER: Q6H	Y-M: 20[redacted] / 47	Y-M: 20[redacted] / 54
DOCUSATE	100 mg	BID	Y-M: 20[redacted] / 47	Y-M: 20[redacted] / 79
ACETYLSALICYLIC ACID	162 mg	BID	Y-M: 20[redacted] / 49	Y-M: 20[redacted] / 79
ERGOCALCIFEROL	1000 IU	QD	Y-M: 20[redacted] / 56	Y-M: 20[redacted] / 60
PARACETAMOL	1000 mg	BID	Y-M: 20[redacted] / 56	Y-M: 20[redacted] / 79
ERGOCALCIFEROL	2000 IU	QD	Y-M: 20[redacted] / 61	ONGOING
CEFALEXIN	500 mg	QID	Y-M: 20[redacted] / 79	Y-M: 20[redacted] / 80
OXYCOCET	5/325 mg	PRN	Y-M: 20[redacted] / 79	Y-M: 20[redacted] / 84
DOCUSATE	100 mg	BID	Y-M: 20[redacted] / 80	ONGOING
OMEPRAZOLE	40 mg	BID	Y-M: 20[redacted] / 80	ONGOING
CEPHALOSPORIN C	1 g	OTHER: Q8H	Y-M: 20[redacted] / 80	Y-M: 20[redacted] / 84
ONDANSETRON	4 mg	OTHER: Q8H	Y-M: 20[redacted] / 80	Y-M: 20[redacted] / 84
PARACETAMOL	650 mg	OTHER: Q6H	Y-M: 20[redacted] / 80	Y-M: 20[redacted] / 84
PNEUMOCOCCAL VACCINE	0.5 mL	OTHER: ONCE	Y-M: 20[redacted] / 82	Y-M: 20[redacted] / 82
FLUOXETINE	40 mg	QD	Y-M: 20[redacted] / 84	ONGOING
IBUPROFEN	600 mg	PRN	Y-M: 20[redacted] / 84	ONGOING
OXYCODONE	5 mg	OTHER: PRN	Y-M: 20[redacted] / 84	Y-M: 20[redacted] / 84
CEFALEXIN	500 mg	OTHER: Q6H	Y-M: 20[redacted] / 85	Y-M: 20[redacted] / 98

Event #1: Serious Adverse Event, Study Specific Adverse Events of Interest

Event Description ACUTE SEPTIC PREPATELLAR BURSITIS OF THE LEFT KNEE (MSSA)

Preferred term ブドウ球菌感染性滑液包炎

AE Onset Date / Rx Day [redacted]20[redacted] / 79

Age at AE Onset 6[redacted]

Laboratory Testing

[redacted]20[redacted] (RX DAY 49): Erythrocytes: 3.7 [4 - 5.1] 10^12/L; Platelets: 291 [130 - 350] 10^9/L; [redacted]20[redacted] (RX DAY 80): Hematocrit: 0.35 [0.33 - 0.44] fraction of 1; Hemoglobin: 113 [110 - 147] g/L; Leukocytes: 18.5 [4.1 - 9.3] 10^9/L; Lymphocytes/Leukocytes: 13 [28 - 42] %; Monocytes/Leukocytes: 10 [4 - 8.5] %; NPTST042-CRP: 253 [0 - 8] mg/L; NPTST113-PT: 11 [9.8 - 11.8] sec; Neutrophils/Leukocytes: 77 [41 - 67] %; [redacted]20[redacted] (RX DAY 82): Erythrocytes: 3 [4.5 - 5.1] 10^12/L; Hematocrit: 0.28 [0.33 - 0.44] fraction of 1; Hemoglobin: 92 [110 - 147] g/L; Leukocytes: 11.8 [4.1 - 9.3] 10^9/L; Lymphocytes/Leukocytes: 25 [28 - 42] %; Monocytes/Leukocytes: 8 [4 - 8.5] %; NPTST013-APTT: 25 [24 - 32] sec; NPTST113-PT: 10.1 [9.8 - 11.8] sec; Neutrophils/Leukocytes: 65 [41 - 67] %; Platelets: 276 [130 - 350] 10^9/L; [redacted]20[redacted] (RX DAY 84): Erythrocytes: 3.4 [4 - 5.1] 10^12/L; Hematocrit: 0.31 [0.33 - 0.44] fraction of 1; Hemoglobin: 101 [110 - 147] g/L; Leukocytes: 7.3 [4.1 - 9.3] 10^9/L; Lymphocytes/Leukocytes: 25 [28 - 42] %; Monocytes/Leukocytes:

12 [4 - 8.5] %; Neutrophils/Leukocytes: 61 [41 - 67] %; Platelets: 368 [130 - 350] 10^9/L

Microbiology

[redacted]20[redacted] (RX DAY 80): OTHER LEFT KNEE BURSA FLUID NPTST011-ANAEROBIC CULTURE ONLY: NEGATIVE-NO ANAEROBIC GROWTH AFTER 5 DAYS; OTHER LEFT KNEE BURSA FLUID NPTST047-CULTURE: NEGATIVE-NO GROWTH IN 5 DAYS; OTHER LEFT KNEE BURSA FLUID NPTST062-FLUID CULTURE AND SMEAR: POSITIVE-POLYMORPHONUCLEAR CELLS, NO ORGANISM SEEN; [redacted]20[redacted] (RX DAY 81): OTHER LEFT KNEE BURSA FLUID NPTST062-FLUID CULTURE AND SMEAR: POSITIVE-2+,POLYMORPHONUCLEAR CELLS; OTHER LEFT KNEE BURSA FLUID NPTST062-FLUID CULTURE AND SMEAR: POSITIVE-1+,STAPHYLOCOCCUS AUREUS, METHICILLIN SUSCEPTIBLE; OTHER LEFT KNEE BURSA FLUID NPTST062-FLUID CULTURE AND SMEAR: NEGATIVE-RARE GRAM POSITIVE COCCI; OTHER LEFT KNEE BURSA FLUID NPTST131-TISSUE CULTURE AND STAIN: POSITIVE-4+ POLYMORPHONUCLEAR CELLS, NO ORGANISM SEEN

SAE Supplemental Procedure

[redacted]20[redacted] (RX DAY 80): X-RAY LEFT KNEE: PREPATELLAR EDEMA, SMALL EFFUSION; 20[redacted] (RX DAY 81): ECG: NORMAL; IRRIGATION, DEBRIDEMENT AND EXCISION OF LEFT PREPATELLAR BURSA: SUBJECT IMPROVED

AE Stopped Rx Day	121 (41 DAYS AFTER LAST TREATMENT)
Duration of AE	43 DAYS
Relation to Study Drug by Investigator	NO REASONABLE POSSIBILITY
Investigator Alternative Etiology	SUBJECT RECENTLY HAD LEFT ANKLE REPAIR SURGERY. THIS AE MAY BE RELATED BUT LEFT ANKLE SURGERY SITE DID NOT SHOW SIGNS OF INFECTION.
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION, OTHER MEDICALLY IMPORTANT SERIOUS EVENT

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554

治験責任医師からの報告。本被験者は米国の 6[redacted] 歳女性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，左膝関節の急性化膿性膝蓋前滑液包炎（MSSA）の事象を発現した。

<u>Event 1 の臨床経過：</u>

関連する病歴は閉経後，両手根管，高血圧，乾癬性関節炎，炎症性腸疾患及び禁酒であった。

20[redacted] 年 [redacted] 月 [redacted] 日，左膝関節の急性化膿性膝蓋前滑液包炎（MSSA）を発現した。

20[redacted] 年 [redacted] 月 [redacted] 日以前に，被験者は左足関節三果骨折（非重篤）を発現した。

20[redacted] 年 [redacted] 月 [redacted] 日以降，左足関節三果骨折修復が軽快していた。20[redacted] 年 [redacted] 月 [redacted] 日，耐え難い左膝痛，紅斑，温感，腫脹及び発熱が認められた。20[redacted] 年 [redacted] 月 [redacted] 日，症状が悪化し，整形外科医は被験者に救急治療室の受診を勧めた。X 線検査により著しい膝蓋骨内滲出液が認められ，左膝関節のデブリードマンが行われた。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は入院した。再度，左膝関節の洗浄とデブリードマンが行われた。滑液包切除術も行われた。培養を行ったところ，メチシリン感受性黄色ブドウ球菌（MSSA）が検出された。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は退院した。

この被験者の治験参加は完全に中止された。20[redacted] 年 [redacted] 月 [redacted] 日，左膝関節の急性化膿性膝蓋前滑液包炎（MSSA）は消失した。

投与された薬剤は，ケフレックス，percocet，ゾシン，タイレノール，イブプロフェン，オキシコドン，セファロスポリン及びセファゾリン IV であった。

Causality for ABT-494 (Blinded)

---

1) Bursitis infectivetaphylococcal (10048894) (Bursitis infective staphylococcal (10048894)) [v.21.0] [10048894]

Causality as per reporter (Drug/Vaccine): No reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Yes

Rechallenge: No rechallenge was done, recurrence is not applicable

Alternative Etiology for ABT-494 (Blinded)

Event of ACUTE SEPTIC PREPATELLAR BURSITIS OF THE LEFT KNEE (MSSA)

- Investigator: The patient recently had left ankle repair surgery. This AE may be related but left ankle surgery site did not show signs of infection.

- AbbVie: The most common mechanisms involved in septic superficial bursitis consist of direct inoculation due to puncture of the overlying skin or contiguous spread from cellulitis. Additional risk factor includes recent ankle surgery.

Relevant Laboratory & Other Diagnostic Tests

[redacted] **20[redacted] ANAEROBIC CULTURE ONLY:** Negative: No anaerobic growth after 5 days

[redacted] **20[redacted] APTT:** 25 SEC (normal 9.8 to 32)

[redacted] **20[redacted] CRP:** 253 MG/L (normal 0 to 8)

[redacted] **20[redacted] CULTURE:** Negative: No growth in 5 days

[redacted] **20[redacted] ECG:** Normal

[redacted] **20[redacted] FLUID CULTURE AND SMEAR:** Positive: Polymorphonuclear cells, no organism seen

[redacted] **20[redacted] FLUID CULTURE AND SMEAR:** Positive: 2+, polymorphonuclear cells

[redacted] **20[redacted] FLUID CULTURE AND SMEAR:** Negative: Rare gram positive cocci

[redacted] **20[redacted] FLUID CULTURE AND SMEAR:** Positive: 1+, staphylococcus aureus, methicillin susceptible

[redacted] **20[redacted] HEMATOCRIT:** 34.7 % (normal 33.0 to 44.0)

[redacted] **20[redacted] HEMATOCRIT:** 28.2 % (normal 33.0 to 44.0)

[redacted] **20[redacted] HEMATOCRIT:** 31 % (normal 33.0 to 44.0)

[redacted] **20[redacted] HEMOGLOBIN:** 11.3 G/DL (normal 11.0 to 14.7)

[redacted] **20[redacted] HEMOGLOBIN:** 9.2 G/DL (normal 11.0 to 14.7)

[redacted] **20[redacted] HEMOGLOBIN:** 10.1 G/DL (normal 11.0 to 14.7)

[redacted] **20[redacted] LYMPHOCYTES %:** 13 % (normal 28 to 42)

[redacted] **20[redacted] LYMPHOCYTES %:** 25 % (normal 28 to 42)

[redacted] **20[redacted] LYMPHOCYTES %:** 25 % (normal 28 to 42)

[redacted] **20[redacted] MONOCYTES %:** 10 % (normal 4 to 8.5)

[redacted] **20[redacted] MONOCYTES %:** 8 % (normal 4 to 8.5)

[redacted] **20[redacted] MONOCYTES %:** 12 % (normal 4 to 8.5)

[redacted] **20[redacted] NEUTROPHILS %:** 77 % (normal 41 to 67)

[redacted] **20[redacted] NEUTROPHILS %:** 65 % (normal 41 to 67)

[redacted] **20[redacted] NEUTROPHILS %:** 61 % (normal 41 to 67)

[redacted] **20[redacted] PLATELET COUNT:** 291 10^3/uL (normal 130 to 350)

[redacted] **20[redacted] PLATELET COUNT:** 276 10^3/uL (normal 130 to 350)

[redacted] **20[redacted] PLATELET COUNT:** 368 10^3/uL (normal 130 to 350)

[redacted] **20[redacted] PT:** 11.0 SEC (normal 9.8 to 11.8)

[redacted] **20[redacted] PT:** 10.1 SEC (normal 9.8 to 11.8)

[redacted] **20[redacted] RED BLOOD CELLS:** 3.65 10^6/uL (normal 4.00 to 5.1)

[redacted] **20[redacted] RED BLOOD CELLS:** 2.99 10^6/uL (normal 4.00 to 5.1)

[redacted] **20[redacted] RED BLOOD CELLS:** 3.35 10^6/uL (normal 4.00 to 5.1)

[redacted] **20[redacted] TISSUE CULTURE AND STAIN:** Positive: 4+ polymorphonuclear cells, no organism seen

[redacted] **20[redacted] WHITE BLOOD CELLS:** 18.5 10^3/uL (normal 4.1 to 9.3)

[redacted] **20[redacted] WHITE BLOOD CELLS:** 11.8 10^3/uL (normal 4.1 to 9.3)

[redacted] **20[redacted] WHITE BLOOD CELLS:** 7.3 10^3/uL (normal 4.1 to 9.3)

[redacted] **20[redacted] X-RAY LEFT KNEE:** Prepatellar edema, small effusion

被験者番号 [redacted] (Investigator [redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
腎結石症	X			
側腹部痛	X			

Treatment Group	Age at Study Start	Sex	Race
ABT-494 15 mg QD	4[redacted]	MALE	WHITE

Medical History	Onset Year
OTHER: PLAQUE PSORIASIS	19[redacted]
OTHER: DIARRHEA OCCASIONAL	19
GASTROESOPHAGEAL REFLUX DISEASE	20
OTHER: TOE FUNGUS	20
OTHER: TRANSAMINITIS	20
OTHER: ANXIETY INTERMITTENT	20
OTHER: SICCA SYNDROME OCCASIONAL	20
OTHER: HEADACHES INTERMITTENT	20
OTHER: SEBACEOUS CYST IN LEFT ARMPIT	20

Prior Procedures	Procedure Year
Not reported.	

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
Not reported.				

Alcohol Use	Status	Number/Day
ALCOHOL	CURRENT	Less than 2

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
ABT-494	15MG	ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 167	167
ABT-494	15MG	ORAL	QD	[redacted]20[redacted] / 168	[redacted]20[redacted] / 385	218
ABT-494	15MG	ORAL	QD	[redacted]20[redacted] / 386	/	

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
CELECOXIB	100 mg	BID	Y-M: 19[redacted]
ROFECOXIB	50 mg	QD	Y-M: 20[redacted]
HYDROCORTISONE	1 OTHER: APP	QD	Y-M: 20[redacted]
DICLOFENAC	100 ng	QD	Y-M: 20[redacted]
INFLIXIMAB	500 mg	OTHER: Q6WK	Y-M: 20[redacted]
ESOMEPRAZOLE	40 mg	QD	Y-M: 20[redacted]
ESCITALOPRAM	10 mg	QD	Y-M: 20[redacted]
ASCORBIC ACID	500 mg	QD	Y-M: 20[redacted]
ERGOCALCIFEROL	25 ug	QD	Y-M: 20[redacted]
ADALIMUMAB	40 mg	EVERY 2 WEEKS	Y-M: 20[redacted]
SULFASALAZINE	3000 mg	QD	Y-M: 20[redacted]
PREDNISONE	10 mg	QD	Y-M: 20[redacted]
FOLIC ACID	1 mg	QD	Y-M: 20[redacted]
METHOTREXATE	7.5 mg	EVERY WEEK	Y-M: 20[redacted]
EFINACONAZOLE	1 OTHER: APP	QD	Y-M: 20[redacted]
SECUKINUMAB	300 mg	OTHER: MONTHLY	Y-M: 20[redacted]
IBUPROFEN	400 mg	PRN	Y-M: 20[redacted]
METHOTREXATE	12.5 mg	EVERY WEEK	Y-M: 20[redacted]
METHOTREXATE	15 mg	EVERY WEEK	Y-M: 20[redacted] / -255
PANTOPRAZOLE	40 mg	QD	Y-M: 20[redacted] / -183
MOMETASONE	1 OTHER: APP	QD	Y-M: 20[redacted] / -139
LORAZEPAM	1 mg	PRN	Y-M: 20[redacted] / -50
CEFALEXIN	500 mg	OTHER: 4 TIMES/DAY	Y-M: 20[redacted] / -35
CELECOXIB	200 mg	BID	Y-M: 20[redacted] / -29
DESONIDE	1 OTHER: APP	OTHER: BID PRN	Y-M: 20[redacted] / -8

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO	Dose/Units	Frequency	Start Year-Month	Stop Year-Month /

Drug)			/ RX Day	RX Day
ASCORBIC ACID	500 mg	QD	Y-M: 20[redacted]	Not reported.
ERGOCALCIFEROL	25 ug	QD	Y-M: 20[redacted]	Not reported.
FOLIC ACID	1 mg	QD	Y-M: 20[redacted]	Not reported.
EFINACONAZOLE	1 OTHER: APP	QD	Y-M: 20[redacted]	Not reported.
METHOTREXATE	15 mg	EVERY WEEK	Y-M: 20[redacted] / -255	Y-M: 20[redacted] / 313
PANTOPRAZOLE	40 mg	QD	Y-M: 20[redacted] / -183	Not reported.
LORAZEPAM	1 mg	PRN	Y-M: 20[redacted] / -50	Y-M: 20[redacted] / -1
CELECOXIB	200 mg	BID	Y-M: 20[redacted] / -29	Y-M: 20[redacted] / 455
DESONIDE	1 OTHER: APP	OTHER: BID PRN	Y-M: 20[redacted] / -8	Not reported.
CIPROFLOXACIN	500 mg	BID	Y-M: 20[redacted] / 13	Y-M: 20[redacted] / 19
TAMSULOSIN	0.4 mg	QD	Y-M: 20[redacted] / 13	Y-M: 20[redacted] / 28
ULTRACET	2 OTHER: TABLET	PRN	Y-M: 20[redacted] / 13	Y-M: 20[redacted] / 28
CIPROFLOXACIN	500 mg	BID	Y-M: 20[redacted] / 56	Y-M: 20[redacted] / 62

Event #1: Serious Adverse Event

Event Description	STONE IN RIGHT KIDNEY
Preferred term	腎結石症
AE Onset Date / Rx Day	[redacted]20[redacted] / 12
Age at AE Onset	4[redacted]

Laboratory Testing
NOT REPORTED

Microbiology
NOT REPORTED

SAE Supplemental Procedure
[redacted]20[redacted] (RX DAY 14): INSERTION OF RENAL STENT: SUCCESSFUL INSERTION.; LAPAROSCOPIC SURGICAL REMOVAL OF RENAL CALCULI: SUCCESSFUL REMOVAL OF RENAL CALCULI

AE Stopped Rx Day	16
Duration of AE	5 DAYS
Relation to Study Drug by Investigator	NO REASONABLE POSSIBILITY
Investigator Alternative Etiology	UNKNOWN AT THIS TIME
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Event #2: Serious Adverse Event

Event Description	RIGHT SIDE FLANK PAIN
Preferred term	側腹部痛
AE Onset Date / Rx Day	[redacted]20[redacted] / 47

Age at AE Onset	4[redacted]

Laboratory Testing
NOT REPORTED

Microbiology
NOT REPORTED

SAE Supplemental Procedure
[redacted]20[redacted] (RX DAY 56): SURGICAL REMOVAL OF RENAL STENT.: SUCCESSFUL REMOVAL OF RENAL STENT.

AE Stopped Rx Day	56
Duration of AE	10 DAYS
Relation to Study Drug by Investigator	NO REASONABLE POSSIBILITY
Investigator Alternative Etiology	PATIENT HAS TEMPORARY STENT IN RIGHT KIDNEY
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION, OTHER MEDICALLY IMPORTANT SERIOUS EVENT

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554

治験責任医師からの報告。本被験者はカナダの 4[redacted] 歳男性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，右腎結石及び右側腹部痛の事象を発現した。

Event 1 及び 2 の臨床経過：

関連する病歴は局面型乾癬，乾癬性関節炎，間欠熱，紙巻タバコ喫煙者（1 日 0.75 箱を 13 年間）及び現飲酒者（1 日 2 杯未満）であった。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は右腎結石を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，右腎結石は消失した。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は右側腹部痛を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，右側腹部痛は消失した。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は，極度の腰痛及び排尿困難により，救急治療室を受診した。被験者は腎結石と診断された。20[redacted] 年 [redacted] 月 [redacted] 日，腹腔鏡下腎結石摘出術及び腎ステント挿入が行われた。手術は成功した。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は退院した。

20[redacted]年[redacted]月[redacted]日，被験者は右側腹部痛のため入院した。20[redacted]年[redacted]月[redacted]日，腎ステントが無事抜去された。20[redacted]年[redacted]月[redacted]日，被験者は退院した。被験者には腎結石の既往歴があったことが治験責任医師から報告された。

投与された薬剤は，tramacet，タムスロシン及びシプロフロキサシンであった。

Causality for ABT-494 (Blinded)

---

1) Kidney stone (10023436) (Nephrolithiasis (10029148)) [v.20.1] [10023436]

Causality as per reporter (Drug/Vaccine): No reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Not Applicable

2) Flank pain (10016750) (Flank pain (10016750)) [v.20.1] [10016750]

Causality as per reporter (Drug/Vaccine): No reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Not Applicable

Alternative Etiology for ABT-494 (Blinded)

Event of STONE IN RIGHT KIDNEY

- Investigator: Unknown at this time.

- AbbVie: Weak temporal association with only 2 week exposure to study drug. Calculi were likely pre-existing. Obesity is an additional risk factor.

Event of RIGHT SIDE FLANK PAIN

- Investigator: Patient has temporary stent in right kidney

- AbbVie: Event more likely a complication of recent renal calculi and recent stent placement

被験者番号 [redacted] (Investigator [redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
肛門性器疣贅	X			X

Treatment Group	Age at Study Start	Sex	Race
ABT-494 30 mg QD	5[redacted]	MALE	ASIAN

Medical History	Onset Year
OTHER: POLLINOSIS	NOT REPORTED
OTHER: CHICKENPOX	19[redacted]
HYPERTENSION	20[redacted]
OTHER: PLAQUE PSORIASIS	20[redacted]
OTHER: INTERSTITIAL PNEUMONIA	20[redacted]
OTHER: GINGIVITIS	20[redacted]
OTHER: LATENT TUBERCULOSIS	20[redacted]

Prior Procedures	Procedure Year
Not reported.	

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
Not reported.				

Alcohol Use	Status	Number/Day
ALCOHOL	CURRENT	Less than 2

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
ABT-494	30MG	ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 167	167
ABT-494	30MG	ORAL	QD	[redacted]20[redacted] / 168	[redacted]20[redacted] / 391	224
ABT-494	30MG	ORAL	QD	[redacted]20[redacted] / 392	/	

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
BCG Vaccine	NOT REPORTED	NOT REPORTED	Y-M: 19[redacted]
CANDESAR A	1 OTHER: TABLET	QD	Y-M: 20[redacted]
BETAMETHASONE	1 OTHER: APPLICATION	BID	Y-M: 20[redacted]
DIFLUPREDNATE	1 OTHER: APPLICATION	BID	Y-M: 20[redacted]
INDOMETACIN	25 mg	BID	Y-M: 20[redacted]
MAXACALCITOL	1 OTHER: APPLICATION	BID	Y-M: 20[redacted]
ADALIMUMAB	80 mg	EVERY 2 WEEKS	Y-M: 20[redacted]
ADALIMUMAB	40 mg	EVERY 2 WEEKS	Y-M: 20[redacted]
FAMOTIDINE	150 mg	BID	Y-M: 20[redacted] / -296
LOXOPROFEN	60 mg	TID	Y-M: 20[redacted] / -296
BETAMETHASONE	1 OTHER: APPLICATION	BID	Y-M: 20[redacted] / -282
DAIVOBET	1 OTHER: APPLICATION	BID	Y-M: 20[redacted] / -282
MELOXICAM	10 mg	QD	Y-M: 20[redacted] / -282
SECUKINUMAB	300 mg	EVERY WEEK	Y-M: 20[redacted] / -258
APREMILAST	30 mg	BID	Y-M: 20[redacted] / -174
ISONIAZID	150 mg	BID	Y-M: 20[redacted] / -21
PYRIDOXINE	0.25 g	BID	Y-M: 20[redacted] / -21
CEFDINIR	100 mg	BID	Y-M: 20[redacted] / -15

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
CANDESAR A	1 OTHER: TABLET	QD	Y-M: 20[redacted]	Not reported.
CARBAZOCHROME	30 mg	QD	Y-M: 20[redacted] /	Not reported.

HEMONASE	1 OTHER: TABLET	BID	Y-M: 20[redacted] / 384	Not reported.
FEXOFENADINE	60 mg	PRN	Y-M: 20[redacted] / 384	Not reported.
AMENAMEVIR	200 mg	QD	Y-M: 20[redacted] / 392	Y-M: 20[redacted] / 589
VIDARABINE	1 OTHER: APPLICATION	BID	Y-M: 20[redacted] / 589	Y-M: 20[redacted] / 595
LOXOPROFEN	60 mg	PRN	Y-M: 20[redacted] / 589	Y-M: 20[redacted] / 595
PARACETAMOL	300 mg	PRN	Y-M: 20[redacted] / 589	Y-M: 20[redacted] / 601
VONOPRAZAN	10 mg	QD	Y-M: 20[redacted] / 589	Y-M: 20[redacted] / 601
LOXOPROFEN	60 mg	PRN	Y-M: 20[redacted] / 594	Y-M: 20[redacted] / 596
PARACETAMOL	300 mg	PRN	Y-M: 20[redacted] / 601	Not reported.
				Not reported.

Event #1: Serious Adverse Event, Study Specific Adverse Events of Interest

Event Description	CONDYLOMA
Preferred term	肛門性器疣贅
AE Onset Date / Rx Day	[redacted]20[redacted] / 365
Age at AE Onset	5[redacted]

Laboratory Testing

NOT REPORTED

Microbiology

NOT REPORTED

SAE Supplemental Procedure

[redacted]20[redacted] (RX DAY 384): DUE TO THE CONDILOMA, HE WAS ADDMITED TO THE OTHER HOSIPITAL.THE CONDYLOMA WAS RESECTED.: THE LESION DISAPPERAED AFTER THE RESECTION.

AE Stopped Rx Day	392
Duration of AE	28 DAYS
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	NOT REPORTED
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554

治験責任医師からの報告。本被験者は日本の 5[redacted] 歳男性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，コンジローマの事象を発現した。

Event 1 の臨床経過：

関連する病歴は元喫煙者（1 日 1 箱を 10 年間），局面型乾癬，乾癬性関節炎及び現飲酒者（1 日 2 杯未満）であった。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者はコンジローマを発現した。20[redacted] 年 [redacted] 月 [redacted] 日，コンジローマは消失した。

被験者は，最初の 24 週間，本治験の盲検プラセボ対照期に組み入れられていた。20[redacted] 年 [redacted] 月 [redacted] 日，ABT-494 の盲検投与が開始された。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は肛門周囲の疼痛及び腫脹を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は入院し，コンジローマ切除術を受けた。手術は成功した。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は退院した。

投与された薬剤は，アドナ及びヘモナーゼであった。

The patient's past medications include:

ANTEBATE for PSORIASIS ([redacted] 20[redacted] - [redacted] 20[redacted], [redacted] 20[redacted] - [redacted] 20[redacted])

INTEBAN for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

MYSER for PSORIASIS ([redacted] 20[redacted] - [redacted] 20[redacted])

OXAROL for PSORIASIS ([redacted] 20[redacted] - [redacted] 20[redacted])

HUMIRA for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted], [redacted] 20[redacted] - [redacted] 20[redacted])

LOXOPROFEN for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

DOVOBET for PSORIASIS ([redacted] 20[redacted] - [redacted] 20[redacted])

MOBIC for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

COSENTYX for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

OTEZLA for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

Causality for UPADACITINIB (Blinded)

---

1) Condyloma (10053433) (Anogenital warts (10059313)) [v.22.0] [10053433]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Yes

Rechallenge: rechallenge was done, reaction did not recur

Alternative Etiology for UPADACITINIB (Blinded)

Event of CONDYLOMA

- Investigator: NOT APPLICABLE

- AbbVie: EVENT'S ETIOLOGY MORE LIKELY RELATED TO HPV INFECTION WHICH IS COMMON IN THE GENERAL POPULATION.

被験者番号 [redacted] (Investigator [redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
尿路感染	X	X		X
卵巣癌	X			X

Treatment Group	Age at Study Start	Sex	Race
ABT-494 30 mg QD	5[redacted]	FEMALE	ASIAN

Medical History	Onset Year
OTHER: DYSMENORRHOEA	NOT REPORTED
OTHER: POLLINOSIS	19[redacted]
OTHER: VARICELLA	19[redacted]
OTHER: PSORIASIS VULGARIS	19[redacted]
OTHER: SINUSITIS	20[redacted]
OTHER: JOINT FLUID DRAINAGE	20[redacted]
ANEMIA: IRON DEFICIENCY	20[redacted]

Prior Procedures	Procedure Year
SURGERY: ADENOTONSILLECTOMY	19[redacted]
SURGERY: SYNOVECTOMY	19[redacted]

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
Not reported.				

Alcohol Use	Status	Number/Day
ALCOHOL	CURRENT	Less than 2

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
ABT-494	30MG	ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 99	99

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
BCG Vaccine	NOT REPORTED	NOT REPORTED	Y-M: 19[redacted]
CICLOSPORIN	50 mg	BID	Y-M: 20[redacted]-
CLOBETASOL	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted]-
INFLIXIMAB	350 mg	OTHER: ONCE DOSE	Y-M: 20[redacted]-
INFLIXIMAB	480 mg	OTHER: EVERY 2 MONTHS	Y-M: 20[redacted]-
BETAMETHASONE	1 OTHER: APPLICATION	OTHER: ONCE DOSE	Y-M: 20[redacted]-
LIDOCAINE	1 OTHER: APPLICATION	OTHER: ONCE DOSE	Y-M: 20[redacted]-
PREDNISOLONE	5 mg	TID	Y-M: 20[redacted]-
PREDNISOLONE	5 mg	QD	Y-M: 20[redacted]-
BETAMETHASONE	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted]-
MAXACALCITOL	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted]-
METHOTREXATE	4 mg	EVERY WEEK	Y-M: 20[redacted]-
FLURBIPROFEN	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted]-
LOXOPROFEN	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted]-
HYDROCORTISONE	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted]-
BETAMETHASONE BUTYRATE PROPIONATE W/MAXACALCI	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted]-
MAXACALCITOL	1 OTHER: 1	OTHER: APPLICATION	Y-M: 20[redacted]-
TACALCITOL	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted]-
LOXOPROFEN	60 mg	PRN	Y-M: 20[redacted]
IXEKIZUMAB	160 mg	OTHER: ONCE DOSE	Y-M: 20[redacted]- / -202
IXEKIZUMAB	80 mg	EVERY 2 WEEKS	Y-M: 20[redacted]- / -166
TEPRENONE	100 mg	BID	Y-M: 20[redacted]- / -166

LOXOPROFEN	60 mg	PRN	Y-M: 20[redacted]- / -152
IXEKIZUMAB	80 mg	OTHER: ONCE DOSE	Y-M: 20[redacted]- / -68

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
LOXOPROFEN	60 mg	PRN	Y-M: 20[redacted]- / -152	Y-M: 20[redacted]- / 73
IRON	100 mg	QD	Y-M: 20[redacted]- / 15	Y-M: 20[redacted]- / 29
PENCICLOVIR	500 mg	TID	Y-M: 20[redacted]- / 45	Y-M: 20[redacted]- / 51
PREGABALIN	25 mg	QD	Y-M: 20[redacted]- / 45	Y-M: 20[redacted]- / 51
NADIFLOXACIN	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted]- / 45	Y-M: 20[redacted]- / 66
MECOBALAMIN	500 ug	TID	Y-M: 20[redacted]- / 45	Y-M: 20[redacted]- / 87
NEUROTONIC	2 OTHER: TABLET	PRN	Y-M: 20[redacted]- / 45	Y-M: 20[redacted]- / 87
PREGABALIN	50 mg	QD	Y-M: 20[redacted]- / 52	Y-M: 20[redacted]- / 57
ACICLOVIR	1 OTHER: APPLICATION	OTHER: 5 TIMES A DAY	Y-M: 20[redacted]- / 52	Y-M: 20[redacted]- / 66
BETAMETHASONE	1 OTHER: APPLICATION	QID	Y-M: 20[redacted]- / 52	Y-M: 20[redacted]- / 66
CLINDAMYCIN	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted]- / 52	Y-M: 20[redacted]- / 66
TEPRENONE	50 mg	PRN	Y-M: 20[redacted]- / 66	Y-M: 20[redacted]- / 100
LIDOCAINE	1 mL	EVERY WEEK	Y-M: 20[redacted]- / 72	Y-M: 20[redacted]- / 100
LIDOCAINE	7 mL	EVERY WEEK	Y-M: 20[redacted]- / 72	Y-M: 20[redacted]- / 100
LOXOPROFEN	60 mg	PRN	Y-M: 20[redacted]- / 74	Y-M: 20[redacted]- / 112
REBAMIPIDE	100 mg	PRN	Y-M: 20[redacted]- / 101	ONGOING
CEFTRIAXONE	2 g	QD	Y-M: 20[redacted]- / 101	Y-M: 20[redacted]- / 101
RINGER-LACTATE	500 mL	QD	Y-M: 20[redacted]- / 101	Y-M: 20[redacted]- / 101
PHYSIO 140	500 mL	TID	Y-M: 20[redacted]- / 101	Y-M: 20[redacted]- / 102

CARBOHYDRATES NOS W/POTASSIUM CHLORIDE/SODIUM	500 mL	QD	Y-M: 20[redacted] / 102 - Y-M: 20[redacted] / 102
CEFTRIAXONE	1 g	BID	Y-M: 20[redacted] / 102 - Y-M: 20[redacted] / 104
TRIFLUID	500 mL	QD	Y-M: 20[redacted] / 102 - Y-M: 20[redacted] / 105
ASCORBIC ACID	500 mg	QD	Y-M: 20[redacted] / 102 - Y-M: 20[redacted] / 118
VITAMEDIN	1 OTHER: APPLICATION	QD	Y-M: 20[redacted] / 102 - Y-M: 20[redacted] / 118
AMINO ACIDS NOS W/ELECTROLYTES NOS/GLUCOSE/TH	1000 mL	QD	Y-M: 20[redacted] / 102 - Y-M: 20[redacted] / 122
SENNOSIDE A+B	24 mg	PRN	Y-M: 20[redacted] / 104 - ONGOING
PIP/TAZO	4.5 g	TID	Y-M: 20[redacted] / 104 - Y-M: 20[redacted] / 108
GLYCEROL	30 g	PRN	Y-M: 20[redacted] / 108 - Y-M: 20[redacted] / 108
MEROPENEM	0.5 g	BID	Y-M: 20[redacted] / 108 - Y-M: 20[redacted] / 108
MEROPENEM	0.5 g	TID	Y-M: 20[redacted] / 109 - Y-M: 20[redacted] / 112
DIMETICONE	5 mL	OTHER: ONCE DOSE	Y-M: 20[redacted] / 112 - Y-M: 20[redacted] / 112
LIDOCAINE	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted] / 112 - Y-M: 20[redacted] / 112
LIDOCAINE	5 mL	OTHER: ONCE DOSE	Y-M: 20[redacted] / 112 - Y-M: 20[redacted] / 112
PRONASE	20000 OTHER: UNIT/KG	OTHER: ONCE DOSE	Y-M: 20[redacted] / 112 - Y-M: 20[redacted] / 112
SODIUM BICARBONATE	1 g	OTHER: ONCE DOSE	Y-M: 20[redacted] / 112 - Y-M: 20[redacted] / 112
LOXOPROFEN	60 mg	PRN	Y-M: 20[redacted] / 113 - ONGOING
PARACETAMOL	1000 mg	OTHER: ONCE DOSE	Y-M: 20[redacted] / 113 - Y-M: 20[redacted] / 113
IOPAMIDOL	100 mL	OTHER: ONCE DOSE	Y-M: 20[redacted] / 114 - Y-M: 20[redacted] / 114
MICAFUNGIN	150 mg	QD	Y-M: 20[redacted] / 114 - Y-M: 20[redacted] / 120
ESOMEPRAZOLE	20 mg	QD	Y-M: 20[redacted] / 115 - Y-M: 20[redacted] / 121
TRIFLUID	1000 mL	QD	Y-M: 20[redacted] / 116 - Y-M: 20[redacted] / 122
BENZETHONIUM	10 mL	OTHER: ONCE DOSE	Y-M: 20[redacted] / 121 - Y-M: 20[redacted] / 121
ALBUMIN HUMAN	12.5 g	PRN	Y-M: 20[redacted] - Y-M: 20[redacted]

			[redacted] / 122 / 122
ANTITHROMBIN III	1500 IU	OTHER: ONCE DOSE	Y-M: 20[redacted]- Y-M: 20[redacted]- [redacted] / 122 / 122
ATROPINE	0.5 mg	OTHER: ONCE DOSE	Y-M: 20[redacted]- Y-M: 20[redacted]- [redacted] / 122 / 122
CALCIUM GLUCONATE	10 mL	OTHER: ONCE DOSE	Y-M: 20[redacted]- Y-M: 20[redacted]- [redacted] / 122 / 122
DEXAMETHASONE	6.6 mg	OTHER: ONCE DOSE	Y-M: 20[redacted]- Y-M: 20[redacted]- [redacted] / 122 / 122
DICLOFENAC	25 mg	PRN	Y-M: 20[redacted]- Y-M: 20[redacted]- [redacted] / 122 / 122
EPHEDRINE	4 mg	OTHER: ONCE DOSE	Y-M: 20[redacted]- Y-M: 20[redacted]- [redacted] / 122 / 122
GLUCOSE INJECTION	10 mL	OTHER: ONCE DOSE	Y-M: 20[redacted]- Y-M: 20[redacted]- [redacted] / 122 / 122
GLYCEROL	60 mL	OTHER: ONCE DOSE	Y-M: 20[redacted]- Y-M: 20[redacted]- [redacted] / 122 / 122
HETASTARCH	500 mL	QD	Y-M: 20[redacted]- Y-M: 20[redacted]- [redacted] / 122 / 122
INSULIN HUMAN	1 IU	OTHER: ONCE DOSE	Y-M: 20[redacted]- Y-M: 20[redacted]- [redacted] / 122 / 122
LEVOBUPIVACAINE	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted]- Y-M: 20[redacted]- [redacted] / 122 / 122
LIDOCAINE	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted]- Y-M: 20[redacted]- [redacted] / 122 / 122
PARACETAMOL	1000 mg	QD	Y-M: 20[redacted]- Y-M: 20[redacted]- [redacted] / 122 / 122
PHENYLEPHRINE	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted]- Y-M: 20[redacted]- [redacted] / 122 / 122
PHYSIO 140	1000 mL	QD	Y-M: 20[redacted]- Y-M: 20[redacted]- [redacted] / 122 / 122
PROPOFOL	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted]- Y-M: 20[redacted]- [redacted] / 122 / 122
RED BLOOD CELLS	400 mL	PRN	Y-M: 20[redacted]- Y-M: 20[redacted]- [redacted] / 122 / 122
REMIFENTANIL	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted]- Y-M: 20[redacted]- [redacted] / 122 / 122
ROCURONIUM	60 mg	PRN	Y-M: 20[redacted]- Y-M: 20[redacted]- [redacted] / 122 / 122
SEVOFLURANE	3 %	OTHER: CONTINUOUS	Y-M: 20[redacted]- Y-M: 20[redacted]- [redacted] / 122 / 122
SUGAMMADEX	200 mg	OTHER: ONCE DOSE	Y-M: 20[redacted]- Y-M: 20[redacted]- [redacted] / 122 / 122
FENTANYL	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted]- Y-M: 20[redacted]- [redacted] / 122 / 123
CARBOHYDRATES NOS W/POTASSIUM CHLORIDE/SODIUM	500 mL	QID	Y-M: 20[redacted]- Y-M: 20[redacted]- [redacted] / 122 / 124
CEFAZOLIN	1 g	BID	Y-M: 20[redacted]- Y-M: 20[redacted]- [redacted]

ENOXAPARIN	2000 IU	BID	[redacted] / 122 / 124 Y-M: 20[redacted] - Y-M: 20[redacted]
CARBOCISTEINE	500 mg	TID	[redacted] / 124 / 124 Y-M: 20[redacted] - Y-M: 20[redacted]
MAGNESIUM OXIDE	330 mg	TID	[redacted] / 124 / 127 Y-M: 20[redacted] - ONGOING
BENZETHONIUM	10 mL	OTHER: ONCE DOSE	[redacted] / 126 Y-M: 20[redacted] - Y-M: 20[redacted]
BENZETHONIUM	10 mL	OTHER: ONCE DOSE	[redacted] / 128 / 128 Y-M: 20[redacted] - Y-M: 20[redacted]
CEFACLOR	250 mg	TID	[redacted] / 129 / 129 Y-M: 20[redacted] - Y-M: 20[redacted]
			[redacted] / 129 / 132

Event #3: Serious Adverse Event, AE Leading to Discontinuation of Study Drug, Study Specific Adverse Events of Interest

Event Description	URINARY TRACT INFECTION
Preferred term	尿路感染
AE Onset Date / Rx Day	[redacted]20[redacted] / 83
Age at AE Onset	5[redacted]

Laboratory Testing

[redacted]20[redacted] (RX DAY 101): Blood: 2+ [-1 - 0] UNIT NOT REPORTED; Creatinine: 43.32 [35.36 - 70.72] umol/L; Erythrocytes: 25 [0 - 4] /HPF; Leukocytes: 55 [0 - 5] /HPF; Leukocytes: 9.8 [3.5 - 8.5] 10^9/L; NPTST001- BACTERIUM: 1+ [NOT REPORTED - NOT REPORTED] UNIT NOT REPORTED; NPTST042-CRP: 26.34 [0 - 0.3] mg/dL; Protein: 2+ [-1 - 0] UNIT NOT REPORTED; [redacted]20[redacted] (RX DAY 104): Creatinine: 38.01 [35.36 - 70.72] umol/L; Erythrocytes: 22 [0 - 4] /HPF; Leukocytes: 11 [0 - 5] /HPF; Leukocytes: 8.5 [3.5 - 8.5] 10^9/L; NPTST019-BACTERIUM: 1+ [NOT REPORTED - NOT REPORTED] UNIT NOT REPORTED; NPTST042-CRP: 26.1 [0 - 0.3] mg/dL; NPTST065-GRANULAR CASTS: 1+ [NOT REPORTED - NOT REPORTED] UNIT NOT REPORTED; [redacted]20[redacted] (RX DAY 107): Blood: ? [-1 - 0] UNIT NOT REPORTED; Creatinine: 36.25 [35.36 - 70.72] umol/L; Erythrocytes: 19 [0 - 4] /HPF; Leukocytes: 1 [0 - 5] /HPF; Leukocytes: 8.7 [3.5 - 8.5] 10^9/L; NPTST042-CRP: 28 [0 - 0.3] mg/dL; Protein: ? [-1 - 0] UNIT NOT REPORTED; [redacted]20[redacted] (RX DAY 112): Creatinine: 38.9 [35.36 - 70.72] umol/L; Leukocytes: 9.7 [3.5 - 8.5] 10^9/L; NPTST042-CRP: 34 [0 - 0.3] mg/dL

Microbiology

NOT REPORTED

SAE Supplemental Procedure

NOT REPORTED

AE Stopped Rx Day	113 (14 DAYS AFTER LAST TREATMENT)
Duration of AE	31 DAYS
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	NOT REPORTED
Discontinued Study Drug Due to the Event	YES
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Event #4: Serious Adverse Event, Study Specific Adverse Events of Interest

Event Description	OVARY CANCER
Preferred term	卵巣癌
AE Onset Date / Rx Day	[redacted]20[redacted] / 113 (14 DAYS AFTER LAST TREATMENT)
Age at AE Onset	5[redacted]

Laboratory Testing

[redacted]20[redacted] (RX DAY 101): Erythrocyte Sedimentation Rate: 96.2 [0 - 15] mm/h; Leukocytes: 9.8 [3.5 - 8.5] 10^9/L; NPTST012-ANTIGEN OF LEGIONELLA: ? [NOT REPORTED - NOT REPORTED] UNIT NOT REPORTED; NPTST042-CRP: 26.3 [0 - 0.3] mg/dL; NPTST106-PNEUMOCOCCUS: ? [NOT REPORTED - NOT REPORTED] UNIT NOT REPORTED; [redacted]20[redacted] (RX DAY 105): NPTST031-C3: 153 [69 - 128] mg/dL; NPTST032-C4: 21 [14 - 36] mg/dL; NPTST038-CH50: 67 [30 - 50] U/mL; NPTST067-HAPTOGLOBIN: 466 [19 - 170] mg/dL; [redacted]20[redacted] (RX DAY 107): Erythrocyte Sedimentation Rate: 90.9 [0 - 15] mm/h; Leukocytes: 8.7 [3.5 - 8.5] 10^9/L; NPTST042-CRP: 28 [0 - 0.3] mg/dL; [redacted]20[redacted] (RX DAY 108): Erythrocyte Sedimentation Rate: 114.4 [0 - 15] mm/h; Leukocytes: 8.3 [3.5 - 8.5] 10^9/L; NPTST003-?-D GLUCAN: LESS THAN 6.0 [NOT REPORTED - 11] UNIT NOT REPORTED; NPTST018-ASO: 258 [0 - 200] IU/mL; NPTST033-C7HRP: ? [NOT REPORTED - NOT REPORTED] UNIT NOT REPORTED; NPTST042-CRP: 27.3 [0 - 0.3] mg/dL; NPTST074-HTLV-1: LESS THAN 16 [NOT REPORTED - 16] UNIT

NOT REPORTED; [redacted]20[redacted] (RX DAY 112): Erythrocyte Sedimentation Rate: 103.2 [0 - 15] mm/h; Leukocytes: 9.7 [3.5 - 8.5] 10^9/L; NPTST042-CRP: 34 [0 - 0.3] mg/dL; [redacted]20[redacted] (RX DAY 115): Erythrocytes: 3 [3.7 - 5.1] 10^12/L; Hemoglobin: 80 [113 - 154] g/L; Leukocytes: 11.4 [3.5 - 8.5] 10^9/L; NPTST042-CRP: 35.16 [0 - 0.3] mg/dL; [redacted]20[redacted] (RX DAY 118): Erythrocyte Sedimentation Rate: 112.7 [0 - 15] mm/h; Erythrocytes: 2.7 [3.7 - 5.1] 10^12/L; Hemoglobin: 72 [113 - 154] g/L; Leukocytes: 10.5 [3.5 -

Microbiology

[redacted]20[redacted] (RX DAY 101): BLOOD NPTST007-AEROBIC CULTURE: NEGATIVE; BLOOD NPTST010-ANAEROBIC CUKTURE: NEGATIVE; [redacted]20[redacted] (RX DAY 102): SPUTUM NPTST005-ACID FAST STAIN: NEGATIVE

SAE Supplemental Procedure

[redacted]20[redacted] (RX DAY 101): CT SCAN(CHEST?ABDOMINAL): PELVIC TUMOR; [redacted]20[redacted] (RX DAY 107): TRANSVAGINAL ECHO: LEFT OVARIAN:SOLID TUMOR OF 10CM IN DIAMETER,IT IS NOT THE CAUSE OF THIS EVENT; [redacted]20[redacted] (RX DAY 109): ECHOCARDIOGRAPHY: NO ABNORMAL FINDINGS; [redacted]20[redacted] (RX DAY 112): ENDOSCOPY UPPER GASTROINTESTINAL TRACT: OESOPHAGEAL HIATAL HERNIA,SEVERAL FUNDIC GLAND POLYP OF 2MM IN DIAMETER; [redacted]20[redacted] (RX DAY 114): CONTRAST-ENHANCED CT SCAN?CHEST?ABDOMINAL?: THYROID GLAND?LOW DENSITY AREA IN THE LEFT LOBE MULTIPLE NODULAR OPACITIES IN BOTH LUNG FIELDS. INFILTRATES AND PLEURAL EFFUSION WERE SHOWED IN THE RIGHT LUNG. PELVIC NEOPLASM AND SMALL AMOUNT OF; [redacted]20[redacted] (RX DAY 115): MRI(UTERINE,OVARY): SOFT TISSUE INCLUDING SOLID COMPONENT ON THE LEFT SIDE OF UTERUS. LYMPH NODES ENLARGED(BILATERAL ILIAC ARTERY,PARAAORTIC LYMPH NODES) PELVIC SMALL AMOUNT OF ASCITES.; [redacted]20[redacted] (RX DAY 122): HISTOLOGIC DIAGNOSIS: HIGH-GRADE ADENOCARCINOMA(LEFT OVARY) ENDOMETRIOID CARCINOMA,GRADE1,PT1A(UTERUS) NO NEOPLASTTIC CHANGE(RIGHT OVARY AND TUBE) LEFT OBTURATOR LYMPH NODE METASTASIS(+); PERITONEAL CYTOLOGIC EXAMINATIONS: NEGATIVE; TOTAL HYSTERECTOMY, BILATERAL SALPINGO-OOPHORECTOMY, OBTURATOR LYMPH NODES RESECTION, OMENTECTOMY: THE OPERATION ENDED AS SCHEDULED. NO RESIDUAL MACROSCOPIC LESIONS.; TRANSFUSION: 6 UNITS OF CONCENTRATED HUMAN RED BLOOD CELLS WERE TRANSFUSED TO THE SUBJECT FOR ANAEMIA DUE TO OVARIAN CANCER DURING THE SURGERY.; [redacted]20[redacted] (RX DAY 128): TRANSVAGINAL ECHO: NO HEMATOMA

AE Stopped Rx Day	ONGOING
Duration of AE	ONGOING
Relation to Study Drug by Investigator	NO REASONABLE POSSIBILITY
Investigator Alternative Etiology	CAUSE UNKNOWN
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554

治験責任医師からの報告。本被験者は日本の 5[redacted] 歳女性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，尿路感染及び卵巣癌の事象を発現した。

Event 3 及び 4 の臨床経過：

関連する病歴は尋常性乾癬，乾癬性関節炎，鉄欠乏性貧血，月経困難症，非喫煙者及び現飲酒者（1 日 2 杯未満）であった。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は尿路感染を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，卵巣癌を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，尿路感染は消失した。

20[redacted] 年 [redacted] 月 [redacted] 日より，被験者は 38°C の発熱が続いていた。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は左背部痛及び左上臍部に間欠性の疼痛を発現した。医師は尿路感染を疑った。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は入院した。CT スキャン検査を行ったところ，骨盤腫瘍が明らかになった。被験者は，悪寒，食欲不振，体重減少，不眠及び貧血を呈していた。20[redacted] 年 [redacted] 月 [redacted] 日，尿検査により改善が認められたが，高熱は続いた。20[redacted] 年 [redacted] 月 [redacted] 日，20[redacted] 年 [redacted] 月 [redacted] 日からの高い炎症反応及び高熱のため，この被験者の治験参加は完全に中止された。20[redacted] 年 [redacted] 月 [redacted] 日，CT スキャン検査が行われ，卵巣癌が疑われた。20[redacted] 年 [redacted] 月 [redacted] 日，子宮全摘術，両側卵管卵巣摘除，大網切除及び閉鎖リンパ節郭清術が行われた。手術所見は，3 cm の子宮類線維症及び 15 cm の卵巣固形腫瘍であった。20[redacted] 年 [redacted] 月 [redacted] 日，手術時に採取された組織検体に基づき，高悪性度腺癌（左卵巣）と，グレード 1 で PT 1A の類内膜癌（子宮）との組織学的診断が下された。右卵巣・卵管には腫瘍性変化は見られなかった。左閉鎖リンパ節転移が認められた。これらの結果から，卵巣癌と診断された。手術は予定どおり終了し，残存顕微鏡病変は認められなかった。治験責任医師はこれらの腫瘍が発熱の原因であったと判断した。術後経過は良好で，被験者は 20[redacted] 年 [redacted] 月 [redacted] 日に退院した。

投与された薬剤は，メロペネム，ソルデム 3A，ロキソプロフェン，ハイアミン，ジクロフェナクナトリウム，献血ノンスロン，セファゾリンナトリウム，クレキサン，セファクロル，エフェドリン，キシロカイン，ブリディオン，ロクロニウム臭化物，フェンタニル，レミフェンタニル，アセリオ，硫酸アトロピン，デキサート，カルチコール，ブドウ糖，ヒューマリン R，ポプスカイン，フィジオ 140，ボルベン，アルブミナー，トリフリード，カルボシステイン，ハイアミン，グリカンチョー液，タゾピペ，セフトリアキソン NA 及びネオシネジンコーワであった。

The patient's past medications include:

LOXONIN for DYSMENORRHEA (20[redacted] - [redacted][redacted] 20[redacted])

Causality for ABT-494 (Blinded)

---

1) Urinary tract infection (10046571) (Urinary tract infection (10046571)) [v.21.1] [10046571]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): Reasonable possibility

Dechallenge: Yes

Rechallenge: No rechallenge was done, recurrence is not applicable

2) Ovarian cancer (10033128) (Ovarian cancer (10033128)) [v.21.1] [10033128]

Causality as per reporter (Drug/Vaccine): No reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Not Applicable

Alternative Etiology for ABT-494 (Blinded)

Event of URINARY TRACT INFECTION

- Investigator: Not applicable

- AbbVie: Not applicable

Event of OVARY CANCER

- Investigator: Cause unknown

- AbbVie: Weak temporal association with little over 3 months of study drug exposure.

Relevant Laboratory & Other Diagnostic Tests

[redacted] **ACID FAST STAIN SPUTUM:** NEGATIVE

[redacted] **AFP:** 3.9 NG/ML (normal 0 to 10)

[redacted] 20[redacted] **ASO:** 258 IU/mL (normal 0 to 200)

[redacted] 20[redacted] **BLOOD AEROBIC CULTURE:** NEGATIVE

[redacted] 20[redacted] **BLOOD ANAEROBIC CULTURE:** NEGATIVE

[redacted] 20[redacted] **BLOOD C3:** 153 mg/dL (normal 69 to 128)

[redacted] 20[redacted] **BLOOD C4:** 21 mg/dL (normal 14 to 36)

[redacted] 20[redacted] **BLOOD CH50:** 67 U/ML (normal 30 to 50)

[redacted] 20[redacted] **BLOOD URINE:** 2+

[redacted] 20[redacted] **BODY TEMPERATURE:** 38 Degrees C

[redacted] 20[redacted] **CA 125:** 68.1 U/ML (normal 0 to 35)

[redacted] 20[redacted] **CA 15-3:** 27 U/ML (normal 0 to 27)

[redacted] 20[redacted] **CA 19-9:** Less than 1.0

[redacted] 20[redacted] **CEA:** 1.5 NG/ML (normal 0 to 5)

[redacted] 20[redacted] **CONTRAST-ENHANCED CT SCAN:** THYROID GLAND：LOW DENSITY AREA IN THE LEFT LOBE MULTIPLE NODULAR OPACITIES IN BOTH LUNG FIELDS. INFILTRATES AND PLEURAL EFFUSION WERE SHOWED IN THE RIGHT LUNG. PELVIC NEOPLASM AND SMALL AMOUNT OF ASCITES WERE FOUND.

[redacted] 20[redacted] **CREATININE:** 0.49 10^2mcL (normal 0.4 to 0.8)

[redacted] 20[redacted] **CRP:** 26.338 mg/dL (normal 0 to 0.3)

[redacted] 20[redacted] **CRP:** 26.3 mg/dL (normal 0 to 0.3)[redacted] 20[redacted] CRP: 28.0 mg/dL (normal 0 to 0.3)

[redacted] 20[redacted] **CRP:** 27.3 mg/dL (normal 0 to 0.3)

[redacted] 20[redacted] **CRP:** 35.155 mg/dL (normal 0 to 0.3)

[redacted] 20[redacted] **CRP:** 29.821 mg/dL (normal 0 to 0.3)

[redacted] 20[redacted] **CRP:** 28.227 mg/dL (normal 0 to 0.3)

[redacted] 20[redacted] **CRP:** 19.984 mg/dL (normal 0 to 0.3)

[redacted] 20[redacted] **CRP:** 5.209 mg/dL (normal 0 to 0.3)

[redacted] 20[redacted] **CRP:** 2.889 mg/dL (normal 0 to 0.3)

[redacted] 20[redacted] **CT SCAN:** PELVIC TUMOR

[redacted] 20[redacted] **ECHOCARDIOGRAPHY:** NO FINDINGS

[redacted] 20[redacted] **ENDOSCOPY UPPER GASTROINTESTINAL TRACT:** OESOPHAGEAL HIATAL HERNIA,SEVERAL FUNDIC GLAND POLYP OF 2MM IN DIAMETER

[redacted] 20[redacted] **ESR:** 96.2 mm/h (normal 0 to 15)

[redacted] 20[redacted] **ESR:** 90.9 mm/h (normal 0 to 15)

[redacted] 20[redacted] **ESR:** 114.4 mm/h (normal 0 to 15)

[redacted] 20[redacted] **ESR:** 103.2 mm/h (normal 0 to 15)

[redacted] 20[redacted] **ESR:** 101.2 mm/h (normal 0 to 15)

[redacted] 20[redacted] **ESR:** 112.7 mm/h (normal 0 to 15)

[redacted] 20[redacted] **HAPTOGLOBIN:** 466 mg/dL (normal 19 to 170)

[redacted] 20[redacted] **HEMOGLOBIN:** 8 G/DL (normal 11.3 to 15.4)

[redacted] 20[redacted] **HEMOGLOBIN:** 7.2 G/DL (normal 11.3 to 15.4)

[redacted] 20[redacted] **HEMOGLOBIN:** 6.8 G/DL (normal 11.3 to 15.4)

[redacted] 20[redacted] **HEMOGLOBIN:** 9.8 G/DL (normal 11.3 to 15.4)

[redacted] 20[redacted] **HTLV-1:** LESS THAN 16 (NORMAL LESS THAN 16 TIMES)

[redacted] 20[redacted] **MRI (UTERINE, OVARY):** SOFT TISSUE INCLUDING SOLID COMPONENT ON THE LEFT SIDE OF UTERUS. LYMPH NODES ENLARGED (BILATERAL ILIAC ARTERY, PARAORTIC LYMPH NODES); PELVIC SMALL AMOUNT OF ASCITES

[redacted] 20[redacted] **PERITONEAL CYTOLOGIC EXAMINATIONS:** Negative

[redacted] 20[redacted] **PROTEIN URINE:** 2+

[redacted] 20[redacted] **RED BLOOD CELLS:** 273 10^2/µL (normal 370 to 510)

[redacted] 20[redacted] **RED BLOOD CELLS:** 266 10^2/µL (normal 370 to 510)

[redacted] 20[redacted] **RED BLOOD CELLS:** 346 10^2/µL (normal 370 to 510)

[redacted] 20[redacted] **RED BLOOD CELLS URINE:** 25 /HPF (normal 0 to 4)

[redacted] 20[redacted] **TRANSVAGINAL ECHO:** LEFT OVARIAN:SOLID TUMOR OF 10CM IN DIAMETER,IT IS NOT THE CAUSE OF THIS EVENT

[redacted] 20[redacted] **TRANSVAGINAL ECHO:** No hematoma in the vaginal stump; small amount of ascites fluid

[redacted] 20[redacted] **TRANSVAAL ECHO:** Normal

[redacted] **20[redacted] URINE ANTIGEN OF LEGIONELLA:** NOT REPORTED

[redacted] **20[redacted] URINE BACTERIUM:** 1+

[redacted] **20[redacted] URINE BLOOD:** +/-

[redacted] **20[redacted] URINE PNEUMOCOCCUS:** NOT REPORTED

[redacted] **20[redacted] URINE PROTEIN:** +/-

[redacted] **20[redacted] URINE RBC:** 19 /HPF (normal <4)

[redacted] **20[redacted] URINE WBC:** 1 /HPF (normal 0 to 5)

[redacted] **20[redacted] WHITE BLOOD CELLS:** 9800 mcl (normal 35 to 85)

[redacted] **20[redacted] WHITE BLOOD CELLS:** 98 10^2/µL (normal 35 to 85)

[redacted] **20[redacted] WHITE BLOOD CELLS:** 87 10^2/µL (normal 35 to 85)

[redacted] **20[redacted] WHITE BLOOD CELLS:** 83 10^2/µL (normal 35 to 85)

[redacted] **20[redacted] WHITE BLOOD CELLS:** 97 10^2/µL (normal 35 to 85)

[redacted] **20[redacted] WHITE BLOOD CELLS URINE:** 55 /HPF (normal 0 to 5)

[redacted] **20[redacted] B-D GLUCAN:** LESS THAN 6.0 (NORMAL LESS THAN 11 PG/ML)

被験者番号 [redacted] (Investigator [redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
間質性肺疾患	X			
気胸	X	X		
汎血球減少症	X	X	X	
ニューモシスチス・イロベチイ肺炎	X			X
サイトメガロウイルス感染	X			X
十二指腸潰瘍	X			

Treatment Group	Age at Study Start	Sex	Race
Placebo/ABT-494 30 mg QD	5[redacted]	MALE	ASIAN

Medical History	Onset Year
DRUG ALLERGIES/REACTIONS: BUFFERIN COMBINATION TABLET	NOT REPORTED
GASTROESOPHAGEAL REFLUX DISEASE	NOT REPORTED
HYPERTENSION	NOT REPORTED
LIVER DISEASE (EXCLUDING HEPATITIS): ALCOHOLIC LIVER DISEASE	NOT REPORTED
OTHER: EDEMA	NOT REPORTED
OTHER: PERIODONTAL DISEASE	NOT REPORTED
OTHER: PLAQUE PSORIASIS	NOT REPORTED
OTHER: PSYCHOSOMATIC DISORDER	NOT REPORTED

Prior Procedures	Procedure Year
Not reported.	

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
Not reported.				

Alcohol Use	Status	Number/Day
ALCOHOL	FORMER	2 - 4

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
PLACEBO		ORAL	QD	[redacted] / 1	[redacted] / 168	168
ABT-494	30MG	ORAL	QD	[redacted] / 169	[redacted] / 392	224
ABT-494	30MG	ORAL	QD	[redacted] / 393	[redacted] / 632	240

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
BCG Vaccine	NOT REPORTED	NOT REPORTED	Y-M: 19[redacted]
LANSOPRAZOLE	30 mg	QD	Y-M: 20[redacted]
LORAZEPAM	0.5 mg	QD	Y-M: 20[redacted]
DEXAMETHASONE	1 OTHER: APPLICATION	QD	Y-M: 20[redacted]
DIFLORASONE	1 OTHER: APPLICATION	BID	Y-M: 20[redacted]
TACALCITOL	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted]
CELECOXIB	100 mg	BID	Y-M: 20[redacted]
HYDROCORTISONE	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted]
RISANKIZUMAB	150 mg	OTHER: PSORIATIC ARTHRITIS, M16-244 TRIAL	Y-M: 20[redacted] / -359
AMLODIPINE BESILATE W/AZILSARTAN	22.5 mg	QD	Y-M: 20[redacted] / -265
METHOTREXATE	8 mg	EVERY WEEK	Y-M: 20[redacted] / -104
FOLIC ACID	5 mg	QD	Y-M: 20[redacted] / -48

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
LANSOPRAZOLE	30 mg	QD	Y-M: 20[redacted]	Y-M: 20[redacted] / 632
LORAZEPAM	0.5 mg	QD	Y-M: 20[redacted]	Y-M: 20[redacted] / 641
CELECOXIB	100 mg	BID	Y-M: 20[redacted]	Y-M: 20[redacted] / 632
AMLODIPINE BESILATE W/AZILSARTAN	22.5 mg	QD	Y-M: 20[redacted] / -265	Y-M: 20[redacted] / 633
ALCLOMETASONE	1 OTHER: APPLICATION	BID	Y-M: 20[redacted] / 15	Y-M: 20[redacted] / 632
BETAMETHASONE	1 OTHER: APPLICATION	BID	Y-M: 20[redacted] / 309	Y-M: 20[redacted] / 632
METOCLOPRAMIDE	10 mg	PRN	Y-M: 20[redacted] / 633	Y-M: 20[redacted] / 633
TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN	7 OTHER: SHEET	PRN	Y-M: 20[redacted] / 633	Y-M: 20[redacted] / 633
SULPERAZON	1 g	PRN	Y-M: 20[redacted] / 633	Y-M: 20[redacted] / 634
CARBAZOCHROME	50 mg	PRN	Y-M: 20[redacted] / 633	Y-M: 20[redacted] / 636
TRANEXAMIC ACID	250 mg	PRN	Y-M: 20[redacted] / 633	Y-M: 20[redacted] / 636
SOLACET F	500 mL	PRN	Y-M: 20[redacted] / 633	Y-M: 20[redacted] / 637
INSULIN ASPART	3 mL	QD	Y-M: 20[redacted] / 633	Y-M: 20[redacted] / 638
I.V. SOLUTIONS	500 mL	PRN	Y-M: 20[redacted] / 633	Y-M: 20[redacted] / 639
FENTANYL	2-10 mL	PRN	Y-M: 20[redacted] / 633	Y-M: 20[redacted] / 642
SIVELESTAT	300 mg	PRN	Y-M: 20[redacted] / 633	Y-M: 20[redacted] / 645
ROCURONIUM	50 mg	PRN	Y-M: 20[redacted] / 633	Y-M: 20[redacted] / 651
TRAMADOL	25 mg	PRN	Y-M: 20[redacted] / 633	Y-M: 20[redacted] / 653
BLOOD AND RELATED PRODUCTS	NA OTHER: UNIT	PRN	Y-M: 20[redacted] / 633	Y-M: 20[redacted] / 657
IRON	100 mg	BID	Y-M: 20[redacted] / 633	Y-M: 20[redacted] / 662
MIDAZOLAM	10 mg	PRN	Y-M: 20[redacted] / 633	Y-M: 20[redacted] / 662
HYDROXYZINE	25 mg	PRN	Y-M: 20[redacted]	Y-M: 20[redacted]

			[redacted] / 634	[redacted] / 637
BIAPENEM	0.3 g	PRN	Y-M: 20[redacted]- [redacted] / 634	Y-M: 20[redacted]- [redacted] / 639
METAMIZOLE	500 mg	PRN	Y-M: 20[redacted]- [redacted] / 634	Y-M: 20[redacted]- [redacted] / 641
PENTAZOCINE	15 ng	PRN	Y-M: 20[redacted]- [redacted] / 636	Y-M: 20[redacted]- [redacted] / 636
REMIFENTANIL	2 mg	PRN	Y-M: 20[redacted]- [redacted] / 636	Y-M: 20[redacted]- [redacted] / 636
REMIFENTANIL	4 mg	PRN	Y-M: 20[redacted]- [redacted] / 636	Y-M: 20[redacted]- [redacted] / 636
DEXMEDETOMIDINE	200 mg	PRN	Y-M: 20[redacted]- [redacted] / 636	Y-M: 20[redacted]- [redacted] / 642
METHYLPREDNISOLONE	1 g	QD	Y-M: 20[redacted]- [redacted] / 637	Y-M: 20[redacted]- [redacted] / 639
BACTRIM	15 mL	QD	Y-M: 20[redacted]- [redacted] / 637	Y-M: 20[redacted]- [redacted] / 652
NAFAMOSTAT	NA mg	QD	Y-M: 20[redacted]- [redacted] / 637	Y-M: 20[redacted]- [redacted] / 659
IMMUNOGLOBULIN HUMAN NORMAL	5 g	PRN	Y-M: 20[redacted]- [redacted] / 638	Y-M: 20[redacted]- [redacted] / 642
SODIUM BICARBONATE	20 mL	PRN	Y-M: 20[redacted]- [redacted] / 638	Y-M: 20[redacted]- [redacted] / 642
DIAZEPAM	10 mg	PRN	Y-M: 20[redacted]- [redacted] / 639	Y-M: 20[redacted]- [redacted] / 639
HALOPERIDOL	5 mg	PRN	Y-M: 20[redacted]- [redacted] / 639	Y-M: 20[redacted]- [redacted] / 639
FLUNITRAZEPAM	2 mg	PRN	Y-M: 20[redacted]- [redacted] / 639	Y-M: 20[redacted]- [redacted] / 640
PREDNISOLONE	60 mg	PRN	Y-M: 20[redacted]- [redacted] / 639	Y-M: 20[redacted]- [redacted] / 662
PARACETAMOL	200 mg	QD	Y-M: 20[redacted]- [redacted] / 640	Y-M: 20[redacted]- [redacted] / 641
GLUCOSE	20 mL	PRN	Y-M: 20[redacted]- [redacted] / 640	Y-M: 20[redacted]- [redacted] / 642
INSULIN HUMAN	10 OTHER: UNIT	PRN	Y-M: 20[redacted]- [redacted] / 640	Y-M: 20[redacted]- [redacted] / 642
MICAFUNGIN	NA mg	PRN	Y-M: 20[redacted]- [redacted] / 640	Y-M: 20[redacted]- [redacted] / 644
LEVOFLOXACIN	500 mg	PRN	Y-M: 20[redacted]- [redacted] / 640	Y-M: 20[redacted]- [redacted] / 645
PROPOFOL	500 mg	PRN	Y-M: 20[redacted]- [redacted] / 640	Y-M: 20[redacted]- [redacted] / 659
CALCIUM POLYSTYRENE SULFONATE	50 g	TID	Y-M: 20[redacted]- [redacted] / 641	Y-M: 20[redacted]- [redacted] / 641
SODIUM CHLORIDE	40 mL	PRN	Y-M: 20[redacted]- [redacted] / 642	Y-M: 20[redacted]- [redacted] / 652
MAGNESIUM SULFATE	20 mL	PRN	Y-M: 20[redacted]-	Y-M: 20[redacted]-

			[redacted] / 642	[redacted] / 656
AMINO ACIDS NOS	NA mL	PRN	Y-M: 20[redacted]- [redacted] / 642	Y-M: 20[redacted]- [redacted] / 662
ELEMEAL	2 mL	PRN	Y-M: 20[redacted]- [redacted] / 642	Y-M: 20[redacted]- [redacted] / 662
LANSOPRAZOLE	30 mg	PRN	Y-M: 20[redacted]- [redacted] / 642	Y-M: 20[redacted]- [redacted] / 662
NEUROBION	5 mL	PRN	Y-M: 20[redacted]- [redacted] / 642	Y-M: 20[redacted]- [redacted] / 662
NOREPINEPHRINE	3 mg	PRN	Y-M: 20[redacted]- [redacted] / 642	Y-M: 20[redacted]- [redacted] / 662
ANTITHROMBIN GAMMA	NA mL	PRN	Y-M: 20[redacted]- [redacted] / 643	Y-M: 20[redacted]- [redacted] / 658
ANTIBIOTICS-RESISTANT LACTIC ACID BACTERIAE	1 g	TID	Y-M: 20[redacted]- [redacted] / 643	Y-M: 20[redacted]- [redacted] / 661
GANCICLOVIR	150 mg	QD	Y-M: 20[redacted]- [redacted] / 644	Y-M: 20[redacted]- [redacted] / 652
HEPARIN	5 mL	QD	Y-M: 20[redacted]- [redacted] / 644	Y-M: 20[redacted]- [redacted] / 656
FACTOR XIII (FIBRIN STABILISING FACTOR)	20 mL	QD	Y-M: 20[redacted]- [redacted] / 645	Y-M: 20[redacted]- [redacted] / 650
UNACID	3 g	PRN	Y-M: 20[redacted]- [redacted] / 646	Y-M: 20[redacted]- [redacted] / 650
ZINC	25 mg	BID	Y-M: 20[redacted]- [redacted] / 646	Y-M: 20[redacted]- [redacted] / 655
REBAMIPIDE	100 mg	TID	Y-M: 20[redacted]- [redacted] / 648	Y-M: 20[redacted]- [redacted] / 655
VONOPRAZAN	20 mg	QD	Y-M: 20[redacted]- [redacted] / 648	Y-M: 20[redacted]- [redacted] / 655
MORPHINE	10 mg	PRN	Y-M: 20[redacted]- [redacted] / 648	Y-M: 20[redacted]- [redacted] / 659
CASPOFUNGIN	70 mg	QD	Y-M: 20[redacted]- [redacted] / 650	Y-M: 20[redacted]- [redacted] / 650
HEPARIN	5 mL	PRN	Y-M: 20[redacted]- [redacted] / 650	Y-M: 20[redacted]- [redacted] / 660
VANCOMYCIN	NA g	PRN	Y-M: 20[redacted]- [redacted] / 650	Y-M: 20[redacted]- [redacted] / 660
MEROPENEM	NA g	PRN	Y-M: 20[redacted]- [redacted] / 650	Y-M: 20[redacted]- [redacted] / 661
CALCIUM GLUCONATE	5 mL	PRN	Y-M: 20[redacted]- [redacted] / 651	Y-M: 20[redacted]- [redacted] / 656
BROMHEXINE	4 mg	PRN	Y-M: 20[redacted]- [redacted] / 651	Y-M: 20[redacted]- [redacted] / 659
CASPOFUNGIN	50 mg	QD	Y-M: 20[redacted]- [redacted] / 651	Y-M: 20[redacted]- [redacted] / 661
FILGRASTIM	75 ug	QD	Y-M: 20[redacted]- [redacted] / 652	Y-M: 20[redacted]- [redacted] / 658
CLINDAMYCIN	600 mg	QD	Y-M: 20[redacted]-	Y-M: 20[redacted]-

AMBROXOL	15 mg	TID	[redacted] / 653 Y-M: 20[redacted]- [redacted] / 653	[redacted] / 654 Y-M: 20[redacted]- [redacted] / 655
ATOVAQUONE	5 mL	QD	Y-M: 20[redacted]- [redacted] / 654	Y-M: 20[redacted]- [redacted] / 654
SODIUM PHOSPHATE	20 mL	PRN	Y-M: 20[redacted]- [redacted] / 654	Y-M: 20[redacted]- [redacted] / 662
POTASSIUM	20 mL	PRN	Y-M: 20[redacted]- [redacted] / 655	Y-M: 20[redacted]- [redacted] / 659
ATOVAQUONE	10 mL	QD	Y-M: 20[redacted]- [redacted] / 655	Y-M: 20[redacted]- [redacted] / 660

Event #1: Serious Adverse Event

Event Description	INTERSTITIAL PNEUMONIA
Preferred term	間質性肺疾患
AE Onset Date / Rx Day	[redacted]20[redacted] / 633 (1 DAY AFTER LAST TREATMENT)
Age at AE Onset	5[redacted]

Laboratory Testing

[redacted]20[redacted] (RX DAY 633): Alanine Aminotransferase: 67 [10 - 42] U/L; Aspartate Aminotransferase: 118 [13 - 30] U/L; Blood Urea Nitrogen: 23.74 [2.86 - 7.14] mmol/L; Creatinine: 211.28 [57.46 - 94.59] umol/L; Erythrocytes: 1.8 [4.4 - 5.6] 10^12/L; Hemoglobin: 76 [137 - 468] g/L; Leukocytes: 2.4 [3.3 - 8.6] 10^9/L; NPTST071-HIV-AB: NEGATIVE [NOT REPORTED - 1] UNIT NOT REPORTED; Platelets: 116 [158 - 348] 10^9/L; Potassium: 5.7 [3.6 - 4.8] mmol/L; [redacted]20[redacted] (RX DAY 634): Erythrocytes: 1.7 [4.4 - 5.6] 10^12/L; Hemoglobin: 71 [137 - 168] g/L; Leukocytes: 3.4 [3.3 - 8.6] 10^9/L; Platelets: 103 [158 - 348] 10^9/L; [redacted]20[redacted] (RX DAY 636): NPTST080-KL-6: 880 [105 - 435] U/mL; [redacted]20[redacted] (RX DAY 637): Erythrocytes: 2.2 [4.4 - 5.6] 10^12/L; Hematocrit: 0.23 [0.41 - 0.5] fraction of 1; Hemoglobin: 83 [137 - 168] g/L; Leukocytes: 4 [3.3 - 8.6] 10^9/L; Lymphocytes/Leukocytes: 5 [16.5 - 49.5] %; Monocytes/Leukocytes: 2 [2 - 10] %; NPTST003-?-D GLUCAN: 266.2 [0 - 11] mg/L; Neutrophils Band Form/Leukocytes: 11 [0.5 - 6.5] %; Neutrophils/Leukocytes: 81 [38 - 74] %; Platelets: 43 [158 - 348] 10^9/L; [redacted]20[redacted] (RX DAY 638): Aspartate Aminotransferase: 50 [13 - 30] U/L; Blood Urea Nitrogen: 20.56 [2.86 - 7.14] mmol/L; Creatinine: 209.52 [362.45 - 450.86] umol/L; Erythrocytes: 2.3 [4.4 - 5.6] 10^12/L; Hemoglobin: 82 [137 - 168] g/L; Leukocytes: 6.5 [3.3 - 8.6] 10^9/L; NPTST042-CRP: 31.59 [0 - 0.14] mg/dL; Platelets: 30 [158 - 348] 10^9/L; [redacted]20[redacted] (RX DAY 639): Erythrocytes: 2.1 [4.4 - 5.6] 10^12/L

Microbiology

[redacted]20[redacted] (RX DAY 633): BLOOD NPTST022-BLOOD CULTURE: NEGATIVE; OTHER RESECTED LUNG TISSUE NPTST066-GROCOTT STAIN: POSITIVE-PNEUMOCYSTIS JIROVECII CYST; OTHER SUCTION SPUTUM NPTST126-SPUTUM CULTURE: POSITIVE-METHICILLIN-SUSCEPTIBLE STAPHYLOCOCCUS AUREUS GRAM-NEGATIVE RODS; [redacted]20[redacted] (RX DAY 642): BLOOD NPTST023-BLOOD CULTURES: NEGATIVE; [redacted]20[redacted] (RX DAY 650): OTHER ENDOTRACHEAL TUBE NPTST126-SPUTUM CULTURE: POSITIVE-STAPHYLOCOCCUS AUREUS

SAE Supplemental Procedure

[redacted]20[redacted] (RX DAY 633): CHEST X-RAY: RIGHT PNEUMOTHORAX,INTERSTITIAL PNEUMONIA LUNG CYST; PLAIN CT: GROUND-GLASS OPACITY; THORACOSCOPIC PNEUMONECTOMY (LUNG CYST SURGERY): DRAINAGE; VITAL SIGNS: BLOOD PRESSURE 160/99, SPO2 60%; [redacted]20[redacted] (RX DAY 636): THORACOSCOPIC LUNG SURGERY: DRAINAGE; [redacted]20[redacted] (RX DAY 637): CHEST IMAGE(CHEST CT): SUBCUTANEOUS EMPHYSEMA INCREASES; STEROID PULSE THERAPY WAS PERFORMED: ONGOING; [redacted]20[redacted] (RX DAY 638): HEMATOLOGY CONSULTATION: PLATELET TRANSFUSION TO THROMBOCYTOPENIA. ADMINISTRATION OF IMMUNOGLOBULIN PREPARATIONS FOR SEVERE INFECTIONS.; ST COMBINATION WAS

STARTED CONSIDERING PNEUMOCYSTIS PNEUMONIA.: ONGOING; [redacted]20[redacted] (RX DAY 639): IMMUNOGLOBULIN ADMINISTRATION START: ONGOING; PLATELET TRANSFUSIONS: NOT IMPROVE.; [redacted]20[redacted] (RX DAY 642): VV?VENO VENOUS?-ECMO?EXTRACORPOREAL MEMBRANE OXYGENATION?: ARTIFICIAL RESPIRATION MANAGEMENT; BRAIN CT: CEREBRAL INFARCTION?LEFT POSTERIOR CEREBRAL ARTERY AREA); [redacted]20[redacted] (RX DAY 648): GASTROLNTESTINAL FIBERSCOPE: DUODENAL ULCER (MULTIPLE); [redacted]20[redacted] (RX DAY 650): GASTROLNTESTINAL FIBERSCOPE: DUODENAL ULCER (MULTIPLE); [redacted]20[redacted] (RX DAY 651): GASTROLNTESTINAL FIBERSCOPE: DUODENAL ULCER (MULTIPLE); [redacted]20[redacted] (RX DAY 652): GASTROLNTESTINAL FIBERSCOPE: DUODENAL ULCER (MULTIPLE); TRACHEOSTOMY: ARTIFICIAL RESPIRATION MANAGEMENT; [redacted]20[redacted] (RX DAY 654): LEFT THORACIC DRAINAGE: LEFT PNEUMOTHORAX

AE Stopped Rx Day	662 (30 DAYS AFTER LAST TREATMENT)
Duration of AE	30 DAYS
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	NOT REPORTED
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION, OTHER MEDICALLY IMPORTANT SERIOUS EVENT, LIFE THREATENING

Event #2: Serious Adverse Event, AE Leading to Discontinuation of Study Drug

Event Description	RIGHT PNEUMOTHORAX
Preferred term	気胸
AE Onset Date / Rx Day	[redacted]20[redacted] / 633 (1 DAY AFTER LAST TREATMENT)
Age at AE Onset	5[redacted]

Laboratory Testing

[redacted]20[redacted] (RX DAY 633): Alanine Aminotransferase: 67 [10 - 42] U/L; Aspartate Aminotransferase: 118 [13 - 30] U/L; Blood Urea Nitrogen: 23.74 [2.86 - 7.14] mmol/L; Creatinine: 211.28 [57.46 - 94.59] umol/L; Erythrocytes: 1.8 [4.4 - 5.6] 10^12/L; Hemoglobin: 76 [137 - 468] g/L; Leukocytes: 2.4 [3.3 - 8.6] 10^9/L; NPTST071-HIV-AB: NEGATIVE [NOT REPORTED - 1] UNIT NOT REPORTED; Platelets: 116 [158 - 348] 10^9/L; Potassium: 5.7 [3.6 - 4.8] mmol/L; [redacted]20[redacted] (RX DAY 634): Erythrocytes: 1.7 [4.4 - 5.6] 10^12/L; Hemoglobin: 71 [137 - 168] g/L; Leukocytes: 3.4 [3.3 - 8.6] 10^9/L; Platelets: 103 [158 - 348] 10^9/L; [redacted]20[redacted] (RX DAY 636): NPTST080-KL-6: 880 [105 - 435] U/mL; [redacted]20[redacted] (RX DAY 637): Erythrocytes: 2.2 [4.4 - 5.6] 10^12/L; Hematocrit: 0.23 [0.41 - 0.5] fraction of 1; Hemoglobin: 83 [137 - 168] g/L; Leukocytes: 4 [3.3 - 8.6] 10^9/L; Lymphocytes/Leukocytes: 5 [16.5 - 49.5] %; Monocytes/Leukocytes: 2 [2 - 10] %; NPTST003-?-D GLUCAN: 266.2 [0 - 11] mg/L; Neutrophils Band Form/Leukocytes: 11 [0.5 - 6.5] %; Neutrophils/Leukocytes: 81 [38 - 74] %; Platelets: 43 [158 - 348] 10^9/L; [redacted]20[redacted] (RX DAY 638): Aspartate Aminotransferase: 50 [13 - 30] U/L; Blood Urea Nitrogen: 20.56 [2.86 - 7.14] mmol/L; Creatinine: 209.52 [362.45 - 450.86] umol/L; Erythrocytes: 2.3 [4.4 - 5.6] 10^12/L; Hemoglobin: 82 [137 - 168] g/L; Leukocytes: 6.5 [3.3 - 8.6] 10^9/L; NPTST042-CRP: 31.59 [0 - 0.14] mg/dL; Platelets: 30 [158 - 348] 10^9/L; [redacted]20[redacted] (RX DAY 639): Erythrocytes: 2.1 [4.4 - 5.6] 10^12/L

Microbiology

[redacted]20[redacted] (RX DAY 633): BLOOD NPTST022-BLOOD CULTURE: NEGATIVE; OTHER RESECTED LUNG TISSUE NPTST066-GROCOTT STAIN: POSITIVE-PNEUMOCYSTIS JIROVECII CYST; OTHER SUCTION SPUTUM NPTST126-SPUTUM CULTURE: POSITIVE-METHICILLIN-SUSCEPTIBLE STAPHYLOCOCCUS AUREUS GRAM-NEGATIVE RODS; [redacted]20[redacted] (RX DAY 642): BLOOD NPTST023-BLOOD CULTURES: NEGATIVE; [redacted]20[redacted] (RX DAY 650): OTHER ENDOTRACHEAL

TUBE NPTST126-SPUTUM CULTURE: POSITIVE-STAPHYLOCOCCUS AUREUS

SAE Supplemental Procedure

[redacted]20[redacted] (RX DAY 633): CHEST X-RAY: RIGHT PNEUMOTHORAX,INTERSTITIAL PNEUMONIA LUNG CYST; PLAIN CT: GROUND-GLASS OPACITY; THORACOSCOPIC PNEUMONECTOMY (LUNG CYST SURGERY): DRAINAGE; VITAL SIGNS: BLOOD PRESSURE 160/99, SPO2 60%; [redacted]20[redacted] (RX DAY 636): THORACOSCOPIC LUNG SURGERY: DRAINAGE; [redacted]20[redacted] (RX DAY 637): CHEST IMAGE(CHEST CT): SUBCUTANEOUS EMPHYSEMA INCREASES; STEROID PULSE THERAPY WAS PERFORMED: ONGOING; [redacted]20[redacted] (RX DAY 638): HEMATOLOGY CONSULTATION: PLATELET TRANSFUSION TO THROMBOCYTOPENIA. ADMINISTRATION OF IMMUNOGLOBULIN PREPARATIONS FOR SEVERE INFECTIONS.; ST COMBINATION WAS STARTED CONSIDERING PNEUMOCYSTIS PNEUMONIA.: ONGOING; [redacted]20[redacted] (RX DAY 639): IMMUNOGLOBULIN ADMINISTRATION START: ONGOING; PLATELET TRANSFUSIONS: NOT IMPROVE.; [redacted]20[redacted] (RX DAY 642): VV?VENO VENOUS?-ECMO?EXTRACORPOREAL MEMBRANE OXYGENATION?: ARTIFICIAL RESPIRATION MANAGEMENT; BRAIN CT: CEREBRAL INFARCTION?LEFT POSTERIOR CEREBRAL ARTERY AREA); [redacted]20[redacted] (RX DAY 648): GASTROLNTESTINAL FIBERSCOPE: DUODENAL ULCER (MULTIPLE); [redacted]20[redacted] (RX DAY 650): GASTROLNTESTINAL FIBERSCOPE: DUODENAL ULCER (MULTIPLE); [redacted]20[redacted] (RX DAY 651): GASTROLNTESTINAL FIBERSCOPE: DUODENAL ULCER (MULTIPLE); [redacted]20[redacted] (RX DAY 652): GASTROLNTESTINAL FIBERSCOPE: DUODENAL ULCER (MULTIPLE); TRACHEOSTOMY: ARTIFICIAL RESPIRATION MANAGEMENT; [redacted]20[redacted] (RX DAY 654): LEFT THORACIC DRAINAGE: LEFT PNEUMOTHORAX

AE Stopped Rx Day	662 (30 DAYS AFTER LAST TREATMENT)
Duration of AE	30 DAYS
Relation to Study Drug by Investigator	NO REASONABLE POSSIBILITY
Investigator Alternative Etiology	A CYST ON THE SURFACE OF THE LUNGS (PRIMARY SIDE) = PRIMARY SPONTANEOUS PNEUMOTHORAX IN WHICH BRA BREV RUPTURES.
Discontinued Study Drug Due to the Event	YES
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION, OTHER MEDICALLY IMPORTANT SERIOUS EVENT, LIFE THREATENING

Event #3: Serious Adverse Event, AE Leading to Discontinuation of Study Drug, Death

Event Description	PANCYTOPENIA
Preferred term	汎血球減少症
AE Onset Date / Rx Day	[redacted]20[redacted] / 637 (5 DAYS AFTER LAST TREATMENT)
Age at AE Onset	5[redacted]

Laboratory Testing

[redacted]20[redacted] (RX DAY 633): Alanine Aminotransferase: 67 [10 - 42] U/L; Aspartate Aminotransferase: 118 [13 - 30] U/L; Blood Urea Nitrogen: 23.74 [2.86 - 7.14] mmol/L; Creatinine: 211.28 [57.46 - 94.59] umol/L; Erythrocytes: 1.8 [4.4 - 5.6] 10^12/L; Hemoglobin: 76 [137 - 468] g/L; Leukocytes: 2.4 [3.3 - 8.6] 10^9/L; NPTST071-HIV-AB: NEGATIVE [NOT REPORTED - 1] UNIT NOT REPORTED; Platelets: 116 [158 - 348] 10^9/L; Potassium: 5.7 [3.6 - 4.8] mmol/L; [redacted]20[redacted] (RX DAY 634): Erythrocytes: 1.7 [4.4 - 5.6] 10^12/L; Hemoglobin: 71 [137 - 168] g/L; Leukocytes: 3.4 [3.3 - 8.6] 10^9/L; Platelets: 103 [158 - 348] 10^9/L; [redacted]20[redacted] (RX DAY 636): NPTST080-KL-6: 880 [105 - 435] U/mL; [redacted]20[redacted] (RX DAY 637): Erythrocytes: 2.2 [4.4 - 5.6] 10^12/L; Hematocrit: 0.23 [0.41 - 0.5] fraction of 1; Hemoglobin: 83 [137 - 168] g/L; Leukocytes: 4 [3.3 - 8.6] 10^9/L; Lymphocytes/Leukocytes: 5 [16.5 - 49.5] %; Monocytes/Leukocytes: 2 [2 - 10] %; NPTST003-?-D GLUCAN: 266.2 [0 - 11] mg/L; Neutrophils Band Form/Leukocytes: 11 [0.5 - 6.5] %; Neutrophils/Leukocytes: 81 [38 - 74] %; Platelets: 43 [158 - 348] 10^9/L; [redacted]20[redacted] (RX DAY 638):

Aspartate Aminotransferase: 50 [13 - 30] U/L; Blood Urea Nitrogen: 20.56 [2.86 - 7.14] mmol/L; Creatinine: 209.52 [362.45 - 450.86] umol/L; Erythrocytes: 2.3 [4.4 - 5.6] 10^12/L; Hemoglobin: 82 [137 - 168] g/L; Leukocytes: 6.5 [3.3 - 8.6] 10^9/L; NPTST042-CRP: 31.59 [0 - 0.14] mg/dL; Platelets: 30 [158 - 348] 10^9/L; [redacted]20[redacted] (RX DAY 639): Erythrocytes: 2.1 [4.4 - 5.6] 10^12/L

Microbiology

[redacted]20[redacted] (RX DAY 633): BLOOD NPTST022-BLOOD CULTURE: NEGATIVE; OTHER RESECTED LUNG TISSUE NPTST066-GROCOTT STAIN: POSITIVE-PNEUMOCYSTIS JIROVECII CYST; OTHER SUCTION SPUTUM NPTST126-SPUTUM CULTURE: POSITIVE-METHICILLIN-SUSCEPTIBLE STAPHYLOCOCCUS AUREUS GRAM-NEGATIVE RODS; [redacted]20[redacted] (RX DAY 642): BLOOD NPTST023-BLOOD CULTURES: NEGATIVE; [redacted]20[redacted] (RX DAY 650): OTHER ENDOTRACHEAL TUBE NPTST126-SPUTUM CULTURE: POSITIVE-STAPHYLOCOCCUS AUREUS

SAE Supplemental Procedure

[redacted]20[redacted] (RX DAY 633): CHEST X-RAY: RIGHT PNEUMOTHORAX,INTERSTITIAL PNEUMONIA LUNG CYST; PLAIN CT: GROUND-GLASS OPACITY; THORACOSCOPIC PNEUMONECTOMY (LUNG CYST SURGERY): DRAINAGE; VITAL SIGNS: BLOOD PRESSURE 160/99, SPO2 60%; [redacted]20[redacted] (RX DAY 636): THORACOSCOPIC LUNG SURGERY: DRAINAGE; [redacted]20[redacted] (RX DAY 637): CHEST IMAGE(CHEST CT): SUBCUTANEOUS EMPHYSEMA INCREASES; STEROID PULSE THERAPY WAS PERFORMED: ONGOING; [redacted]20[redacted] (RX DAY 638): HEMATOLOGY CONSULTATION: PLATELET TRANSFUSION TO THROMBOCYTOPENIA. ADMINISTRATION OF IMMUNOGLOBULIN PREPARATIONS FOR SEVERE INFECTIONS.; ST COMBINATION WAS STARTED CONSIDERING PNEUMOCYSTIS PNEUMONIA.: ONGOING; [redacted]20[redacted] (RX DAY 639): IMMUNOGLOBULIN ADMINISTRATION START: ONGOING; PLATELET TRANSFUSIONS: NOT IMPROVE.; [redacted]20[redacted] (RX DAY 642): VV?VENO VENOUS?-ECMO?EXTRACORPOREAL MEMBRANE OXYGENATION?: ARTIFICIAL RESPIRATION MANAGEMENT; BRAIN CT: CEREBRAL INFARCTION?LEFT POSTERIOR CEREBRAL ARTERY AREA); [redacted]20[redacted] (RX DAY 648): GASTROLNTESTINAL FIBERSCOPE: DUODENAL ULCER (MULTIPLE); [redacted]20[redacted] (RX DAY 650): GASTROLNTESTINAL FIBERSCOPE: DUODENAL ULCER (MULTIPLE); [redacted]20[redacted] (RX DAY 651): GASTROLNTESTINAL FIBERSCOPE: DUODENAL ULCER (MULTIPLE); [redacted]20[redacted] (RX DAY 652): GASTROLNTESTINAL FIBERSCOPE: DUODENAL ULCER (MULTIPLE); TRACHEOSTOMY: ARTIFICIAL RESPIRATION MANAGEMENT; [redacted]20[redacted] (RX DAY 654): LEFT THORACIC DRAINAGE: LEFT PNEUMOTHORAX

AE Stopped Rx Day	662 (30 DAYS AFTER LAST TREATMENT)
Duration of AE	26 DAYS
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	NOT REPORTED
Discontinued Study Drug Due to the Event	YES
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION, LIFE THREATENING, RESULTS IN DEATH

Event #4: Serious Adverse Event, Study Specific Adverse Events of Interest

Event Description	PNEUMOCYSTIS PNEUMONIA
Preferred term	ニューモシスチス・イロベチイ肺炎
AE Onset Date / Rx Day	[redacted]20[redacted] / 637 (5 DAYS AFTER LAST TREATMENT)
Age at AE Onset	5[redacted]

Laboratory Testing

[redacted]20[redacted] (RX DAY 633): Alanine Aminotransferase: 67 [10 - 42] U/L; Aspartate Aminotransferase: 118 [13 - 30] U/L; Blood Urea Nitrogen: 23.74 [2.86 - 7.14] mmol/L; Creatinine: 211.28 [57.46 - 94.59] umol/L; Erythrocytes: 1.8 [4.4 - 5.6] 10^12/L; Hemoglobin: 76 [137 - 468] g/L; Leukocytes: 2.4 [3.3 - 8.6] 10^9/L; NPTST071-HIV-AB: NEGATIVE [NOT REPORTED - 1] UNIT NOT REPORTED; Platelets: 116 [158 - 348] 10^9/L; Potassium: 5.7 [3.6 - 4.8] mmol/L; [redacted]20[redacted] (RX DAY 634): Erythrocytes: 1.7 [4.4 - 5.6] 10^12/L; Hemoglobin: 71 [137 - 168] g/L; Leukocytes: 3.4 [3.3 - 8.6] 10^9/L; Platelets: 103 [158 - 348] 10^9/L; [redacted]20[redacted] (RX DAY 636): NPTST080-KL-6: 880 [105 - 435] U/mL; [redacted]20[redacted] (RX DAY 637): Erythrocytes: 2.2 [4.4 - 5.6] 10^12/L; Hematocrit: 0.23 [0.41 - 0.5] fraction of 1; Hemoglobin: 83 [137 - 168] g/L; Leukocytes: 4 [3.3 - 8.6] 10^9/L; Lymphocytes/Leukocytes: 5 [16.5 - 49.5] %; Monocytes/Leukocytes: 2 [2 - 10] %; NPTST003-?-D GLUCAN: 266.2 [0 - 11] mg/L; Neutrophils Band Form/Leukocytes: 11 [0.5 - 6.5] %; Neutrophils/Leukocytes: 81 [38 - 74] %; Platelets: 43 [158 - 348] 10^9/L; [redacted]20[redacted] (RX DAY 638): Aspartate Aminotransferase: 50 [13 - 30] U/L; Blood Urea Nitrogen: 20.56 [2.86 - 7.14] mmol/L; Creatinine: 209.52 [362.45 - 450.86] umol/L; Erythrocytes: 2.3 [4.4 - 5.6] 10^12/L; Hemoglobin: 82 [137 - 168] g/L; Leukocytes: 6.5 [3.3 - 8.6] 10^9/L; NPTST042-CRP: 31.59 [0 - 0.14] mg/dL; Platelets: 30 [158 - 348] 10^9/L; [redacted]20[redacted] (RX DAY 639): Erythrocytes: 2.1 [4.4 - 5.6] 10^12/L

Microbiology

[redacted]20[redacted] (RX DAY 633): BLOOD NPTST022-BLOOD CULTURE: NEGATIVE; OTHER RESECTED LUNG TISSUE NPTST066-GROCOTT STAIN: POSITIVE-PNEUMOCYSTIS JIROVECII CYST; OTHER SUCTION SPUTUM NPTST126-SPUTUM CULTURE: POSITIVE-METHICILLIN-SUSCEPTIBLE STAPHYLOCOCCUS AUREUS GRAM-NEGATIVE RODS; [redacted]20[redacted] (RX DAY 642): BLOOD NPTST023-BLOOD CULTURES: NEGATIVE; [redacted]20[redacted] (RX DAY 650): OTHER ENDOTRACHEAL TUBE NPTST126-SPUTUM CULTURE: POSITIVE-STAPHYLOCOCCUS AUREUS

SAE Supplemental Procedure

[redacted]20[redacted] (RX DAY 633): CHEST X-RAY: RIGHT PNEUMOTHORAX,INTERSTITIAL PNEUMONIA LUNG CYST; PLAIN CT: GROUND-GLASS OPACITY; THORACOSCOPIC PNEUMONECTOMY (LUNG CYST SURGERY): DRAINAGE; VITAL SIGNS: BLOOD PRESSURE 160/99, SPO2 60%; [redacted]20[redacted] (RX DAY 636): THORACOSCOPIC LUNG SURGERY: DRAINAGE; [redacted]20[redacted] (RX DAY 637): CHEST IMAGE(CHEST CT): SUBCUTANEOUS EMPHYSEMA INCREASES; STEROID PULSE THERAPY WAS PERFORMED: ONGOING; [redacted]20[redacted] (RX DAY 638): HEMATOLOGY CONSULTATION: PLATELET TRANSFUSION TO THROMBOCYTOPENIA. ADMINISTRATION OF IMMUNOGLOBULIN PREPARATIONS FOR SEVERE INFECTIONS.; ST COMBINATION WAS STARTED CONSIDERING PNEUMOCYSTIS PNEUMONIA.: ONGOING; [redacted]20[redacted] (RX DAY 639): IMMUNOGLOBULIN ADMINISTRATION START: ONGOING; PLATELET TRANSFUSIONS: NOT IMPROVE.; [redacted]20[redacted] (RX DAY 642): VV?VENO VENOUS?-ECMO?EXTRACORPOREAL MEMBRANE OXYGENATION?: ARTIFICIAL RESPIRATION MANAGEMENT; BRAIN CT: CEREBRAL INFARCTION?LEFT POSTERIOR CEREBRAL ARTERY AREA); [redacted]20[redacted] (RX DAY 648): GASTROLNTESTINAL FIBERSCOPE: DUODENAL ULCER (MULTIPLE); [redacted]20[redacted] (RX DAY 650): GASTROLNTESTINAL FIBERSCOPE: DUODENAL ULCER (MULTIPLE); [redacted]20[redacted] (RX DAY 651): GASTROLNTESTINAL FIBERSCOPE: DUODENAL ULCER (MULTIPLE); [redacted]20[redacted] (RX DAY 652): GASTROLNTESTINAL FIBERSCOPE: DUODENAL ULCER (MULTIPLE); TRACHEOSTOMY: ARTIFICIAL RESPIRATION MANAGEMENT; [redacted]20[redacted] (RX DAY 654): LEFT THORACIC DRAINAGE: LEFT PNEUMOTHORAX

AE Stopped Rx Day	662 (30 DAYS AFTER LAST TREATMENT)

Duration of AE	26 DAYS
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	NOT REPORTED
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION, OTHER MEDICALLY IMPORTANT SERIOUS EVENT, LIFE THREATENING

Event #5: Serious Adverse Event, Study Specific Adverse Events of Interest

Event Description	CYTOMEGALOVIRUS INFECTION
Preferred term	サイトメガロウイルス感染
AE Onset Date / Rx Day	[redacted]20[redacted] / 640 (8 DAYS AFTER LAST TREATMENT)
Age at AE Onset	5[redacted]

Laboratory Testing
NOT REPORTED

Microbiology
NOT REPORTED

SAE Supplemental Procedure
NOT REPORTED

AE Stopped Rx Day	662 (30 DAYS AFTER LAST TREATMENT)
Duration of AE	23 DAYS
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	NOT REPORTED
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION, OTHER MEDICALLY IMPORTANT SERIOUS EVENT

Event #7: Serious Adverse Event

Event Description	DUODENAL ULCER
Preferred term	十二指腸潰瘍
AE Onset Date / Rx Day	[redacted]20[redacted] / 648 (16 DAYS AFTER LAST TREATMENT)
Age at AE Onset	5[redacted]

Laboratory Testing
[redacted]20[redacted] (RX DAY 633): Alanine Aminotransferase: 67 [10 - 42] U/L; Aspartate Aminotransferase: 118 [13 - 30] U/L; Blood Urea Nitrogen: 23.74 [2.86 - 7.14] mmol/L; Creatinine: 211.28 [57.46 - 94.59] umol/L; Erythrocytes: 1.8 [4.4 - 5.6] 10^12/L; Hemoglobin: 76 [137 - 468] g/L; Leukocytes: 2.4 [3.3 - 8.6] 10^9/L; NPTST071-HIV-AB: NEGATIVE [NOT REPORTED - 1] UNIT NOT REPORTED; Platelets: 116 [158 - 348] 10^9/L; Potassium: 5.7 [3.6 - 4.8] mmol/L; [redacted]20[redacted] (RX DAY 634): Erythrocytes: 1.7 [4.4 - 5.6] 10^12/L; Hemoglobin: 71 [137 - 168] g/L; Leukocytes: 3.4 [3.3 - 8.6] 10^9/L; Platelets: 103 [158 - 348] 10^9/L; [redacted]20[redacted] (RX DAY 636): NPTST080-KL-6: 880 [105 - 435] U/mL; [redacted]20[redacted] (RX DAY 637): Erythrocytes: 2.2 [4.4 - 5.6] 10^12/L; Hematocrit: 0.23 [0.41 - 0.5] fraction of 1; Hemoglobin: 83 [137 - 168] g/L; Leukocytes: 4 [3.3 - 8.6] 10^9/L; Lymphocytes/Leukocytes: 5 [16.5 - 49.5] %; Monocytes/Leukocytes: 2 [2

- 10] %; NPTST003-?-D GLUCAN: 266.2 [0 - 11] mg/L; Neutrophils Band Form/Leukocytes: 11 [0.5 - 6.5] %; Neutrophils/Leukocytes: 81 [38 - 74] %; Platelets: 43 [158 - 348] 10^9/L; [redacted]20[redacted] (RX DAY 638): Aspartate Aminotransferase: 50 [13 - 30] U/L; Blood Urea Nitrogen: 20.56 [2.86 - 7.14] mmol/L; Creatinine: 209.52 [362.45 - 450.86] umol/L; Erythrocytes: 2.3 [4.4 - 5.6] 10^12/L; Hemoglobin: 82 [137 - 168] g/L; Leukocytes: 6.5 [3.3 - 8.6] 10^9/L; NPTST042-CRP: 31.59 [0 - 0.14] mg/dL; Platelets: 30 [158 - 348] 10^9/L; [redacted]20[redacted] (RX DAY 639): Erythrocytes: 2.1 [4.4 - 5.6] 10^12/L

Microbiology

[redacted]20[redacted] (RX DAY 633): BLOOD NPTST022-BLOOD CULTURE: NEGATIVE; OTHER RESECTED LUNG TISSUE NPTST066-GROCOTT STAIN: POSITIVE-PNEUMOCYSTIS JIROVECII CYST; OTHER SUCTION SPUTUM NPTST126-SPUTUM CULTURE: POSITIVE-METHICILLIN-SUSCEPTIBLE STAPHYLOCOCCUS AUREUS GRAM-NEGATIVE RODS; [redacted]20[redacted] (RX DAY 642): BLOOD NPTST023-BLOOD CULTURES: NEGATIVE; [redacted]20[redacted] (RX DAY 650): OTHER ENDOTRACHEAL TUBE NPTST126-SPUTUM CULTURE: POSITIVE-STAPHYLOCOCCUS AUREUS

SAE Supplemental Procedure

[redacted]20[redacted] (RX DAY 633): CHEST X-RAY: RIGHT PNEUMOTHORAX,INTERSTITIAL PNEUMONIA LUNG CYST; PLAIN CT: GROUND-GLASS OPACITY; THORACOSCOPIC PNEUMONECTOMY (LUNG CYST SURGERY): DRAINAGE; VITAL SIGNS: BLOOD PRESSURE 160/99, SPO2 60%; [redacted]20[redacted] (RX DAY 636): THORACOSCOPIC LUNG SURGERY: DRAINAGE; [redacted]20[redacted] (RX DAY 637): CHEST IMAGE(CHEST CT): SUBCUTANEOUS EMPHYSEMA INCREASES; STEROID PULSE THERAPY WAS PERFORMED: ONGOING; [redacted]20[redacted] (RX DAY 638): HEMATOLOGY CONSULTATION: PLATELET TRANSFUSION TO THROMBOCYTOPENIA. ADMINISTRATION OF IMMUNOGLOBULIN PREPARATIONS FOR SEVERE INFECTIONS.; ST COMBINATION WAS STARTED CONSIDERING PNEUMOCYSTIS PNEUMONIA.: ONGOING; [redacted]20[redacted] (RX DAY 639): IMMUNOGLOBULIN ADMINISTRATION START: ONGOING; PLATELET TRANSFUSIONS: NOT IMPROVE.; [redacted]20[redacted] (RX DAY 642): VV?VENO VENOUS?-ECMO?EXTRACORPOREAL MEMBRANE OXYGENATION?: ARTIFICIAL RESPIRATION MANAGEMENT; BRAIN CT: CEREBRAL INFARCTION?LEFT POSTERIOR CEREBRAL ARTERY AREA); [redacted]20[redacted] (RX DAY 648): GASTROLNTESTINAL FIBERSCOPE: DUODENAL ULCER (MULTIPLE); [redacted]20[redacted] (RX DAY 650): GASTROLNTESTINAL FIBERSCOPE: DUODENAL ULCER (MULTIPLE); [redacted]20[redacted] (RX DAY 651): GASTROLNTESTINAL FIBERSCOPE: DUODENAL ULCER (MULTIPLE); [redacted]20[redacted] (RX DAY 652): GASTROLNTESTINAL FIBERSCOPE: DUODENAL ULCER (MULTIPLE); TRACHEOSTOMY: ARTIFICIAL RESPIRATION MANAGEMENT; [redacted]20[redacted] (RX DAY 654): LEFT THORACIC DRAINAGE: LEFT PNEUMOTHORAX

AE Stopped Rx Day	662 (30 DAYS AFTER LAST TREATMENT)
Duration of AE	15 DAYS
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	NOT REPORTED
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION, OTHER MEDICALLY IMPORTANT SERIOUS EVENT, LIFE THREATENING

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554

治験責任医師からの報告。本被験者は日本の5[redacted]歳男性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，致死的な汎血球減少症，ニューモシスチス肺炎，間質性肺炎，右気胸，サイトメガロウイルス感染及び十二指腸潰瘍の事象を発現した。

Event 1～5 及び 7 の臨床経過：

関連する病歴は乾癬性関節炎，胃食道逆流性疾患，心身症，アルコール性肝疾患，浮腫，高血圧，局面型乾癬，紙巻タバコ喫煙者（1 日 1 箱を 32 年間）及び元飲酒者（1 日 2～4 杯）であった。

被験者は，最初の 24 週間，本治験の盲検プラセボ対照期に組み入れられていた。20[redacted]年[redacted]月[redacted]日，ABT-494 の盲検投与が開始された。

20[redacted]年[redacted]月[redacted]日，被験者は間質性肺炎及び右気胸を発現した。20[redacted]年[redacted]月[redacted]日，被験者は汎血球減少症及びニューモシスチス肺炎を発現した。20[redacted]年[redacted]月[redacted]日，被験者はサイトメガロウイルス感染を発現した。20[redacted]年[redacted]月[redacted]日，被験者は十二指腸潰瘍を発現した。20[redacted]年[redacted]月[redacted]日，被験者は死亡した。死因は汎血球減少症と報告された。剖検が実施された。

20[redacted]年[redacted]月[redacted]日，被験者は高血圧のため内科医を受診した。被験者は体調が悪そうであり，顔面蒼白及び労作時呼吸困難を伴っていた。また，血圧が高値で，酸素飽和度が低値であった。胸部 X 線検査が行われ，右気胸が認められた。内科医は治療として右第 1 肋間穿刺による脱気を行った。脱気後，被験者は救急サービスを介して病院に搬送され，同日入院した。

入院後，HIV 検査が行われ，結果は陰性であった。右気胸に変化は見られず，肺瘻が認められた。肺瘻はコントロール不能であった。その後，分離肺換気が行われた。換気により右気胸の回復が認められたが，気漏は持続していた。肺瘻閉鎖術が緊急に行われた。その後，CT 検査が行われ，すりガラス陰影が認められたことから間質性肺炎が明らかとなった。また，肺嚢胞（X 線画像で発覚）に対する緊急胸腔鏡下肺全摘除と，継続的な胸腔ドレナージが行われた。

20[redacted]年[redacted]月[redacted]日，再度，胸腔鏡下肺手術とドレナージが行われた。ドレーン挿入に起因すると思われる右肺損傷に対する肺縫縮術が行われた。肺縫縮術後，外科医は人工呼吸器のウィーニングを試みたが，酸素飽和度が低下した。被験者は ICU に入院となり，そこでも換気補助が必要な状態であった。20[redacted]年[redacted]月[redacted]日，間質性肺炎に対し，ステロイドパルス療法が行われ，バクトラミンの静脈内投与が開始された。また，血液検査で KL-6 及び β-D-グルカンの増加が認められたことからニューモシスチス肺炎が疑われた。20[redacted]年[redacted]月[redacted]日，被験者は播種性血管内凝固（非重篤）を発現した。同日，血液専門医による診察が行われた。20[redacted]年[redacted]月[redacted]日，右肺

切除部の検体から気腫性嚢胞及びニューモシスチス・イロベチイが検出された。右肺ドレナージ及び左肺機能低下のため，換気が継続された。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は，ニューモシスチス肺炎による持続的な炎症反応を伴う ARDS を発症した。被験者は心肺バイパス装置に繋がれた。同日，脳 CT 検査により塞栓性が疑われる急性脳梗塞（非重篤）が明らかとなり，ヘパリンが投与された。20[redacted] 年 [redacted] 月 [redacted] 日，サイトメガロウイルス性抗原血症に対するデノシン静脈内投与が開始された。

20[redacted] 年 [redacted] 月 [redacted] 日，血便が認められ，消化管ファイバースコープ（GIF）で十二指腸潰瘍が見つかった。出血点のクリッピングにより止血が達成されたが，別の部位で新たな出血が起こった。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は左気胸を発症し，左胸腔ドレナージが行われた。両肺に持続的な気漏が認められた。

20[redacted] 年 [redacted] 月 [redacted] 日，Bactrim（スルファメトキサゾール・トリメトプリム合剤）及びデノシンに起因する汎血球減少症より，骨髄抑制が示唆された。これらの 2 剤は中止された。また，連日にわたって血小板輸血が行われた。血小板輸血にもかかわらず，血小板数は 80,000/mL を上回ることはなかった。20[redacted] 年 [redacted] 月 [redacted] 日，この被験者に対する治療は限界と判断されたため，血小板輸血は家族の同意の下に中止された。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は死亡した。実施された剖検は画像診断のみであった。

入院前に CMV の血清学的検査は行われなかった。さらに，被験者が症状を呈していなかったため，入院前及び入院中に EBV 及びパルボウイルス B19 の血清学的検査も行われなかった。

医療記録によると，20[redacted] 年 [redacted] 月に，CMV の再検査が行われ，結果は陽性であった。20[redacted] 年 [redacted] 月 [redacted] 日，メレナが認められ，ヘパリンが減量された。20[redacted] 年 [redacted] 月 [redacted] 日，GIF が行われ，十二指腸潰瘍が認められたため，露出血管をクリッピングした。20[redacted] 年 [redacted] 月 [redacted] 日，十二指腸潰瘍が再び出血し，再 GIF が行われ，緊急クリッピングが必要となった。20[redacted] 年 [redacted] 月 [redacted] 日，GIF が再度行われ，別の部位からの出血が認められたため，その出血部位をクリッピングした。同日，気管切開が行われた。

退院時サマリーによると，複数回の輸血が行われた。十二指腸潰瘍からの胃腸出血が複数回発生し，露出血管をクリッピングするために GIF が行われた。20[redacted] 年 [redacted] 月 [redacted] 日，被験者はメレナを発現した。

投与された薬剤は，免疫グロブリン，酸素，bactrim（スルファメトキサゾール・トリメトプリム合剤），クエン酸第一鉄ナトリウム，バクトラミン，ダラシン-S，サムチレール，ソル・メ

ルコート，グラン，フィブロガミン P，デノシン，濃厚血小板（10 単位），カンサイダス，ヘパリン，血液，DHPG，タケキャブ，レバミピド，アンヒバ，レミフェンタニル，アドナ，トランサミン，グロベニン I，プレドニン，クラビット，ファンガード，タケプロン，モルヒネ塩酸塩，スルバシリン，バンコマイシン，クエン酸第一鉄ナトリウム及びメロペネムであった。

The patient's past medications include:

BONALFA for PSORIASIS ([redacted])

DIFLAL for PSORIATIC ARTHROPATHY ([redacted])

METHADERM for PSORIATIC ARTHROPATHY ([redacted])

LOCOID for ARTHROPATHIC PSORIASIS ([redacted])

RISANKIZUMAB for PSORIATIC ARTHRITIS ([redacted])

RHEUMATREX for ARTHROPATHIC PSORIASIS ([redacted])

HIRUDOID for PSORIASIS ([redacted])

BUFFERIN COMBINATION for UNKNOWN INDICATION

Causality for UPADACITINIB (Blinded)

---

1) Pancytopenia (10033661) (Pancytopenia (10033661)) [v.22.0] [10033661]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Not Applicable

2) Pneumocystis pneumonia (10035661) (Pneumocystis jirovecii pneumonia (10073755)) [v.22.0] [10035661]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): Reasonable possibility

Dechallenge: Not Applicable

3) Interstitial pneumonia (10022617) (Interstitial lung disease (10022611)) [v.22.0] [10022617]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Unknown

4) Pneumothorax (10035759) (Pneumothorax (10035759)) [v.22.0] [10035759]

Causality as per reporter (Drug/Vaccine): No reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Unknown

5) Cytomegalovirus infection (10011831) (Cytomegalovirus infection (10011831)) [v.22.0] [10011831]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Not Applicable

6) Duodenal ulcer (10013836) (Duodenal ulcer (10013836)) [v.22.0] [10013836]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Not Applicable

Alternative Etiology for UPADACITINIB (Blinded)

Event of PANCYTOPENIA

- Investigator: Not applicable

- AbbVie: Risk factors include pre-existing alcoholic liver disease and underlying systemic inflammatory disease.

Event of PNEUMOCYSTIS PNEUMONIA

- Investigator: Not applicable

- AbbVie: Not applicable

Event of INTERSTITIAL PNEUMONIA

- Investigator: Not applicable

- AbbVie: Event is more likely related to current, extensive smoking history of one pack a day for 32 years.

Event of RIGHT PNEUMOTHORAX

- Investigator: A cyst on the surface of the lungs (primary side) = primary spontaneous pneumothorax in which Bra Brev ruptures.

- AbbVie: Risk factors include concurrent interstitial pneumonia and current cigarette smoker (1 PPD for 32 years).

Event of CYTOMEGALOVIRUS INFECTION

- Investigator: Not Applicable

- AbbVie: risk factors include recent hospitalization, recent surgeries, and recent use of steroid pulse therapy.

Event of DUODENAL ULCER

- Investigator: Not applicable.

- AbbVie: Risk factors include concomitant heparin treatment, disseminated intravascular coagulation, acute critical illness, and current, extensive smoking history of one pack per day for 32 years.

Relevant Laboratory & Other Diagnostic Tests

[redacted] **20[redacted] ALANINE AMINO TRANSFERASE:** 67 U/L (normal 10 to 42)

[redacted] **20[redacted] ANTI-HEP B SURFACE AG2 QUAL:** negative

[redacted] **20[redacted] ASPARTATE AMINO TRANSFERASE:** 118 U/L (normal 13 to 30)

[redacted] **20[redacted] ASPARTATE AMINO TRANSFERASE:** 50 U/L (normal 13 to 30)

[redacted] **20[redacted] B-D GLUCAN:** 266.2 PG/ML (normal 0 to 11.0)

[redacted] **20[redacted] BANDS %:** 11 % (normal 0.5 to 6.5)

[redacted] **20[redacted] BANDS %:** 1.0 % (normal 0.5 to 6.5)

[redacted] **20[redacted] BLOOD CULTURE:** Negative

[redacted] **20[redacted] BLOOD CULTURES:** Negative.

[redacted] **20[redacted] BLOOD PRESSURE:** 160/90 mmHg

[redacted] **20[redacted] BLOOD UREA NITROGEN:** 66.5 mg/dL (normal 8 to 20.0)

[redacted] **20[redacted] BLOOD UREA NITROGEN:** 57.6 mg/dL (normal 8 to 20.0)

[redacted] **20[redacted] BRAIN CT:** Low density area is well-defined from Left occipital lobe to mesial temporal lobe and left posterior limb of internal capsule. Diagnosed as cerebral infraction at the sub acute stage or the later stage. There is no detectable bleeding.. Cerebral infarction (left posterior cerebral artery area)

[redacted] **20[redacted] CHEST CT:** Subcutaneous emphysema increases.

[redacted] **20[redacted] CHEST X-RAY:** Normal

[redacted] **20[redacted] CHEST X-RAY:** Normal

[redacted] **20[redacted] CHEST X-RAY:** Right pneumothorax, interstitial pneumonia

[redacted] **20[redacted] CREATININE (BLOOD):** 2.39 mg/dL (normal 0.65 to 1.07)

[redacted] **20[redacted] CREATININE (BLOOD):** 2.37 mg/dL (normal 0.65 to 1.07)

[redacted] **20[redacted] CRP:** 31.59 mg/dL (normal 0.0 to 0.14)

[redacted] **20[redacted] CT:** Ground-glass opacity.

[redacted] **20[redacted] CYTOMEGALOVIRUS ANTIGENEMIA:** 8 NA (normal 0 to 0)

[redacted] **20[redacted] CYTOMEGALOVIRUS TEST:** 6 NA (normal 0 to 0)

[redacted] **20[redacted] EOSINOPHILS %:** 7.0 % (normal 0.0 to 8.5)

[redacted] **20[redacted] ERYTHROBLAST:** 7.0 % (normal 0 to 0)

[redacted] **20[redacted] Gastrointestinal Fiberscope:** Duodenal ulcer (multiple): A1 stage was observed, visible vessels were clipped.

[redacted] 20[redacted] **Gastrointestinal Fiberscope:** Duodenal ulcer (multiple).

[redacted] 20[redacted] **Gastrointestinal Fiberscope:** Duodenal ulcer (multiple). Bleeding started again and was clipped

[redacted] 20[redacted] **Gastrointestinal Fiberscope:** Duodenal ulcer (multiple).The bleeding was detected from the different part and the bleeding part was clipped.

[redacted] 20[redacted] **HEMOGLOBIN:** 7.6 G/DL (normal 13.7 to 16.8)

[redacted] 20[redacted] **HEMOGLOBIN:** 7.1 G/DL (normal 13.7 to 16.8)

[redacted] 20[redacted] **HEMOGLOBIN:** 8.2 G/DL (normal 13.7 to 16.8)

[redacted] 20[redacted] **HEMOGLOBIN:** 7.6 G/DL (normal 13.7 to 16.8)

[redacted] 20[redacted] **HEP B SURFACE AG:** negative

[redacted] 20[redacted] **HEPATITIS B CORE TOTAL:** negative

[redacted] 20[redacted] **HEPATITIS C VIRUS ANTIBODY-QT:** negative

[redacted] 20[redacted] **HGB:** 9.6 G/DL (normal 12.7 to 18.1)

[redacted] 20[redacted] **HIV TEST:** Negative

[redacted] 20[redacted] **KL-6:** 880 U/ML (normal 105 to 435)

[redacted] 20[redacted]**LUNG PATHOLOGY:** THORACOSCOPIC PNEUMONECTOMY: Bulla and Pneumocystis jirovecii cyst were found from the right-lung resected specimen.

[redacted] 20[redacted] **LYMPHOCYTES %:** 5.0 % (normal 16.5 to 49.5)

[redacted] 20[redacted] **LYMPHOCYTES %:** 26.0 % (normal 16.5 to 49.5)

[redacted] 20[redacted] **LYMPHOCYTES %:** 1.0 % (normal 16.5 to 49.5)

[redacted] 20[redacted] **MONOCYTE %:** 7.0 % (normal 2.0 to 10.0)

[redacted] 20[redacted] **MONOCYTES %:** 2.0 % (normal 2.0 to 10.0)

[redacted] 20[redacted] **NEUTORPHILS %:** 58.0 % (normal 38.0 to 74.0)

[redacted] 20[redacted] **NEUTROPHILS %:** 81.0 % (normal 38.0 to 74.0)

[redacted] 20[redacted] **PLATELET COUNT:** 116 X10**3/MCL (normal 158 to 348)

[redacted] 20[redacted] **PLATELET COUNT:** 103 X10**3/MCL (normal 158 to 348)

[redacted] 20[redacted] **PLATELET COUNT:** 30 X10**3/MCL (normal 158 to 348)

[redacted] 20[redacted] **PLATELET COUNT:** 21 X10**3/MCL (normal 158 to 348)

[redacted] **20[redacted] PLATELET COUNT:** 91 X10**3/MCL (normal 158 to 348)

[redacted] **20[redacted] PLATELET COUNT:** 5 X10**3/MCL (normal 158 to 348)

[redacted] **20[redacted] POTASSIUM:** 5.7 MMOL/L (normal 3.6 to 4.8)

[redacted] **20[redacted] RBC MORPH:** Anisocytosis Polychromatophilia

[redacted] **20[redacted] RED BLOOD CELLS:** 1.81 X10**6/MCL (normal 4.35 to 5.55)

[redacted] **20[redacted] RED BLOOD CELLS:** 2.25 X10**6/MCL (normal 4.35 to 5.55)

[redacted] **20[redacted] RED BLOOD CELLS:** 2.49 X10**6/MCL (normal 4.35 to 5.55)

[redacted] **20[redacted] SPO2:** 60 %

[redacted] **20[redacted] SPUTUM CULTURE:** Suction: Positive - Methicillin-susceptible Staphylococcus aureus gram-negative Rods

[redacted] **20[redacted] SPUTUM CULTURE:** Endotracheal tube: Positive - Staphylococcus aureus

[redacted] **20[redacted] WHITE BLOOD CELL COUNT:** 2.36 X10**3/MCL (normal 3.80 to 10.70)

[redacted] **20[redacted] WHITE BLOOD CELLS:** 2.35 X10**3/MCL (normal 3.30 to 8.60)

[redacted] **20[redacted] WHITE BLOOD CELLS:** 3.43 X10**3/MCL (normal 3.30 to 8.60)

[redacted] **20[redacted] WHITE BLOOD CELLS:** 6.46 X10**3/MCL (normal 3.30 to 8.60)

[redacted] **20[redacted] WHITE BLOOD CELLS:** 0.73 X10**3/MCL (normal 3.30 to 8.60)

[redacted] **20[redacted] WHITE BLOOD CELLS:** 0.55 X10**3/MCL (normal 3.30 to 8.60)

[redacted] **20[redacted] WHITE BLOOD CELLS:** 0.28 X10**3/MCL (normal 3.30 to 8.60)

被験者番号 [redacted] (Investigator [redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
小腸潰瘍	X	X		

Treatment Group	Age at Study Start	Sex	Race
ABT-494 30 mg QD	4[redacted]	MALE	ASIAN

Medical History	Onset Year
HYPERTENSION	19[redacted]
OTHER: PSORIASIS VULGARIS	20
OTHER: INFECTIOUS ATHEROMA	20
OTHER: HEMATURIA	20
OTHER: OBESITY	20
OTHER: BASEMENT MEMBRANE THINNING DISEASE, KIDNEY	20
OTHER: LOWER LIMB EDEMA	20
OTHER: LUMBER SPINAL STENOSIS-L4	20
OTHER: OBESITY-RELATED NEPHROPATHY	20
OTHER: PSORIATIC SPONDYLITIS	20

Prior Procedures	Procedure Year
Not reported.	

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
Not reported.				

Alcohol Use	Status	Number/Day
ALCOHOL	NEVER	

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
ABT-494	30MG	ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 35	35

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
BCG Vaccine	NOT REPORTED	NOT REPORTED	Y-M: 19[redacted]
FOLIC ACID	5 mg	QD	Y-M: 20[redacted]
METHOTREXATE	6 mg	EVERY WEEK	Y-M: 20[redacted]
CLOBETASOL	NA OTHER: NA	BID	Y-M: 20[redacted]-
TACALCITOL	NA OTHER: NA	BID	Y-M: 20[redacted]-
LOXOPROFEN	60 mg	TID	Y-M: 20[redacted]-
TILDRAKIZUMAB	200 mL	OTHER: EVERY 4 WEEKS	Y-M: 20[redacted]-
DIFLUPREDNATE	NA OTHER: NA	QD	Y-M: 20[redacted]-
BETAMETHASONE	NA OTHER: NA	BID	Y-M: 20[redacted]-
DIFLUPREDNATE	NA OTHER: NA	BID	Y-M: 20[redacted]-
INFLIXIMAB	100 mL	OTHER: EVERY 8 WEEKS	Y-M: 20[redacted]-
OLMESARTAN	30 mg	QD	Y-M: 20[redacted]-
PREGABALIN	50 mg	BID	Y-M: 20[redacted]- / -308
SODIUM CHLORIDE	250 mL	OTHER: EVERY 8 WEEKS	Y-M: 20[redacted]- / -76

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
FOLIC ACID	5 mg	QD	Y-M: 20[redacted]	Y-M: 20[redacted] / 38
METHOTREXATE	6 mg	EVERY WEEK	Y-M: 20[redacted]	Y-M: 20[redacted] / 38
OLMESARTAN	30 mg	QD	Y-M: 20[redacted]	ONGOING
HYOSCINE	10 mg	PRN	Y-M: 20[redacted] / 27	Y-M: 20[redacted] / 31
LAC-B GRANULAR POWDER N	1 g	TID	Y-M: 20[redacted] / 27	Y-M: 20[redacted] / 31
LEVOFLOXACIN	500 mg	QD	Y-M: 20[redacted] / 27	Y-M: 20[redacted] / 31
METOCLOPRAMIDE	5 mg	TID	Y-M: 20[redacted] / 27	Y-M: 20[redacted] / 31
PARACETAMOL	200 mg	PRN	Y-M: 20[redacted] / 27	Y-M: 20[redacted] / 31
REBAMIPIDE	100 mg	TID	Y-M: 20[redacted] / 27	Y-M: 20[redacted] / 31
SOLITA-T1	500 mL	PRN	Y-M: 20[redacted] / 29	Y-M: 20[redacted] / 29
FOSFOMYCIN	500 mg	QD	Y-M: 20[redacted] / 29	Y-M: 20[redacted] / 41
ELECTROLYTES NOS	500 mL	PRN	Y-M: 20[redacted] / 31	Y-M: 20[redacted] / 41
LEVOFLOXACIN	500 mg	QD	Y-M: 20[redacted] / 31	Y-M: 20[redacted] / 41
SODIUM BICARBONATE	500 mL	PRN	Y-M: 20[redacted] / 31	Y-M: 20[redacted] / 41
VITAMEDIN	1 OTHER: VIAL	PRN	Y-M: 20[redacted] / 31	Y-M: 20[redacted] / 41
PARACETAMOL	1000 mg	PRN	Y-M: 20[redacted] / 31	Y-M: 20[redacted] / 45
OMEPRAZOLE	20 mg	PRN	Y-M: 20[redacted] / 34	Y-M: 20[redacted] / 41
PARACETAMOL	400 mg	TID	Y-M: 20[redacted] / 37	Y-M: 20[redacted] / 41
REBAMIPIDE	100 mg	TID	Y-M: 20[redacted] / 38	Y-M: 20[redacted] / 41
GANCICLOVIR	500 mg	BID	Y-M: 20[redacted] / 43	Y-M: 20[redacted] / 56
VONOPRAZAN	20 mg	QD	Y-M: 20[redacted] / 45	Y-M: 20[redacted] / 92
NUTRIENTS NOS	250 mL	QD	Y-M: 20[redacted] / 56	Y-M: 20[redacted] / 57
NUTRIENTS NOS	250 mL	QD	Y-M: 20[redacted] / 56	Y-M: 20[redacted] / 58
HYDROCORTISONE	NA OTHER: NA	BID	Y-M: 20[redacted] / 58	Y-M: 20[redacted] / 87
IRON	50 mg	QD	Y-M: 20[redacted] / 64	ONGOING
DAIVOBET	NA OTHER: NA	QD	Y-M: 20[redacted] / 66	Y-M: 20[redacted] / 87

Event #1: Serious Adverse Event, AE Leading to Discontinuation of Study Drug

Event Description	SMALL INTESTINAL ULCER
Preferred term	小腸潰瘍
AE Onset Date / Rx Day	[redacted]20[redacted] / 31
Age at AE Onset	4[redacted]

Laboratory Testing

[redacted]20[redacted] (RX DAY 35): Hemoglobin: 77 [137 - 168] g/L; [redacted]20[redacted] (RX DAY 42): Alanine Aminotransferase: 33 [10 - 20] U/L; Albumin: 24 [41 - 51] g/L; Aspartate Aminotransferase: 28 [13 - 30] U/L; Bilirubin: 17.1 [6.84 - 25.66] umol/L; Blood Urea Nitrogen: 12.07 [2.86 - 7.14] mmol/L; Creatinine: 93.71 [57.46 - 94.59] umol/L; Erythrocytes: 1.5 [4.4 - 5.6] 10^12/L; Hemoglobin: 44 [137 - 168] g/L; Leukocytes: 22.8 [3.3 - 8.6] 10^9/L; NPTST042-CRP: 3.93 [0 - 0.14] mg/dL; NPTST056-EGFR: 60.3 [60 - 120] mL/min/1.73m2; NPTST059-FE: 44 [40 - 188] ug/dL; NPTST060-FERRITIN: 194.4 [50 - 200] ng/mL; NPTST084-LDH: 152 [124 - 222] U/L; NPTST119-RETICULOCYTE: 10.7 [8 - 22] %; NPTST130-TIBC: 243 [253 - 365] ug/dL; NPTST133-TRANSFERRIN: 193 [199 - 318] mg/dL; NPTST140-UNSATURATED IRON BINDING CAPACI: 199 [111 - 255] ug/dL; Platelets: 382 [158 - 348] 10^9/L; Protein: 43 [66 - 81] g/L

Microbiology
NOT REPORTED
SAE Supplemental Procedure
[redacted]20[redacted] (RX DAY 42): CT?[redacted].[redacted].[redacted].[redacted]20[redacted]?ABDOMEN, PELVIS?: NO PERFORATION OF DIGESTIVE TRACT. [redacted].[redacted]20[redacted].IMPROVEMENT TREND; GASTRO-INTESTINAL FIBERSCOPY (GIF) [redacted].[redacted].[redacted]20[redacted].[redacted]20[redacted]: WITHOUT IMPROVING THE ULCER. [redacted].[redacted]20[redacted]THE ULCER IS PARTIALLY SCARRED.; HISTOLOGICAL EXAMINATION FOR CMV SCRUTINY.: NEGATIVE

AE Stopped Rx Day	92 (57 DAYS AFTER LAST TREATMENT)
Duration of AE	62 DAYS
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	NOT REPORTED
Discontinued Study Drug Due to the Event	YES
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION, OTHER MEDICALLY IMPORTANT SERIOUS EVENT, LIFE THREATENING

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554

治験責任医師からの報告。本被験者は日本の 4[redacted] 歳男性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，小腸潰瘍の事象を発現した。

Event 1 の臨床経過：

関連する病歴は高血圧，尋常性乾癬，乾癬性関節炎，血尿，肥満，紙巻タバコ喫煙者（1 日 1 箱を 26 年間）及び禁酒であった。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は小腸潰瘍を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，小腸潰瘍は消失した。

本事象発現前の 20[redacted] 年 [redacted] 月 [redacted] 日，被験者は嘔吐及び腹痛を呈し，胃腸炎（非重篤）と診断された。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は上腹部痛，貧血，白血球増加，低アルブミン血症，胃腸出血及びメレナで入院した。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は他院に転院となり，CT 検査及び消化管ファイバースコープが行われた。ファイバースコープにより，十二指腸下行部から肛門側にかけて複数の穿孔性潰瘍が検出された。十二指腸下行部では筋層が露出しており，肛門にスコープを挿

入することができなかった。デノシンの静脈内投与が行われた。被験者は20[redacted]年[redacted]月[redacted]日に食事を開始した。20[redacted]年[redacted]月[redacted]日，消化管ファイバースコープが再度行われ，潰瘍の軽快と部分的な瘢痕形成が認められた。20[redacted]年[redacted]月[redacted]日，被験者は退院した。本事象により治験薬の投与が完全に中止された。

投与された薬剤は，デノシン，ホスミシン，ビカーボン，ビタメジン，クラビット，アセリオ，オメプラゾール，カロナール，レバミピド及びソリタ-T であった。

Causality for UPADACITINIB (Blinded)

---

1) Small intestine ulcer (10041133) (Small intestine ulcer (10041133)) [v.22.0] [10041133]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Yes

Rechallenge: No rechallenge was done, recurrence is not applicable

Alternative Etiology for UPADACITINIB (Blinded)

Event of SMALL INTESTINAL ULCER

- **Investigator:** Not applicable

- **AbbVie:** Risk factors include current smoking status and concomitant therapy with Metolate.

Relevant Laboratory & Other Diagnostic Tests

[redacted]20[redacted] **ALBUMIN:** 2.4 G/DL (normal 4.1 to 5.1)

[redacted]20[redacted] **BUN:** 33.8 mg/dL (normal 8 to 20)

[redacted]20[redacted] **CREATININE:** 1.06 mg/dL (normal 0.65 to 1.07)

[redacted]20[redacted] **CRP:** 3.93 mg/dL (normal 0 to 0.14)

[redacted] 20[redacted] **ENDOSCOPY:** the Intestinal wall was very thin

[redacted] 20[redacted] **FE:** 44 MCG/DL (normal 40 to 188)

[redacted] 20[redacted] **FERRITIN:** 194.4 NG/ML (normal 50 to 200)

[redacted] 20[redacted] **GASTRO-INTESTINAL FIBROSCOPY:** Multiple punched ulcers were detected from the descending portion of the duodenum to the anal side. The decending portion of duodenum have muscle layer exposure, the scope could not be inserted into anus.

[redacted] 20[redacted] **GASTRO-INTESTINAL FIBROSCOPY:** improving ulcer, partial scarring

[redacted] 20[redacted] **HB:** 7.7 G/DL

[redacted] 20[redacted] **HB:** 4 G/DL

[redacted] 20[redacted] **HEMOGLOBIN:** 7.7 G/DL (normal 13.7 to 16.8)

[redacted] 20[redacted] **HGB:** 4.4 G/DL (normal 13.7 to 16.8)

[redacted] 20[redacted] **RBC:** 1.45 X10**6/MCL (normal 4.35 to 5.55)

[redacted] 20[redacted] **RETICULOCYTE:** 10.7 % (normal 8 to 22)

[redacted] 20[redacted] **TIBC:** 243 MCG/DL (normal 253 to 365)

[redacted] 20[redacted] **TOTAL PROTEIN:** 4.3 G/DL (normal 6.6 to 8.1)

[redacted] 20[redacted] **TRANSFERRIN:** 193 mg/dL (normal 199 to 318)

[redacted] 20[redacted] **UNSATURATED IRON BINDING CAPACITY:** 199 MCG/DL (normal 111 to 255)

[redacted] 20[redacted] **WBC:** Over 20,000

[redacted] 20[redacted] **WBC:** 22.78 X10**3/MCL (normal 3.30 to 8.60)

被験者番号 [redacted] (Investigator [redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
糖尿病	X			

Treatment Group	Age at Study Start	Sex	Race
Placebo/ABT-494 15 mg QD	4[redacted]	MALE	ASIAN

Medical History	Onset Year
OTHER: PLAQUE PSORIASIS	NOT REPORTED
OTHER: GASTRIC ULCER	20[redacted]
PANCREATITIS: ACUTE PANCREATITIS	20[redacted]
OTHER: DIABETES MELLITUS	20[redacted]
TUBERCULOSIS: LATENT TUBERCULOSIS	20[redacted]
DIABETES MELLITUS: WORSENINNG OF DIABETES MELLITUS	20[redacted]
OTHER: RETINOPATHY	20[redacted]

Prior Procedures	Procedure Year
Not reported.	

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
Not reported.				

Alcohol Use	Status	Number/Day
ALCOHOL	FORMER	Less than 2

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
PLACEBO		ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 168	168
ABT-494	15MG	ORAL	QD	[redacted]20[redacted] / 169	/	

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
BCG Vaccine	NOT REPORTED	NOT REPORTED	Y-M: 19[redacted]
INSULIN ASPART W/INSULIN DEGLUDEC	9-20 OTHER: UNITS	BID	Y-M: 20[redacted]
MIGLITOL	75 mg	TID	Y-M: 20[redacted]
FOLIC ACID	5 mg	QD	Y-M: 20[redacted]
LOXOPROFEN	60 mg	BID	Y-M: 20[redacted]
METHOTREXATE	6 mg	EVERY WEEK	Y-M: 20[redacted]
REBAMIPIDE	100 mg	BID	Y-M: 20[redacted]
ISONIAZID	100 mg	TID	Y-M: 20[redacted]
INFLIXIMAB	300 mg	OTHER: EVERY 8 WEEKS	Y-M: 20[redacted]
SODIUM CHLORIDE	250 mL	OTHER: EVERY 8 WEEKS	Y-M: 20[redacted]
SECUKINUMAB	300 mg	OTHER: ONCE A MONTH	Y-M: 20[redacted]
ADALIMUMAB	40 mg	EVERY 2 WEEKS	Y-M: 20[redacted]
REBAMIPIDE	100 mg	BID	Y-M: 20[redacted] / -315
INSULIN ASPART	2-6 OTHER: UNITS	QD	Y-M: 20[redacted] / -238
METHOTREXATE	8 mg	EVERY WEEK	Y-M: 20[redacted] / -91

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
MIGLITOL	75 mg	TID	Y-M: 20[redacted]	Not reported.
INSULIN ASPART W/INSULIN DEGLUDEC	9-20 OTHER: UNITS	BID	Y-M: 20[redacted]	Y-M: 20[redacted] / 307
FOLIC ACID	5 mg	QD	Y-M: 20[redacted]	Not reported.
LOXOPROFEN	60 mg	BID	Y-M: 20[redacted]	Not reported.
REBAMIPIDE	100 mg	BID	Y-M: 20[redacted] / -315	Y-M: 20[redacted] / 308
INSULIN ASPART	2-6 OTHER: UNITS	QD	Y-M: 20[redacted] / -238	Not reported.
METHOTREXATE	8 mg	EVERY WEEK	Y-M: 20[redacted] / -91	Not reported.
ESOMEPRAZOLE	20 mg	QD	Y-M: 20[redacted] / 216	Not reported.
REBAMIPIDE	100 mg	QD	Y-M: 20[redacted] / 307	Not reported.
GLUCOSE	10 g	PRN	Y-M: 20[redacted] /	Y-M: 20[redacted] /

MIGLITOL	75 mg	TID	Y-M: 20[redacted]-[redacted] / 307	Y-M: 20[redacted]-[redacted] / 310
INSULIN DEGLUDEC	3 OTHER: UNIT	QD	Y-M: 20[redacted]-[redacted] / 307	Not reported. 315

Event #1: Serious Adverse Event

Event Description	WORSENING OF DIABETES MELLITUS
Preferred term	糖尿病
AE Onset Date / Rx Day	[redacted]20[redacted] / 281
Age at AE Onset	4[redacted]
Laboratory Testing	[redacted]20[redacted] (RX DAY 281): Glucose: 16.93 [4.05 - 6.05] mmol/L; [redacted]20[redacted] (RX DAY 308): Glucose: 4.05 [4.05 - 6.05] mmol/L
Microbiology	NOT REPORTED
SAE Supplemental Procedure	NOT REPORTED
AE Stopped Rx Day	NOT REPORTED
Duration of AE	NOT REPORTED
Relation to Study Drug by Investigator	NO REASONABLE POSSIBILITY
Investigator Alternative Etiology	THERE IS NO CAUSAL RELATIONSHIP BECAUSE IT IS AGGRAVATED BY POOR CONTROL OF BLOOD GLUCOSE.
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554

治験責任医師からの報告。本被験者は日本の 4[redacted] 歳男性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，糖尿病の悪化の事象を発現した。

Event 1 の臨床経過：

関連する病歴は糖尿病，潜伏結核，乾癬性関節炎，元紙巻タバコ喫煙者（1 日 0.75 箱を 31.10 年間），糖尿病の悪化，血糖値コントロール目的の入院，局面型乾癬，電子タバコ使用者（1 日 0.75 回を 0.40 年間）及び元飲酒者（1 日 2 杯未満）であった。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は糖尿病の悪化を発現した。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は血糖値コントロール不良のため入院した。随伴症状は頭痛及び高血糖症であった。インスリンの用量調節を行ったところ，血糖値がコントロールされた。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は退院した。本事象発現前の使用薬剤や生活習慣の変更は報告されなかった。

投与された薬剤は，ミグリトール及びトレシーバであった。

The patient's past medications include:

REMICADE for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

COSENTYX for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

HUMIRA for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

Causality for UPADACITINIB (Blinded)

---

1) Diabetes mellitus aggravated (10012603) (Diabetes mellitus (10012601)) [v.22.0] [10012603]

Causality as per reporter (Drug/Vaccine): No reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Not Applicable

Alternative Etiology for UPADACITINIB (Blinded)

Event of WORSENING OF DIABETES MELLITUS

- **Investigator:** THERE IS NO CAUSAL RELATIONSHIP BECAUSE IT IS AGGRAVATED BY POOR CONTROL OF BLOOD GLUCOSE.

- **AbbVie:** Event is more likely related to pre-existing diabetes mellitus. Additionally, the subject was hospitalized prior to study drug administration for blood glucose control purposes ([redacted] 20[redacted]).

Relevant Laboratory & Other Diagnostic Tests

[redacted] **20[redacted] BLOOD GLUCOSE:** 73 mg/dL (normal 73 to 109)

[redacted] **20[redacted] BLOOD GLUCOSE:** 305 mg/dL (normal 73 to 109)

被験者番号 [redacted] (Investigator [redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
顔面麻痺	X			
ウイルス性胃腸炎	X			X

Treatment Group	Age at Study Start	Sex	Race
Placebo/ABT-494 30 mg QD	4[redacted]	FEMALE	ASIAN

Medical History	Onset Year
OTHER: PASORIASIS VULGARIS	19[redacted]
DEGENERATIVE DISC DISEASE: LUMBAGO HERNIA	19
ASTHMA: BRONCHIAL ASTHEMA	20
OTHER: GENETIAL ITCHING FEMALE	20
OTHER: CHRONIC URTICARIA	20
EYE DISEASE/DISORDER: BILATERAL MYOPIA	20
DIABETES MELLITUS	20
OBESITY	20
ANEMIA: IRON DEFICIENCY ANEMIA	20
OTHER: FATTY LIVER	20
OTHER: TOE AND NAIL TINEA	20
TUBERCULOSIS: LATENT TUBERCULOSIS	20
OTHER: CELLULITIS	20
OTHER: FURUNCULOSIS	20
OTHER: BACTERIAL GASTROENTERITIS	20
HYPERTENSION	20
MIGRAINE HEADACHE	20

Prior Procedures	Procedure Year
SURGERY: APPENDECTOMY	19[redacted]

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
Not reported.				

Alcohol Use	Status	Number/Day
ALCOHOL	CURRENT	Less than 2

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
PLACEBO		ORAL	QD	[redacted] / 1	[redacted] / 168	168
ABT-494	30MG	ORAL	QD	[redacted] / 169	[redacted] / 385	217
ABT-494	30MG	ORAL	QD	[redacted] / 386	/	

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
ANERON	1 OTHER: CAPSULE	PRN	Y-M: [redacted]
FEMININA	1 OTHER: APPLICATION	PRN	Y-M: [redacted]
TOCOPHEROL	1 OTHER: APPLICATION	PRN	Y-M: [redacted]
TRAVELMIN	1 OTHER: TABLET	PRN	Y-M: [redacted]
TRIAMCINOLONE	2.5 mL	QD	Y-M: [redacted]
METHOTREXATE	12 mg	EVERY WEEK	Y-M: [redacted]
CELECOXIB	200 mg	BID	Y-M: [redacted]
LANSOPRAZOLE	30 mg	QD	Y-M: [redacted]
DICLOFENAC	25 mg	PRN	Y-M: [redacted]
ISONIAZID	100 mg	TID	Y-M: [redacted]
PYRIDOXAL	10 mg	TID	Y-M: [redacted]
ADALIMUMAB	80 mg	EVERY 2 WEEKS	Y-M: [redacted]
METHOTREXATE	12 mg	EVERY WEEK	Y-M: [redacted]
FOLIC ACID	5 mg	QD	Y-M: [redacted]
CETIRIZINE	10 mg	QD	Y-M: [redacted]
OLOPATADINE	10 mg	BID	Y-M: [redacted]
CELECOXIB	200 mg	BID	Y-M: [redacted]
PREDNISOLONE	1 OTHER: APPLICATION	BID	Y-M: [redacted]
TACALCITOL	1 OTHER: APPLICATION	BID	Y-M: [redacted]
MOILIP	1 OTHER: APPLICATION	PRN	Y-M: [redacted]
DIFLUCORTOLONE	1 OTHER: APPLICATION	BID	Y-M: [redacted]
KETOPROFEN	1 OTHER: PATCH	QD	Y-M: [redacted]
IGURATIMOD	25 mg	QD	Y-M: [redacted]
IGURATIMOD	25 mg	BID	Y-M: [redacted]
FEXOFENADINE	60 mg	BID	Y-M: [redacted]
EXENATIDE	2 mg	EVERY WEEK	Y-M: [redacted]

METFORMIN	250 mg	BID	Y-M: 20[redacted]
DAPAGLIFLOZIN	5 mg	QD	Y-M: 20[redacted]
IRON	105 mg	QD	Y-M: 20[redacted] / -315
HEPARINOID	1 OTHER: APPLICATION	QD	Y-M: 20[redacted] / -196
TELMISARTAN	40 mg	QD	Y-M: 20[redacted] / -134
LOXOPROFEN	60 mg	PRN	Y-M: 20[redacted] / -71
INDOMETACIN	1 OTHER: APPLICATION	QD	Y-M: 20[redacted] / -70
WHITE SOFT PARAFFIN	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted] / -35

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
ANERON	1 OTHER: CAPSULE	PRN	Y-M: 20[redacted]	Not reported.
FEMININA	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted]	Not reported.
TOCOPHEROL	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted]	Not reported.
TRAVELMIN	1 OTHER: TABLET	PRN	Y-M: 20[redacted]	Not reported.
LANSOPRAZOLE	30 mg	QD	Y-M: 20[redacted]	Y-M: 20[redacted] / 428
ISONIAZID	100 mg	TID	Y-M: 20[redacted]	Not reported.
PYRIDOXAL	10 mg	TID	Y-M: 20[redacted]	Not reported.
METHOTREXATE	12 mg	EVERY WEEK	Y-M: 20[redacted]	Not reported.
FOLIC ACID	5 mg	QD	Y-M: 20[redacted]	Not reported.
CETIRIZINE	10 mg	QD	Y-M: 20[redacted]	Y-M: 20[redacted] / 428
CELECOXIB	200 mg	BID	Y-M: 20[redacted]	Not reported.
MOILIP	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted]	Not reported.
IGURATIMOD	25 mg	BID	Y-M: 20[redacted]	Not reported.
FEXOFENADINE	60 mg	BID	Y-M: 20[redacted]	Not reported.
METFORMIN	250 mg	BID	Y-M: 20[redacted]	Y-M: 20[redacted] / 597
DAPAGLIFLOZIN	5 mg	QD	Y-M: 20[redacted]	Y-M: 20[redacted] / 597
IRON	105 mg	QD	Y-M: 20[redacted] / -315	Not reported.
TELMISARTAN	40 mg	QD	Y-M: 20[redacted] / -134	Not reported.
LOXOPROFEN	60 mg	PRN	Y-M: 20[redacted] / -71	Not reported.
WHITE SOFT PARAFFIN	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted] / -35	Not reported.
OLOPATADINE	5 mg	QD	Y-M: 20[redacted] / 2	Not reported.

PROCATEROL	1 OTHER: INHALATION	PRN	Y-M: 20[redacted] / 36	Not reported.
BILASTINE	20 mg	QD	Y-M: 20[redacted] / 57	Y-M: 20[redacted] / 428
DIPHENHYDRAMINE	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted] / 113	Not reported.
FUSIDIC ACID	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted] / 113	Y-M: 20[redacted] / 483
BREO ELLIPTA	1 OTHER: INHALATION	QD	Y-M: 20[redacted] / 141	Not reported.
ROHTO	1 OTHER: DROPS	PRN	Y-M: 20[redacted] / 212	Not reported.
POVIDONE-IODINE	1 OTHER: GARGLE	PRN	Y-M: 20[redacted] / 351	Y-M: 20[redacted] / 574
MYDRIN P	0.3 mL	OTHER: ONCE	Y-M: 20[redacted] / 429	Y-M: 20[redacted] / 429
VALACICLOVIR	500 mg	BID	Y-M: 20[redacted] / 429	Y-M: 20[redacted] / 434
ADENOSINE	40 mg	QD	Y-M: 20[redacted] / 429	Y-M: 20[redacted] / 436
FAMOTIDINE	20 mg	QD	Y-M: 20[redacted] / 429	Y-M: 20[redacted] / 436
MECOBALAMIN	1 mL	QD	Y-M: 20[redacted] / 429	Y-M: 20[redacted] / 436
PREDNISOLONE	80 mg	QD	Y-M: 20[redacted] / 429	Y-M: 20[redacted] / 436
ESOMEPRAZOLE	20 mg	QD	Y-M: 20[redacted] / 429	Y-M: 20[redacted] / 439
ADENOSINE	1 g	TID	Y-M: 20[redacted] / 429	Y-M: 20[redacted] / 456
HYALURONIC ACID	1 OTHER: DROPS	TID	Y-M: 20[redacted] / 429	Y-M: 20[redacted] / 456
MECOBALAMIN	500 ug	TID	Y-M: 20[redacted] / 429	Y-M: 20[redacted] / 456
BROTIZOLAM	0.25 mg	PRN	Y-M: 20[redacted] / 431	Y-M: 20[redacted] / 439
LANSOPRAZOLE	30 mg	QD	Y-M: 20[redacted] / 440	Not reported.
CETIRIZINE	10 mg	QD	Y-M: 20[redacted] / 440	Y-M: 20[redacted] / 483
BILASTINE	20 mg	QD	Y-M: 20[redacted] / 440	Y-M: 20[redacted] / 597
NADIFLOXACIN	1 OTHER: APPLICATION	QD	Y-M: 20[redacted] / 449	Y-M: 20[redacted] / 454
LIRANAFTATE	1 OTHER: APPLICATION	QD	Y-M: 20[redacted] / 457	Not reported.
CLOBETASONE	1 OTHER: APPLICATION	BID	Y-M: 20[redacted] / 457	Y-M: 20[redacted] / 489

BENFOTIAMINE	25 mg	QD	Y-M: 20[redacted] / 480	Not reported.
VIDARABINE	1 OTHER: APPLICATION	BID	Y-M: 20[redacted] / 569	Y-M: 20[redacted] / 580
VALACICLOVIR	500 mg	BID	Y-M: 20[redacted] / 570	Y-M: 20[redacted] / 576
GUALENIC ACID	1 OTHER: GARGLE	PRN	Y-M: 20[redacted] / 575	Not reported.
FUSIDIC ACID	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted] / 576	Y-M: 20[redacted] / 582
CARBOHYDRATES NOS W/POTASSIUM CHLORIDE/SODIUM	500 mL	OTHER: ONCE	Y-M: 20[redacted] / 597	Y-M: 20[redacted] / 597
HYOSCINE	1 mL	OTHER: ONCE	Y-M: 20[redacted] / 597	Y-M: 20[redacted] / 597
BIO-THREE	1 OTHER: TABLETS	TID	Y-M: 20[redacted] / 597	Y-M: 20[redacted] / 598
LOPERAMIDE	1 OTHER: CAPSULES	BID	Y-M: 20[redacted] / 597	Y-M: 20[redacted] / 598
INSULIN HUMAN	5 IU	QD	Y-M: 20[redacted] / 598	Y-M: 20[redacted] / 598
INSULIN HUMAN	5 IU	BID	Y-M: 20[redacted] / 599	Y-M: 20[redacted] / 602
TERBINAFINE	1 OTHER: APPLICATION	QD	Y-M: 20[redacted] / 599	Y-M: 20[redacted] / 615
CLOSTRIDIUM BUTYRICUM	1 OTHER: TABLETS	TID	Y-M: 20[redacted] / 602	Y-M: 20[redacted] / 604
INSULIN HUMAN	5 IU	QD	Y-M: 20[redacted] / 603	Y-M: 20[redacted] / 603
BILASTINE	20 mg	QD	Y-M: 20[redacted] / 606	Not reported.
PARACETAMOL	400 mg	QD	Y-M: 20[redacted] / 606	Y-M: 20[redacted] / 606
BROTIZOLAM	0.25 mg	PRN	Y-M: 20[redacted] / 607	Not reported.
SENNOSIDE A+B	24 mg	OTHER: ONCE	Y-M: 20[redacted] / 608	Y-M: 20[redacted] / 608
INDIGO CARMINE	10 mL	OTHER: ONCE	Y-M: 20[redacted] / 609	Y-M: 20[redacted] / 609
LIDOCAINE	10 g	OTHER: ONCE	Y-M: 20[redacted] / 609	Y-M: 20[redacted] / 609
MIDAZOLAM	10 mg	OTHER: ONCE	Y-M: 20[redacted] / 609	Y-M: 20[redacted] / 609
MUBEN	500 mL	OTHER: ONCE	Y-M: 20[redacted] / 609	Y-M: 20[redacted] / 609
DAPAGLIFLOZIN	5 mg	QD	Y-M: 20[redacted] / 611	Not reported.
METFORMIN	250 mg	BID	Y-M: 20[redacted] /	Not reported.

ROSUVASTATIN	7.5 mg	QD	Y-M: 20[redacted]-[redacted] / 611	Y-M: 20[redacted]-[redacted] / 615
NERIPROCT	2 OTHER: PIECES	BID	Y-M: 20[redacted]-[redacted] / 612	Not reported.
GLYCEROL	60 mL	TID	Y-M: 20[redacted]-[redacted] / 613	Y-M: 20[redacted]-[redacted] / 613
LIDOCAINE	10 g	OTHER: ONCE	Y-M: 20[redacted]-[redacted] / 613	Y-M: 20[redacted]-[redacted] / 613

Event #1: Serious Adverse Event

Event Description	LEFT FACIAL NERVE PALSY
Preferred term	顔面麻痺
AE Onset Date / Rx Day	[redacted]20[redacted] / 428
Age at AE Onset	4[redacted]

Laboratory Testing

[redacted]20[redacted] (RX DAY 429): Basophils/Leukocytes: 0.3 [0 - 2.5] %; Eosinophils/Leukocytes: 2.2 [0 - 8.5] %; Leukocytes: 10.9 [3.3 - 8.6] 10^9/L; Lymphocytes/Leukocytes: 26.5 [16.5 - 49.5] %; Monocytes/Leukocytes: 5.5 [2 - 10] %; NPTST030-C-REACTIVE PROTEIN: 0.97 [NOT REPORTED - 0.3] mg/dL; NPTST068-HBA1C: 6.3 [4.6 - 6.2] %; NPTST072-HSV-IGG: 80.0 [NOT REPORTED - 1.9] UNIT NOT REPORTED; NPTST073-HSV-IGM: 0.17 [NOT REPORTED - 0.79] UNIT NOT REPORTED; NPTST145-VZV IGG: 13.3 [NOT REPORTED - 1.9] UNIT NOT REPORTED; NPTST146-VZV-IGM: 0.12 [NOT REPORTED - 0.79] UNIT NOT REPORTED; Neutrophils/Leukocytes: 65.5 [38.5 - 80.5] %; [redacted]20[redacted] (RX DAY 437): Basophils/Leukocytes: 0.3 [0 - 2.5] %; Eosinophils/Leukocytes: 1.9 [0 - 8.5] %; Leukocytes: 10.3 [3.3 - 8.6] 10^9/L; Lymphocytes/Leukocytes: 27.9 [16.5 - 49.5] %; Monocytes/Leukocytes: 6.9 [2 - 10] %; NPTST068-HBA1C: 6.4 [4.6 - 6.2] %; Neutrophils/Leukocytes: 63 [38.5 - 80.5] %

Microbiology

NOT REPORTED

SAE Supplemental Procedure

NOT REPORTED

AE Stopped Rx Day	457
Duration of AE	30 DAYS
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	NOT REPORTED
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION, OTHER MEDICALLY IMPORTANT SERIOUS EVENT

Event #2: Serious Adverse Event, Study Specific Adverse Events of Interest

Event Description	VIRAL ENTERITIS
Preferred term	ウイルス性胃腸炎
AE Onset Date / Rx Day	[redacted]20[redacted] / 597
Age at AE Onset	4[redacted]

Laboratory Testing

[redacted]20[redacted] (RX DAY 597): Leukocytes: 12.5 [3.3 - 8.6] 10^9/L; [redacted]20[redacted] (RX DAY 598): Leukocytes: 9.2

[3.3 - 8.6] 10^9/L; NPTST030-C-REACTIVE PROTEIN: 14.64 [NOT REPORTED - 0.3] mg/dL; NPTST070-HEMOGLOBIN A1C: 6.3 [4.6 - 6.2] %; [redacted]20[redacted] (RX DAY 602): Leukocytes: 7 [3.3 - 8.6] 10^9/L; NPTST030-C-REACTIVE PROTEIN: 2.66 [NOT REPORTED - 0.3] mg/dL; [redacted]20[redacted] (RX DAY 609): Leukocytes: 7.6 [3.3 - 8.6] 10^9/L; NPTST030-C-REACTIVE PROTEIN: 0.66 [NOT REPORTED - 0.3] mg/dL; [redacted]20[redacted] (RX DAY 612): Leukocytes: 9 [3.3 - 8.6] 10^9/L; NPTST030-C-REACTIVE PROTEIN: 0.50 [NOT REPORTED - 0.3] mg/dL; [redacted]20[redacted] (RX DAY 613): Leukocytes: 7.5 [3.3 - 8.6] 10^9/L; NPTST030-C-REACTIVE PROTEIN: 0.47 [NOT REPORTED - 0.3] mg/dL

Microbiology

[redacted]20[redacted] (RX DAY 598): STOOL NPTST092-MICROBIOLOGY EXAMINATION: NEGATIVE; URINE NPTST092-MICROBIOLOGY EXAMINATION: POSITIVE-ESCHERICHIA COLI; BLOOD NPTST092-MICROBIOLOGY EXAMINATION: NEGATIVE

SAE Supplemental Procedure

[redacted]20[redacted] (RX DAY 597): BODY TEMPERATURE: 38.0 C; [redacted]20[redacted] (RX DAY 598): BLOOD PRESSURE: 110/62; BODY TEMPERATURE: 37.5?C; CT (ABDOMINAL): NO ABNORMALITY; PULSE: 104; [redacted]20[redacted] (RX DAY 605): BODY PRESSURE: 124/75; BODY TEMPERATURE: 36.5 C; PULSE: 66; [redacted]20[redacted] (RX DAY 609): COLONOSCOPY: COLORECTAL POLYPS(ADENOMA),SIGMOID COLON DIVERTICULUM; [redacted]20[redacted] (RX DAY 613): COLONOSCOPY: HEMORRHOID

AE Stopped Rx Day	615
Duration of AE	19 DAYS
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	NOT REPORTED
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554

治験責任医師からの報告。本被験者は日本の 4[redacted] 歳女性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，左顔面神経麻痺の事象を発現した。

Event 1 の臨床経過：

関連する病歴は尋常性乾癬，元喫煙者（1 日 1 箱を 18 年間），糖尿病，肥満，潜伏結核，乾癬性関節炎，高血圧，片頭痛及び現飲酒者（1 日 2 杯未満）であった。

被験者は，最初の 24 週間，本治験の盲検プラセボ対照期に組み入れられていた。20[redacted] 年 [redacted] 月 [redacted] 日，ABT-494 の盲検投与が開始された。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は左顔面神経麻痺を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，左顔面神経麻痺は消失した。

20[redacted] 年 [redacted] 月 [redacted] 日の事象発現前，口唇単純ヘルペスの再燃（非重篤）が認められた。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は左眼の流涙を自覚した。左眼は完全に閉じることができなかった。また被験者は，口唇左側があまり動かないことに気づいた。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は皮膚科医を受診した。そのとき，顔面の痛みはまったくなかった。帯状疱疹を示唆する皮膚発疹もなかった。被験者は耳鼻咽喉科医を受診し，左顔面神経麻痺と診断された。被験者は，柳原法による顔面麻痺評価で，40 点中 7 点と評価された。聴覚障害は報告されなかった。20[redacted] 年 [redacted] 月 [redacted] 日，被験者はステロイド注入のため入院した。20[redacted] 年 [redacted] 月 [redacted] 日，症状は改善した。被験者は，柳原法により，40 点中 21 点と評価された。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は退院した。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は耳鼻咽喉科及び皮膚科を受診し，舌不快感を訴えた。顔面神経麻痺は軽快したと報告された。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は，柳原法により，40 点中 40 点と評価された。被験者は回復したと判断された。検査結果から原因ウイルスは特定されなかった。

投与された薬剤は，ファモチジン，アデホス-L，バラシクロビル，メチコバール，アデホスコーワ，ヒアレイン，プレドニン及びヒアルロン酸 NA であった。

The patient's past medications include:

DICLOFENAC NA for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

HUMIRA for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

BONALFA for PSORIASIS ([redacted] 20[redacted] - [redacted] 20[redacted])

LIDOMEX KOWA for PSORIASIS ([redacted] 20[redacted] - [redacted] 20[redacted])

MOHRUS for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

NERISONA for PSORIASIS ([redacted] 20[redacted] - [redacted] 20[redacted])

BYDUREON for DIABETES MELLITUS ([redacted] 20[redacted] - [redacted] 20[redacted])

HEPARINOID for PSORIASIS ([redacted] 20[redacted] - [redacted] 20[redacted])

INTEBAN for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

FAMVIR for HERPES SIMPLEX REACTIVATION(LIP) ([redacted] 20[redacted] - [redacted] 20[redacted])

Causality for ABT-494 (Blinded)

---

1) Facial palsy (10016060) (Facial paralysis (10016062)) [v.22.0] [10016060]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): Reasonable possibility

Dechallenge: Yes

Rechallenge: rechallenge was done, reaction did not recur

Alternative Etiology for ABT-494 (Blinded)

Event of LEFT FACIAL NERVE PALSY

- Investigator: Not applicable

- AbbVie: Not applicable

Relevant Laboratory & Other Diagnostic Tests

[redacted] **C REACTIVE PROTEIN:** 0.97 mg/dL (normal <0.3)

[redacted] **ELECTRONEUROGRAPHY:** 36.6%- Compound muscle action potential (CMAP) of affected side

[redacted] **HSV IGM:** 0.17 no unit (normal <0.79)

[redacted] **HSV-IGG:** 80.0 no unit (normal <1.9)

[redacted] **VZV IGG:** 13.3 no unit (normal <1.9)

[redacted] **VZV IGM:** 0.12 no unit (normal <0.79)

[redacted] **WHITE BLOOD CELLS:** 10.93 X10**3/MCL (normal 3.3 to 8.6)
Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554

治験責任医師からの報告。本被験者は日本の4[redacted]歳女性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，ウイルス性小腸炎の事象を発現した。

Event 2 の臨床経過：

関連する病歴は尋常性乾癬，元喫煙者（1 日 1 箱を 18 年間），糖尿病，肥満，細菌性胃腸炎及び現飲酒者（1 日 2 杯未満）であった。

被験者は，最初の 24 週間，本治験の盲検プラセボ対照期に組み入れられていた。20[redacted]年[redacted]月[redacted]日，ABT-494 の盲検投与が開始された。

20[redacted]年[redacted]月[redacted]日，被験者はウイルス性小腸炎を発現した。20[redacted]年[redacted]月[redacted]日，ウイルス性小腸炎は消失した。

20[redacted]年[redacted]月[redacted]日，被験者は悪心及び下痢（水様便が 1 日 5～6 回）を来した。被験者は内科を受診し，ブスコパン及びソルデム 3A を投与された。ロペミン及びビオスリーが処方され，その後，被験者は帰宅した。来院時には発熱はなかったが，夜間に 38°C の発熱を来した。20[redacted]年[redacted]月[redacted]日，悪心及び下痢（水様便が 1 日 10 回）が続いた。被験者は内科を再受診し，急性胃腸炎（ウイルス性小腸炎の疑い）のため，同日入院した。被験者は左腰部痛及び腹痛も訴えた。絶食及び点滴が開始された。被験者は下痢の原因と考えられる食物を思いつかなかった。20[redacted]年[redacted]月[redacted]日，水様便は 1 日 3 回に減少し，悪心はなく，さらなる左腰部痛もなかった。20[redacted]年[redacted]月[redacted]日，「泥状」便が 1 日 1～3 回認められた。臨床検査値は改善し，被験者は食事を開始した。20[redacted]年[redacted]月[redacted]日，悪心及び腹痛を伴う「泥状」便が 1 回認められた。20[redacted]年[redacted]月[redacted]日，微生物学的検査の結果は陰性であったが，被験者は依然として悪心及び腹痛を呈していたため，ウイルス性小腸炎と診断された。20[redacted]年[redacted]月[redacted]日，便は正常で，悪心や腹痛も伴っていなかった。20[redacted]年[redacted]月[redacted]日，結腸内視鏡検査が行われた。大腸ポリープ（腺腫，非重篤）及び S 状結腸憩室（非重篤）との診断が下された。20[redacted]年[redacted]月[redacted]日，便中に血液が認められた。20[redacted]年[redacted]月[redacted]日，結腸内視鏡検査で直腸痔核（非重篤）が明らかとなった。便中の血液は痔核からの出血ではないかと考えられた。これについては経過観察を行うこととなった。20[redacted]年[redacted]月[redacted]日，ウイルス性小腸炎は消失したと判断され，被験者は退院した。20[redacted]年[redacted]月[redacted]日，治験責任医師は被験者に電話し，被験者の状態はもう問題ないと伝えた。治験薬の投与が再開された。

投与された薬剤は，ロペミン，ビオスリー，ヒューマリン R，ミヤ BM，ブスコパン及びソルデム 3A であった。

Causality for UPADACITINIB (Blinded)

---

1) Viral gastroenteritis (10047445) (Gastroenteritis viral (10017918)) [v.22.0] [10047445]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Yes

Rechallenge: rechallenge was done, reaction did not recur

Alternative Etiology for UPADACITINIB (Blinded)

Event of VIRAL ENTERITIS

- Investigator: Not applicable

- AbbVie: Event is common in the general population.

Relevant Laboratory & Other Diagnostic Tests

[redacted] **BLOOD CULTURE:** negative

[redacted] **BLOOD PRESSURE:** 110/62 mmHg

[redacted] **BLOOD PRESSURE:** 124/75 mmHg

[redacted] **BODY TEMPERATURE:** 38 Degrees C

[redacted] **BODY TEMPERATURE:** 37.5 Degrees C

[redacted] **BODY TEMPERATURE:** 36.5 Degrees C

[redacted] **C REACTIVE PROTEIN:** 14.64 mg/dL (normal <0.30)

[redacted] **C REACTIVE PROTEIN:** 2.66 mg/dL (normal <0.30)

[redacted] **C REACTIVE PROTEIN:** 0.47 mg/dL (normal <0.30)

[redacted] **COLONOSCOPY:** colorectal polyps (adenoma) and sigmoid colon diverticulum

[redacted] **COLONOSCOPY:** hemorrhoids in rectum

[redacted] **CT ABDOMEN:** no abnormality

[redacted] **20[redacted] HEART RATE:** 104 bpm

[redacted] **20[redacted] HEMOGLOBIN A1C:** 6.3 % (normal 4.6 to 6.2)

[redacted] **20[redacted] STOOL CULTURE:** negative

[redacted] **20[redacted] URINE CULTURE:** positive: Escherichia coli

[redacted] **20[redacted] WBC:** 12.53 10^3/ul (normal 3.30 to 8.60)

[redacted] **20[redacted] WBC:** 9.23 10^3/ul (normal 3.30 to 8.60)

[redacted] **20[redacted] WBC:** 7.46 10^3/ul (normal 3.30 to 8.60)

被験者番号 [redacted] (Investigator [redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
ウイルス性胃腸炎	X			X

Treatment Group	Age at Study Start	Sex	Race
ABT-494 15 mg QD	3[redacted]	MALE	ASIAN

Medical History	Onset Year
OTHER: PSORIASIS VULGARIS	20[redacted]
OTHER: POLLINOSIS	20[redacted]
DIABETES MELLITUS	20[redacted]
LIVER DISEASE (EXCLUDING HEPATITIS): FATTY LIVER	20[redacted]
HYPERLIPIDEMIA: HYPERCHOLESTEROLEMIA	20[redacted]
SEIZURE DISORDER/CONVULSIONS: CONTROLLED BY MEDICATION	20[redacted]
OTHER: PIGMENTED NEVUS RESECTION	20[redacted]
SLEEP APNEA	20[redacted]

Prior Procedures	Procedure Year
Not reported.	

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
Not reported.				

Alcohol Use	Status	Number/Day
ALCOHOL	FORMER	Less than 2

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
ABT-494	15MG	ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 170	170
ABT-494	15MG	ORAL	QD	[redacted]20[redacted] / 171	[redacted]20[redacted] / 392	222
ABT-494	15MG	ORAL	QD	[redacted]20[redacted] / 393	/	

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day

HERPES ZOSTER IMMUNIZATION	NOT REPORTED	NOT REPORTED	Y-M: 19[redacted]
TACALCITOL	1 OTHER: APPLICATION	QD	Y-M: 20[redacted]
VALISONE-G	1 OTHER: APPLICATION	QD	Y-M: 20[redacted]
DICLOFENAC	37.5 mg	BID	Y-M: 20[redacted]
METHOTREXATE	8 mg	EVERY WEEK	Y-M: 20[redacted]
BETAMETHASONE	1 OTHER: APPLICATION	QD	Y-M: 20[redacted]
LIRAGLUTIDE	0.9 mg	QD	Y-M: 20[redacted]
BETAMETHASONE	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted]
INFLIXIMAB	550 mg	OTHER: EVERY8WEEK	Y-M: 20[redacted]
BEZAFIBRATE	200 mg	QD	Y-M: 20[redacted]
METFORMIN	500 mg	TID	Y-M: 20[redacted]
DAIVOBET	1 OTHER: APPLICATION	QD	Y-M: 20[redacted]
ADALIMUMAB	80 mg	EVERY 2 WEEKS	Y-M: 20[redacted]
LEVETIRACETAM	1000 mg	BID	Y-M: 20[redacted] / -256
BEPOTASTINE	10 mg	BID	Y-M: 20[redacted] / -245
BETAMETHASONE BUTYRATE PROPIONATE W/MAXACALCI	1 OTHER: APPLICATION	QD	Y-M: 20[redacted] / -245
LOXOPROFEN	1 OTHER: APPLICATION	QD	Y-M: 20[redacted] / -245
MAXACALCITOL	1 OTHER: APPLICATION	QD	Y-M: 20[redacted] / -245
MAXACALCITOL	1 OTHER: APPLICATION	QD	Y-M: 20[redacted] / -235
INSULIN DEGLUDEC	6 IU	QD	Y-M: 20[redacted] / -182
CELECOXIB	200 mg	BID	Y-M: 20[redacted] / -126
FOLIC ACID	10 mg	EVERY WEEK	Y-M: 20[redacted] / -123
LACOSAMIDE	50 mg	BID	Y-M: 20[redacted] / -112
ZOLPIDEM	10 mg	QD	Y-M: 20[redacted] / -112
METHOTREXATE	10 mg	EVERY WEEK	Y-M: 20[redacted] / -90
FLURBIPROFEN	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted] / -33
LANSOPRAZOLE	15 mg	QD	Y-M: 20[redacted] / -33

HEPARINOID		1 OTHER: APPLICATION	QD	Y-M: 20[redacted] / -32

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
LIRAGLUTIDE	0.9 mg	QD	Y-M: 20[redacted]	Y-M: 20[redacted] / 365
BEZAFIBRATE	200 mg	QD	Y-M: 20[redacted]	Not reported.
METFORMIN	500 mg	TID	Y-M: 20[redacted]	Not reported.
FOLIC ACID	10 mg	EVERY WEEK	Y-M: 20[redacted] / -123	Y-M: 20[redacted] / 360
ZOLPIDEM	10 mg	QD	Y-M: 20[redacted] / -112	Not reported.
METHOTREXATE	10 mg	EVERY WEEK	Y-M: 20[redacted] / -90	Y-M: 20[redacted] / 359
FLURBIPROFEN	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted] / -33	Not reported.
LANSOPRAZOLE	15 mg	QD	Y-M: 20[redacted] / -33	Not reported.
WHITE SOFT PARAFFIN	1 OTHER: APPLICATION	QD	Y-M: 20[redacted] / 15	Not reported.
ESCITALOPRAM	20 mg	QD	Y-M: 20[redacted] / 61	Not reported.
LEVETIRACETAM	2000 mg	QD	Y-M: 20[redacted] / 61	Y-M: 20[redacted] / 555
CLOBETASOL	1 OTHER: APPLICATION	QD	Y-M: 20[redacted] / 113	Not reported.
INSULIN DEGLUDEC	12 IU	QD	Y-M: 20[redacted] / 204	Y-M: 20[redacted] / 365
LACOSAMIDE	100 mg	QD	Y-M: 20[redacted] / 255	Not reported.
LACOSAMIDE	50 mg	QD	Y-M: 20[redacted] / 255	Not reported.
CELECOXIB	200 mg	PRN	Y-M: 20[redacted] / 262	Not reported.
URSODEOXYCHOLIC ACID	100 mg	BID	Y-M: 20[redacted] / 311	Not reported.
LAMOTRIGINE	5 mg	BID	Y-M: 20[redacted] / 345	Y-M: 20[redacted] / 358
LAMOTRIGINE	10 mg	BID	Y-M: 20[redacted] / 359	Y-M: 20[redacted] / 380
LACTOMIN	1 OTHER: TABLET	OTHER: ONCE	Y-M: 20[redacted] / 364	Y-M: 20[redacted] / 364
EUFUSOL	500 mL	OTHER: ONCE	Y-M: 20[redacted] / 366	Y-M: 20[redacted] / 366
SODIUM CHLORIDE	500 mL	OTHER: ONCE	Y-M: 20[redacted] / 366	Y-M: 20[redacted] / 366

SULTAMICILLIN	3 g	TID	Y-M: 20[redacted] / 366	Y-M: 20[redacted] / 366
INSULIN HUMAN	2 IU	BID	Y-M: 20[redacted] / 366	Y-M: 20[redacted] / 367
PARACETAMOL	500 mg	PRN	Y-M: 20[redacted] / 366	Y-M: 20[redacted] / 368
INSULIN LISPRO	2 IU	OTHER: ONCE	Y-M: 20[redacted] / 367	Y-M: 20[redacted] / 367
INSULIN LISPRO	6 IU	OTHER: ONCE	Y-M: 20[redacted] / 367	Y-M: 20[redacted] / 367
UNACID	3 g	QID	Y-M: 20[redacted] / 367	Y-M: 20[redacted] / 368
INSULIN DEGLUDEC	12 IU	QD	Y-M: 20[redacted] / 368	Not reported.
INSULIN LISPRO	2 IU	OTHER: ONCE	Y-M: 20[redacted] / 368	Y-M: 20[redacted] / 368
LIRAGLUTIDE	0.9 mg	QD	Y-M: 20[redacted] / 369	Not reported.
INSULIN LISPRO	2 IU	OTHER: ONCE	Y-M: 20[redacted] / 369	Y-M: 20[redacted] / 369
UNACID	3 g	TID	Y-M: 20[redacted] / 369	Y-M: 20[redacted] / 369

Event #1: Serious Adverse Event, Study Specific Adverse Events of Interest

Event Description	VIRAL GASTROENTEROCOLITIS
Preferred term	ウイルス性胃腸炎
AE Onset Date / Rx Day	[redacted]20[redacted] / 366
Age at AE Onset	3[redacted]

Laboratory Testing

[redacted]20[redacted] (RX DAY 366): Alanine Aminotransferase: 63 [10 - 42] U/L; Aspartate Aminotransferase: 61 [13 - 30] U/L; Leukocytes: 8.7 [3.3 - 8.6] 10^9/L; NPTST042-CRP: 0.04 [0 - 0.14] mg/dL; NPTST049-CULTURE INSPECTION TEST: NEGATIVE [NOT REPORTED - NOT REPORTED] UNIT NOT REPORTED; NPTST049-CULTURE INSPECTION TEST: NEGATIVE [NOT REPORTED - NOT REPORTED] UNIT NOT REPORTED; NPTST056-EGFR: 84.6 [NOT REPORTED - NOT REPORTED] UNIT NOT REPORTED; NPTST144-VIROLOGY INSPECTION: NEGATIVE [NOT REPORTED - NOT REPORTED] UNIT NOT REPORTED; [redacted]20[redacted] (RX DAY 367): Alanine Aminotransferase: 50 [10 - 42] U/L; Aspartate Aminotransferase: 47 [13 - 30] U/L; Leukocytes: 4.6 [3.3 - 8.6] 10^9/L; NPTST042-CRP: 2.23 [0 - 0.14] mg/dL; NPTST056-EGFR: 70.7 [NOT REPORTED - NOT REPORTED] UNIT NOT REPORTED; [redacted]20[redacted] (RX DAY 369): Alanine Aminotransferase: 50 [10 - 42] U/L; Aspartate Aminotransferase: 46 [13 - 30] U/L; Leukocytes: 4.8 [3.3 - 8.6] 10^9/L; NPTST042-CRP: 0.62 [0 - 0.14] mg/dL; NPTST056-EGFR: 81.4 [NOT REPORTED - NOT REPORTED] UNIT NOT REPORTED; [redacted]20[redacted] (RX DAY 374): Alanine Aminotransferase: 73 [10 - 42] U/L; Aspartate Aminotransferase: 47 [13 - 30] U/L; Leukocytes: 5.6 [3.3 - 8.6] 10^9/L; NPTST042-CRP: 0.21 [0 - 0.14] mg/dL; NPTST056-EGFR: 98.7 [NOT REPORTED - NOT REPORTED] UNIT NOT REPORTED

Microbiology

NOT REPORTED

SAE Supplemental Procedure

[redacted]20[redacted] (RX DAY 366): CHEST CT: NO ABNORMAL CHANGE; CHEST X-RAY: NO ABNORMAL CHANG.; PLEVIS CT: NO ABNORMAL CHANGE; TEMPERATURE: 38.7?; [redacted]20[redacted] (RX DAY 367): TEMPERATURE: 36.8?

AE Stopped Rx Day	374
Duration of AE	9 DAYS
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	NOT REPORTED
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554

治験責任医師からの報告。本被験者は日本の3[redacted]歳男性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，ウイルス性胃腸炎の事象を発現した。

Event 1 の臨床経過：

関連する病歴は糖尿病，現喫煙者（1 日 0.5 箱を 15 年間）及び元飲酒者（1 日 2 杯未満）であった。

被験者は，最初の 24 週間，本治験の盲検プラセボ対照期に組み入れられていた。20[redacted] 年 [redacted] 月 [redacted] 日，ABT-494 の盲検投与が開始された。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者はウイルス性胃腸炎を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，ウイルス性胃腸炎は消失した。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は咽喉痛，咳嗽及び下痢を呈した。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は発熱，からだのゆれ及び悪寒で入院した。抗生物質の静脈内投与が行われた。20[redacted] 年 [redacted] 月 [redacted] 日，発熱は消失し，被験者の全身状態は改善した。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は退院した。

投与された薬剤は，スルバシリン，ヴィーン-F，生理食塩液，ヒューマリン R，ヒューマログ，ビクトーザ，トレシーバ，ビオフェルミン及びカロナールであった。

The patient's past medications include:

LOXONIN TAPE for PSORIATIC ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

TALION for PSORIASIS VULGARIS ([redacted] 20[redacted] - [redacted] 20[redacted])

Causality for ABT-494 (Blinded)

---

1) Viral gastroenteritis (10047445) (Gastroenteritis viral (10017918)) [v.21.1] [10047445]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Yes

Rechallenge: rechallenge was done, reaction did not recur

Alternative Etiology for ABT-494 (Blinded)

Event of VIRAL GASTROENTEROCOLITIS

- Investigator: Not applicable

- AbbVie: Event is common in the general population

Relevant Laboratory & Other Diagnostic Tests

[redacted] **20[redacted] ALANINE AMINO TRANSFERASE:** 73 IU/L (normal 10 to 42)

[redacted] **20[redacted] ALANINE AMINOTRANSFERASE:** 63 U/L (normal 10 to 42)

[redacted] **20[redacted] ALKALINE AMINO PHOSPHATASE:** 50 U/L (normal 10 to 30)

[redacted] **20[redacted] ASPARTATE AMINO TRANSFERASE:** 61 IU/L (normal 13 to 30)

[redacted] **20[redacted] ASPARTATE AMINO TRANSFERASE:** 46 IU/L (normal 13 to 30)

[redacted] **20[redacted] ASPARTATE AMINO TRANSFERASE:** 47 IU/L (normal 13 to 30)

[redacted] **20[redacted] BLOOD CULTURE:** Negative

[redacted] **20[redacted] BODY TEMP:** 38.6 Degrees C

[redacted] **20[redacted] BODY TEMP:** 36.8 Degrees C

[redacted] **20[redacted] CHEST X-RAY:** No Abnormal change

[redacted] **20[redacted] CRP:** 0.04 mg/dL (normal 0 to 0.14)

[redacted] **20[redacted] CRP:** 2.23 mg/dL (normal 0 to 0.14)

[redacted] **20[redacted] CRP:** 0.62 mg/dL (normal 0 to 0.14)

[redacted] **20[redacted] CRP:** 0.21 mg/dL (normal 0 to 0.14)

[redacted] **20[redacted] CT CHEST:** No Abnormal change

[redacted] **20[redacted] CT PELVIS:** No Abnormal change

[redacted] **20[redacted] EGFR:** 84.6 No units

[redacted] **20[redacted] EGFR:** 70.7 No units

[redacted] **20[redacted] EGFR:** 81.4 No units

[redacted] **20[redacted] EGFR:** 98.7 No units

[redacted] **20[redacted] NASAL MUSCUS VIROLOGY INSPECTION:** Negative

[redacted] [redacted] **20**[redacted] **WHITE BLOOD CELLS:** 8.74 X10**3/MCL (normal 3.3 to 8.6)

[redacted] [redacted] **20**[redacted] **WHITE BLOOD CELLS:** 4.76 X10**3/MCL (normal 3.3 to 8.6)

[redacted] [redacted] **20**[redacted] **WHITE BLOOD CELLS:** 5.56 X10**3/MCL (normal 3.3 to 8.6)

被験者番号 [redacted] (Investigator [redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
肺炎	X	X		X

Treatment Group	Age at Study Start	Sex	Race
ABT-494 30 mg QD	6[redacted]	MALE	ASIAN

Medical History	Onset Year
TUBERCULOSIS: TUBERCULOSIS IN CHILDHOOD(ACTIVE TB)	19[redacted]
OTHER: PSORIASIS VULGARIS	19[redacted]
DEGENERATIVE DISC DISEASE: LUMBER HERNIA	19[redacted]
EYE DISEASE/DISORDER: UVEITIS	20[redacted]
OTHER: HYPERURICEMIA	20[redacted]
OTHER: INSOMUNIA	20[redacted]

Prior Procedures	Procedure Year
SURGERY: APPENDECTOMY	20[redacted]

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
Not reported.				

Alcohol Use	Status	Number/Day
ALCOHOL	NEVER	

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
ABT-494	30MG	ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 118	118

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
ALLOPURINOL	100 mg	QD	Y-M: 20[redacted]
ZOLPIDEM	5 mg	PRN	Y-M: 20[redacted]
FLUOROMETHOLONE	1 OTHER: APPLICATION	TID	Y-M: 20[redacted]
CERTOLIZUMAB PEGOL	200 mg	EVERY 2 WEEKS	Y-M: 20[redacted]
FOLIC ACID	5 mg	EVERY WEEK	Y-M: 20[redacted]
METHOTREXATE	8 mg	EVERY WEEK	Y-M: 20[redacted]
DEXAMETHASONE	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted] / -365
DIPHENHYDRAMINE	1 OTHER: APPLICATION	BID	Y-M: 20[redacted] / -365
DIFLUPREDNATE	1 OTHER: APPLICATION	BID	Y-M: 20[redacted] / -197
CALCIPOTRIOL	1 OTHER: APPLICATION	BID	Y-M: 20[redacted] / -169
LOXOPROFEN	60 mg	PRN	Y-M: 20[redacted] / -155
METHOTREXATE	10 mg	EVERY WEEK	Y-M: 20[redacted] / -85
ISONIAZID	100 mg	TID	Y-M: 20[redacted] / -23
PYRIDOXAL	10 mg	TID	Y-M: 20[redacted] / -23
LOXOPROFEN	60 mg	TID	Y-M: 20[redacted] / -21

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
ALLOPURINOL	100 mg	QD	Y-M: 20[redacted]	Y-M: 20[redacted] / 149
ZOLPIDEM	5 mg	PRN	Y-M: 20[redacted]	ONGOING
FOLIC ACID	5 mg	EVERY WEEK	Y-M: 20[redacted]	Y-M: 20[redacted] / 115
METHOTREXATE	10 mg	EVERY WEEK	Y-M: 20[redacted] / -85	Y-M: 20[redacted] / 119
ISONIAZID	100 mg	TID	Y-M: 20[redacted] / -23	Y-M: 20[redacted] / 140
PYRIDOXAL	10 mg	TID	Y-M: 20[redacted] / -23	Y-M: 20[redacted] / 140
LOXOPROFEN	60 mg	TID	Y-M: 20[redacted] / -21	Y-M: 20[redacted] / 141
LANSOPRAZOLE	15 mg	QD	Y-M: 20[redacted] / 1	ONGOING
LULICONAZOLE	1 OTHER: APPLICATION	QD	Y-M: 20[redacted] / 85	Y-M: 20[redacted] / 168
AZITHROMYCIN	500 mg	QD	Y-M: 20[redacted] / 119	Y-M: 20[redacted] / 121
PARACETAMOL	500 mg	OTHER: ONCE	Y-M: 20[redacted] / 122	Y-M: 20[redacted] / 122
SODIUM CHLORIDE	10 mL	QD	Y-M: 20[redacted] / 122	Y-M: 20[redacted] / 123
METHYLPREDNISOLONE	1000 mg	QD	Y-M: 20[redacted] / 122	Y-M: 20[redacted] / 124
BACTRIM	3 OTHER: TABLETS	TID	Y-M: 20[redacted] / 122	Y-M: 20[redacted] / 125
HEPARIN	10 mL	QD	Y-M: 20[redacted] / 122	Y-M: 20[redacted] / 125
MEROPENEM	0.5 g	TID	Y-M: 20[redacted] / 122	Y-M: 20[redacted] / 127
CALCIUM POLYSTYRENE SULFONATE	25 g	TID	Y-M: 20[redacted] / 123	Y-M: 20[redacted] / 126
INSULIN LISPRO	2 IU	PRN	Y-M: 20[redacted] / 123	Y-M: 20[redacted] / 126
INSULIN LISPRO	4 IU	PRN	Y-M: 20[redacted] / 123	Y-M: 20[redacted] / 127
BACTRIM	2 OTHER: TABLETS	TID	Y-M: 20[redacted] / 125	Y-M: 20[redacted] / 126
PREDNISOLONE	10-30 mg	TID	Y-M: 20[redacted] / 125	Y-M: 20[redacted] / 128
ALENDRONIC ACID	35 mg	EVERY WEEK	Y-M: 20[redacted] / 125	Y-M: 20[redacted] / 152

ALFACALCIDOL	0.5 ug	QD	Y-M: 20[redacted]-[redacted] 125	/ Y-M: 20[redacted]-[redacted] 155 /
BACTRIM	1 OTHER: TABLET	QD	Y-M: 20[redacted]-[redacted] 127	/ Y-M: 20[redacted]-[redacted] 134 /
PREDNISOLONE	20-15 mg	BID	Y-M: 20[redacted]-[redacted] 129	/ Y-M: 20[redacted]-[redacted] 132 /
PREDNISOLONE	20-5 mg	BID	Y-M: 20[redacted]-[redacted] 133	/ Y-M: 20[redacted]-[redacted] 135 /
AMPHOTERICIN B	1 OTHER: APPLICATION	QID	Y-M: 20[redacted]-[redacted] 134	/ Y-M: 20[redacted]-[redacted] 142 /
HEPARINOID	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted]-[redacted] 135	/ ONGOING
XYLOCAINE-EPINEPHRINE	5 mL	OTHER: ONCE	Y-M: 20[redacted]-[redacted] 135	/ Y-M: 20[redacted]-[redacted] 135 /
LEVOCETIRIZINE	5 mg	QD	Y-M: 20[redacted]-[redacted] 135	/ Y-M: 20[redacted]-[redacted] 141 /
PREDNISOLONE	15 mg	QD	Y-M: 20[redacted]-[redacted] 136	/ Y-M: 20[redacted]-[redacted] 141 /
LOXOPROFEN	60 mg	PRN	Y-M: 20[redacted]-[redacted] 142	/ ONGOING
PREDNISOLONE	7.5 mg	QD	Y-M: 20[redacted]-[redacted] 142	/ Y-M: 20[redacted]-[redacted] 148 /
PREDNISOLONE	2.5 mg	QD	Y-M: 20[redacted]-[redacted] 149	/ Y-M: 20[redacted]-[redacted] 155 /

Event #1: Serious Adverse Event, AE Leading to Discontinuation of Study Drug, Study Specific Adverse Events of Interest

Event Description	DRUG INDUCED PNEUMONIA
Preferred term	肺炎
AE Onset Date / Rx Day	[redacted]20[redacted] / 118
Age at AE Onset	6[redacted]
Laboratory Testing	

NOT REPORTED

Microbiology

[redacted]20[redacted] (RX DAY 122): URINE NPTST002- LEGIONELLA PNEUMOPHILA ANTIGEN: NEGATIVE; BLOOD NPTST004-?D GLUCAN: NEGATIVE; BLOOD NPTST022-BLOOD CULTURE: NEGATIVE; BLOOD NPTST054-CYTOMEGALOVIRUS ANTIGEN: NEGATIVE; OTHER NASAL MUCUS NPTST076-INFLUENZA TEST: NEGATIVE; SPUTUM NPTST093-MYCOBACTERIUM TUBERCULOSIS: NEGATIVE; OTHER THROAT SWAB NPTST104-PHARYNX MYCOPLASMA: NEGATIVE; URINE NPTST107-PNEUMOCOCCUS THEA ANTIGEN: NEGATIVE

SAE Supplemental Procedure

[redacted]20[redacted] (RX DAY 122): CT: PNEUMONITIS; X-RAY: PNEUMONITIS; [redacted]20[redacted] (RX DAY 128): CHEST CT: IMPROVEMENT OF PNEUMONIA.; [redacted]20[redacted] (RX DAY 141): CHEST X-RAY: IMPROVEMENT; [redacted]20[redacted] (RX DAY 148): CHEST X-RAY: IMPROVEMENT; [redacted]20[redacted] (RX DAY 155): CHEST X-RAY: IMPROVEMENT; [redacted]20[redacted] (RX DAY 169): CHEST X-RAY: IMPROVEMENT

AE Stopped Rx Day	169 (51 DAYS AFTER LAST TREATMENT)
Duration of AE	52 DAYS
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	NOT REPORTED
Discontinued Study Drug Due to the Event	YES
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M15-554

治験責任医師からの報告。本被験者は日本の6[redacted]歳男性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬が投与され，薬剤誘発性肺炎の事象を発現した。

Event 1 の臨床経過：

関連する病歴は小児期の結核，尋常性乾癬，乾癬性関節炎，ぶどう膜炎，非喫煙者及び非飲酒者であった。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は薬剤誘発性肺炎を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，薬剤誘発性肺炎は消失した。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は，咽喉痛を伴う悪寒戦慄，咳嗽，発熱，鼻分泌物及び労作時呼吸困難を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は 38°C の発熱を来し，咳嗽が続いた。治験薬の投与が完全に中止された。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は 39°C の発熱で来院した。同日，被験者は入院し，肺臓炎と診断された。20[redacted] 年 [redacted] 月 [redacted] 日，コンピュータ断層撮影（CT）検査及び胸部 X 線検査が行われ，肺臓炎が明らかになった。血液培養とレジオネラ及び肺炎球菌の尿中抗原検査の結果は陰性であった。20[redacted] 年 [redacted] 月 [redacted] 日，薬剤誘発性肺炎が強く疑われた。20[redacted] 年 [redacted] 月 [redacted] 日，胸部 CT 検査が行われ，肺炎の軽快が確認された。20[redacted] 年 [redacted] 月 [redacted] 日，臨床所見は改善し，自覚症状も消失した。同日，被験者は退院した。

ステロイド療法下にて再度胸部 X 線検査が行われ，軽快が確認された。20[redacted] 年 [redacted] 月 [redacted] 日，ステロイド療法が中止され，胸部 X 線検査により著明な変化は認められなかった。被験者に症状はなく，本事象は消失したと判断された。

投与された薬剤は，ジスロマック，メロペネム，メチルプレドニゾロンコハク酸エステルナトリウム，プレドニン，カロナール及びダイフェンであった。

The patient's past medications include:

PROPETO for PSORIASIS VULGARIS ([redacted] 20[redacted] - [redacted] 20[redacted])

Causality for ABT-494 (Blinded)

---

1) Pneumonia (10035664) (Pneumonia (10035664)) [v.21.1] [10035664]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): Reasonable possibility

Dechallenge: Yes

Rechallenge: No rechallenge was done, recurrence is not applicable

Alternative Etiology for ABT-494 (Blinded)

Event of DRUG INDUCED PNEUMONIA

- Investigator: Not applicable

- AbbVie: Not applicable

Relevant Laboratory & Other Diagnostic Tests

[redacted] **20[redacted] BLOOD CULTURE:** Negative

[redacted] **20[redacted] CHEST CT:** Improvement of pneumonia

[redacted] **20[redacted] CHEST X-RAY:** Calcification of paratracheal lymph node

[redacted] **20[redacted] CHEST X-RAY:** Improved (on steroid therapy)

[redacted] **20[redacted] CHEST X-RAY:** Improved (on steroid therapy)

[redacted] **20[redacted] CHEST X-RAY:** Improved (steroid therapy stopped)

[redacted] **20[redacted] CHEST X-RAY:** No remarkable change (off steroid therapy)

[redacted] **20[redacted] CT:** PNEUMONITS

[redacted] **20[redacted] CXR:** PNEUMONITIS

[redacted] **20[redacted] CYTOMEGALOVIRUS ANTIGEN BLOOD:** Negative

[redacted] **20[redacted] INFLUENZA TEST (NASAL MUCUS):** Negative

[redacted] **20[redacted] LEGIONELLA PNEUMOPHILA ANTIGEN URINE:** Negative

[redacted] **20[redacted] MYCOBACTERIUM TUBERCULOSIS SPUTUM:** Negative

[redacted] **20[redacted] PHARYNX MYCOPLASMA (THROAT SWAB):** Negative

[redacted] **20[redacted] PNEUMOCUCCUS THEA ANTIGEN URINE:** Negative

[redacted] **20[redacted] B-D GLUCAN BLOOD:** Negative